modspcecvabioipooqpmxgkmtaacsedmhmsslgtq length 6 251725 page 251725 <!DOCTYPE html>
<html xmlns="https://www.w3.org/1999/xhtml" lang="en" xml:lang="en">
<HEAD><!--ccm   -->
				<script id="cookieConsentScript" async src="https://img.lb.wbmdstatic.com/webmd_static_vue/file-explorer/webmd/consumer_assets/site_images/webmd-ccm/ccm_oo.min.js"></script>
<meta charset="UTF-8">
<script>
    // Flag set to know we are using the newest Global Ads coded
    var globalAsyncAdsCode = false;
</script>
<link rel="preconnect" href="https://securepubads.g.doubleclick.net" crossorigin>
<link rel="preconnect" href="https://assets.adobedtm.com" crossorigin>
<link rel="preconnect" href="https://img.webmd.com" crossorigin>

<link rel="shortcut icon" href="https://www.rxlist.com/images/fav/rx.ico" />
<link rel="apple-touch-icon" href="https://www.rxlist.com/images/mobile/rxlist-icon.png" />

<link rel="preconnect" href="https://images.rxlist.com">
<link rel="preload" href="https://images.rxlist.com/fonts/open-sans-v20-latin/open-sans-v20-latin-regular.woff2" as="font" type="font/woff2" crossorigin>
<link rel="preload" href="https://images.rxlist.com/fonts/open-sans-v20-latin/open-sans-v20-latin-600.woff2" as="font" type="font/woff2" crossorigin>
<link rel="preload" href="//assets.adobedtm.com/2c8c1e17b98c/bd8b7ed95b8d/launch-a2e2197ecad5.min.js" as="script" />
<link rel="preload" href="https://img.wbmdstatic.com/webmd_static_vue/webmd-share-static-files/webmd/PageBuilder_Assets/JS/api/oo_shim_head.min.js" as="script">
<link rel="preload" href="https://img.wbmdstatic.com/webmd_static_vue/webmd-share-static-files/webmd/PageBuilder_Assets/JS/api/oo_shim_body.min.js" as="script">
<link rel="preload" href="https://img.webmd.com/bi_common/bi_oocommon.js" as="script">
<style>/*** Icomoon ***/@font-face {font-family: 'icomoon';src: url(data:application/x-font-ttf;charset=utf-8;base64,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)format('truetype');font-weight: normal;font-style: normal;font-display: block}[class^="icon-"],[class*=" icon-"] {font-family: 'icomoon' !important;speak: never;font-style: normal;font-weight: normal;font-variant: normal;text-transform: none;line-height: 1;-webkit-font-smoothing: antialiased;-moz-osx-font-smoothing: grayscale}.icon-facebook:before {content: "\e608"}.icon-twitter:before {content: "\e607"}.icon-shield:before {content: "\e906"}.icon-search:before {content: "\e612"}.icon-menu:before {content: "\e613"}.icon-close:before {content: "\e624"}.icon-arrow-right2:before {content: "\e605"}.icon-slide:before,.icon-slideshow:before,#artPromoCunk .slide:before {content: "\e604"}.icon-image:before,#artPromoCunk .image:before {content: "\e623"}.icon-quiz:before,#artPromoCunk .quiz:before {content: "\e602"}.icon-right:before {content: "\e628"}.icon-wrong:before {content: "\e629"}.icon-start-over:before {content: "\e630"}.icon-pro:before {content: "\e901"}.icon-consumer:before {content: "\e902"}.icon-side-effect:before {content: "\e903"}.icon-drug-interaction:before {content: "\e905"}.icon-pill-id:before {content: "\e907"}.icon-drug-class:before {content: "\e908"}.icon-drug-cf:before {content: "\e900"}.icon-vit:before {content: "\e904"}.icon-map:before {content: "\e600"}.icon-toc-arrow:before {content: "\e909"}/*** Font ***/@font-face {font-family: 'Open Sans';font-style: normal;font-display: swap;font-weight: 400;src: local(''), url('https://images.rxlist.com/fonts/open-sans-v20-latin/open-sans-v20-latin-regular.woff2') format('woff2'), url('https://images.rxlist.com/fonts/open-sans-v20-latin/open-sans-v20-latin-regular.woff') format('woff')}@font-face {font-family: 'Open Sans';font-style: normal;font-display: swap;font-weight: 600;src: local(''), url('https://images.rxlist.com/fonts/open-sans-v20-latin/open-sans-v20-latin-600.woff2') format('woff2'), url('https://images.rxlist.com/fonts/open-sans-v20-latin/open-sans-v20-latin-600.woff') format('woff')}/*** Normalize ***/html {line-height: 1.15;-webkit-text-size-adjust: 100%}body {margin: 0}main {display: block;max-width:1250px;width: calc(100vw - 80px);margin: 0 auto;}h1 {font-size: 2em;margin: 0.67em 0}hr {box-sizing: content-box;height: 0;overflow: visible}pre {font-size: 1em}a {background-color: transparent}abbr[title] {border-bottom: none;text-decoration: underline;text-decoration: underline dotted}b,strong {font-weight: bolder}code,kbd,samp {font-size: 1em}small {font-size: 80%}sub,sup {font-size: 75%;line-height: 0;position: relative;vertical-align: baseline}sub {bottom: -0.25em}sup {top: -0.5em}img {border-style: none}button,input,optgroup,select,textarea {font-size: 100%;line-height: 1.15;margin: 0}button,input {overflow: visible}button,select {text-transform: none}button,[type="button"],[type="reset"],[type="submit"] {-webkit-appearance: button}button::-moz-focus-inner,[type="button"]::-moz-focus-inner,[type="reset"]::-moz-focus-inner,[type="submit"]::-moz-focus-inner {border-style: none;padding: 0}button:-moz-focusring,[type="button"]:-moz-focusring,[type="reset"]:-moz-focusring,[type="submit"]:-moz-focusring {outline: 1px dotted ButtonText}fieldset {padding: 0.35em 0.75em 0.625em}legend {box-sizing: border-box;color: inherit;display: table;max-width: 100%;padding: 0;white-space: normal}progress {vertical-align: baseline}textarea {overflow: auto}[type="checkbox"],[type="radio"] {box-sizing: border-box;padding: 0}[type="number"]::-webkit-inner-spin-button,[type="number"]::-webkit-outer-spin-button {height: auto}[type="search"] {-webkit-appearance: textfield;outline-offset: -2px}[type="search"]::-webkit-search-decoration {-webkit-appearance: none}::-webkit-file-upload-button {-webkit-appearance: button;font: inherit}details {display: block}summary {display: list-item}template {display: none}[hidden] {display: none}/*** Owl Carousel (core) ***/.owl-carousel {display: none;width: 100%;-webkit-tap-highlight-color: transparent;position: relative;z-index: 1}.owl-carousel .owl-stage {position: relative;-ms-touch-action: pan-Y;touch-action: manipulation;-moz-backface-visibility: hidden}.owl-carousel .owl-stage:after {content: ".";display: block;clear: both;visibility: hidden;line-height: 0;height: 0}.owl-carousel .owl-stage-outer {position: relative;overflow: hidden;-webkit-transform: translate3d(0px, 0px, 0px)}.owl-carousel .owl-wrapper,.owl-carousel .owl-item {-webkit-backface-visibility: hidden;-moz-backface-visibility: hidden;-ms-backface-visibility: hidden;-webkit-transform: translate3d(0, 0, 0);-moz-transform: translate3d(0, 0, 0);-ms-transform: translate3d(0, 0, 0)}.owl-carousel .owl-item {position: relative;min-height: 1px;float: left;-webkit-backface-visibility: hidden;-webkit-tap-highlight-color: transparent;-webkit-touch-callout: none}.owl-carousel .owl-item img {display: block;width: 100%}.owl-carousel .owl-nav.disabled,.owl-carousel .owl-dots.disabled {display: none}.owl-carousel .owl-nav .owl-prev,.owl-carousel .owl-nav .owl-next,.owl-carousel .owl-dot {cursor: pointer;-webkit-user-select: none;-khtml-user-select: none;-moz-user-select: none;-ms-user-select: none;user-select: none}.owl-carousel .owl-nav button.owl-prev,.owl-carousel .owl-nav button.owl-next,.owl-carousel button.owl-dot {background: none;color: inherit;border: none;padding: 0 !important;font: inherit}.owl-carousel.owl-loaded {display: block}.owl-carousel.owl-loading {opacity: 0;display: block}.owl-carousel.owl-hidden {opacity: 0}.owl-carousel.owl-refresh .owl-item {visibility: hidden}.owl-carousel.owl-drag .owl-item {-ms-touch-action: none;touch-action: none;-webkit-user-select: none;-moz-user-select: none;-ms-user-select: none;user-select: none}.owl-carousel.owl-grab {cursor: move;cursor: grab}.owl-carousel.owl-rtl {direction: rtl}.owl-carousel.owl-rtl .owl-item {float: right}.no-js .owl-carousel {display: block}.owl-carousel .owl-item .owl-lazy {opacity: 0;transition: opacity 400ms ease}.owl-carousel .owl-item img.owl-lazy {transform-style: preserve-3d}/*** Common ***/html {font-family: 'Open Sans', sans-serif;font-size: 17px;font-weight: 400;color:#232323;}b,strong,optgroup,h1,h2,h3,h4,h5,h6 {font-weight: 600;}h1{font-size:55px;line-height:57px;}h2{font-size:26px;line-height:30px;}h3{font-size:20px;line-height:30px;}h4{font-size:20px;line-height:30px;margin:5px 0px;}p{line-height:25.5px;font-size:17px;margin:5px 0px;}a {color: #2196f3;text-decoration: none;cursor: pointer}a:hover {text-decoration: underline}::-moz-selection {background: #000;text-shadow: none;color: #fff}::selection {background: #000;text-shadow: none;color: #fff}a[data-title]:hover:before {content: attr(data-title);padding: 4px 8px;color: #fff;position: absolute;z-index: 9999;border-radius: 3px;background: #333;font-size: 12px;margin: 35px 15px 0 0;line-height: normal}.apPage h2, #apPage h2 {border-left: 5px solid #2196f3;padding: 5px 10px;}#backTop {display: none;position: fixed;right: 20px;top: calc(100vh - 60px);z-index: 49}#backTop .icon-arrow-right2:before{background: #2196F3;    border-radius: 50px;    box-shadow: 0px 4px 4px rgb(0 0 0 / 25%);color:#fafafa;padding:7px;} #backTop span {color: #232323;font-size: 36px;padding: 3px;transform: rotate(-90deg);display: block;transition: all 250ms}#backTop span:hover {cursor: pointer;color: #fff;}main ::-webkit-scrollbar-track {-webkit-box-shadow: inset 0 0 5px rgba(0, 0, 0, 0.3);background: #f4f4f4}main ::-webkit-scrollbar {width: 5px;background: #f4f4f4}main ::-webkit-scrollbar-thumb {background: #000}.sc-modal button {color: #fff;font-size: 14px;font-weight: normal;line-height: normal;text-decoration: none;text-transform: uppercase;text-align: center;padding: 17px;margin: 15px 0;background: #2196f3;width: 250px;border: none;outline: none;display: inline-block;position: relative;z-index: 1;overflow: hidden}.sc-modal button:hover {text-decoration: none;cursor: pointer}.sc-modal button:after {content: "";background: #000;position: absolute;z-index: -1;left: 0;right: 0;top: -100%;bottom: 100%;transition: all 250ms}.sc-modal button:hover:after {left: 0;right: 0;top: 0;bottom: 0}.stickyColLeft {display: none}.icon-arrow-left2:before {content: "\e605";display: inline-block;transform: rotate(180deg)}.w-full {width: 100%}/*** AD ***/body>header.fixed {margin-top: 100px}.adTopWrapper {border-bottom: #e2e2e2 solid 1px;width: 100%;min-height: 100px;z-index: 1;position: relative;background-color: #fff;position: sticky;top: 68px;}.adTopWrapper #bannerAd_rdr,.ad-slot.content-ads {background: url(https://images.rxlist.com/images/ads/1atopbannerside.gif) no-repeat 0 center;margin: 0 auto;padding: 5px 10px;position: relative;display: table}.adTopWrapper #bannerAd_fmt {padding: 4px;border: 1px solid #ccc;min-width: 738px;min-height: 90px}#rightAd_rdr:after,#leftAd_rdr:after {content: '';background: url(https://images.medicinenet.com/images/ads/rightad_toptransparent.gif) no-repeat center 0;height: 10px;display: block}.rightAd_BG_fmt {width: 300px;min-height: 250px;padding: 0px;border: 1px solid #ddd}.leftAd_BG_fmt {width: 160px;min-height: 600px;padding: 4px;border: 1px solid #ddd}.leaderboard_fmt {background: url(https://images.medicinenet.com/images/ads/1atopbannerside.gif) no-repeat 0 20px;width: 738px;margin: 30px auto;padding: 16px 10px;clear: both}.leaderboard_fmt>div {padding: 4px;border: 1px solid #ddd;width: 728px;height: 90px}.ad-slot.content-ads {min-height: 90px;min-width: 748px;}/*** Modal ***/.innerBox iframe {position: absolute;top: 0;left: 0;padding: 0;margin: 0;border: 0}.modalBox .logo {text-indent: -9999px;margin-top: -33px;background: url(https://images.rxlist.com/images/mobile/rxlist/logo-rxl-reverse.png) no-repeat 0 2px/130px 24px}.modalClose:after {content: "\e624";font-family: 'icomoon';font-size: 28px;right: 0;top: -38px;z-index: 1;position: absolute;color: #FFF;padding: 4px 6px;line-height: 30px}.modalClose:hover:after {color: #47638D}.modalBox {border-top: 38px solid #6896DA;box-shadow: 0 0 15px #000;background: #fff;z-index: 99999999;position: absolute}.modalBox>a {text-decoration: none}.blockPage {position: absolute;top: 0;left: 0;background: rgba(0, 0, 0, 0.6);z-index: 99999998}.innerBox a {background: #47638D !important}.innerBox a:hover {background: #000 !important}.sc-modal {text-align: center;position: fixed;top: 0;right: 0;bottom: 0;left: 0;background: rgba(0, 0, 0, .8);overflow: auto;overscroll-behavior: contain;z-index: 1000000}.sc-modal-dialog {max-height: 80vh;max-width: 80vw;min-width: 300px;background: #fff;padding: 30px;position: absolute;top: 50%;left: 50%;transform: translate(-50%, -50%)}.sc-modal-title {display: none}.sc-modal .close {color: #232323;font-size: 26px;line-height: 20px;text-decoration: none;padding: 5px;border: 1px solid #ccc;background: rgba(255, 255, 255, .9);right: 10px;top: 10px;position: absolute;transition: all 250ms}.sc-modal .close:hover {cursor: pointer;color: #fff;background: #000;border-color: #000;text-decoration: none}.sc-modal h3 {font-size: 17px;font-weight: 400;line-height: 24px}/*** Module ***/.extra .from_webmd {width: 65%}.from_webmd {margin: 40px auto;border-collapse: separate;border-spacing: 5px;border-radius: 10px;background: #E4F3FA;padding: 20px;}.from_webmd h2, .from_webmd h3 {letter-spacing: 1px;margin: 0;text-decoration: none !important;font-size: 26px;padding-bottom: 10px;border-bottom: 1px solid #000;}.from_webmd .logoTitle {height: 18px;margin-top: -5px}.from_webmd .content {display: flex}.from_webmd .wrapper {padding-right: 24px;flex-grow: 1;}.from_webmd h5 {font-size: 18px;color: #000;line-height: 16px;margin: 10px 0;}.from_webmd .content ul {padding: 0;margin: 0;list-style: none}.from_webmd ul li {padding: 10px 0;line-height: 15px}.from_webmd ul li a {font-size: 15px}.webmdrx a {background: #1D72A8;border-radius: 3px;padding: 5px 15px;text-align: center;display:inline-block;transition: background 250ms}.webmdrx p {font-size: 14px;color: #fff;margin: 0}.webmdrx_img {background: url(https://images.rxlist.com/images/rxlist/webmdrx-btn.png) 0 0 no-repeat;width: 91px;height: 15px;float: right;margin: 5px 0 0 6px}.webmdrx a:hover {background: #000;text-decoration: none}/*** Header ***/body.freeze {position: fixed;overflow-y: scroll;width: 100%}body>header:after {content: '';background: rgba(0, 0, 0, 0);width: 100%;height: 100vh;position: fixed;top: 50px;z-index: -1;transition: all 400ms}body.freeze>header:after,body>header.miniMenu:after {background: rgba(0, 0, 0, .7);z-index: 9999}.masterhead {height: 65px;background: #fff;border-bottom: 1px solid #ddd;z-index: 999999;position: relative;margin: 0}.masterhead .wrapper {position: relative}.masterhead .menu>span {padding: 18px;font-size: 29px;display: inline-block;cursor: pointer;transition: color 250ms}.masterhead .menu>span:hover,.masterhead .search button:hover {color: #2196f3}.masterhead .logo {top: 18px;left: 55px;position: absolute}.masterhead .search {top: 0;right: 90px;position: absolute}.masterhead .search button {border: none;background: transparent;outline: none;font-size: 19px;color: #232323;padding: 24px 8px 18px;transition: color 250ms;cursor: pointer}.masterhead .search button .icon-close {font-size: 26px;margin: -4px;display: block}.masterSub,.searchBar {background: #fff;width: 100%;top: -100vh;z-index: 99999;position: fixed;transition: .4s top ease}.masterSub {overflow-x: hidden}.masterSub.on,.searchBar.on {top: 175px}.masterSub nav {max-width: 1645px;min-width: 843px;height: 45vh;padding: 18px 0 55px;}.masterSub nav .wrapper {width: 35%;margin: 0 20px;float: left}.masterSub nav .wrapper h3 {border-bottom: 1px solid #ddd;padding: 5px 8px}.masterSub nav a {color: #232323;font-size: 16px;text-decoration: none;padding: 10px;display: block;transition: all 250ms}.masterSub nav .trustBadge {position: static;border: none}.masterSub nav .trustBadge .icon-shield {display: none}.masterSub nav a:hover {background: #000;color: #fff}.masterSub .stack .icon-arrow-right2 {vertical-align: middle}.masterSub .stack .sideBar {background: #6896DA;width: calc(100vw - 350px);height: 45vh;top: 0;left: 100vw;padding: 30px;z-index: 99999;position: absolute;transition: .3s left ease}.masterSub .stack.on {background: #6896DA;transition: all 250ms}.masterSub .stack.on a {color: #fff}.masterSub .stack.on a:hover {background: none}.masterSub .stack.on .sideBar {left: calc(100vw - 40%)}.masterSub .stack .sideBar a {color: #fff;width: 300px}.masterSub .stack .sideBar a:hover {background: #fff;color: #000}.socialWrapper {top: 22px;right: 20px;position: absolute}.socialWrapper li {list-style: none;float: left}.socialWrapper li a {color: #232323;font-size: 20px;padding: 20px 8px 19px;transition: all 250ms;cursor: pointer}.socialWrapper li a:hover {color: #2196f3;text-decoration: none}.socialWrapper a[data-title]:hover:before {right: -15px}.sc-searchbox {position: relative}.sc-searchbox .sc-searchbox-input-wrapper {display: flex}.sc-searchbox .sc-searchbox-input {flex-grow: 1}.sc-searchbox .sc-searchbox-list {position: absolute;width: 100%;z-index: 50;background: #fff;box-sizing: border-box}.sc-searchbox .sc-searchbox-list .sc-searchbox-list-item.sc-searchbox-item-active {background: #f5f5f5}.nav-search.sc-searchbox .sc-searchbox-form {padding: 125px 20%}.nav-search.sc-searchbox .sc-searchbox-input {font-size: 18px;padding: 12px 20px;border: none;outline: none;background: #f5f5f5}.nav-search.sc-searchbox .sc-searchbox-input:focus {background: #000;color: #fff}.nav-search.sc-searchbox .icon-search:before {display: none}.nav-search.sc-searchbox .sc-searchbox-button {padding: 7px 25px;font-weight: 600;background: #6896DA;color: #fff;outline: none;border: none;transition: all 250ms}.nav-search.sc-searchbox .sc-searchbox-button:hover {background: #000 !important}.nav-search.sc-searchbox .sc-searchbox-list {background: #fff;padding: 6px;border: 1px solid #ddd;border-top: none;color: #232323;width: 60%;z-index: 1000}.nav-search.sc-searchbox .sc-searchbox-list .sc-searchbox-list-item.sc-searchbox-item-active {background: #000;color: #fff;cursor: pointer}.nav-search.sc-searchbox .sc-searchbox-list-item {padding: 5px 8px;border-radius: 3px}/*** Footer ***/#sponsors {margin: 40px auto;padding: 20px;clear: both;max-width: 1250px;width: calc(100vw - 80px);}.hstitle {font-size: 26px;font-weight: 600;margin: 0 0 15px 0}.hstitle span {font-size: 14px;font-weight: 400}#sponsors .wrapper ul {list-style: none;padding: 0;margin: 0;column-count: 3;column-gap: 50px}#sponsors .wrapper li {font-size: 13px;line-height: 15px;padding: 5px 0;break-inside: avoid}#sponsors .wrapper li a {color: #2196f3;text-decoration: none;cursor: pointer;word-break: break-word}#sponsors .wrapper li a:hover {text-decoration: underline}footer {max-width: 1250px;margin: 130px auto 50px;padding: 0 20px;position: relative;width: calc(100vw - 80px);}footer .social-section {list-style: none;margin: 0;padding: 0;top: -40px;right: 30px;position: absolute}footer .social-section li {float: left}footer .social-section li a {color: #232323;font-size: 20px;padding: 8px;cursor: pointer;transition: all 250ms}footer .social-section li a:hover {color: #2196f3;text-decoration: none}footer .social-section a[data-title]:hover:before {right: 0}footer nav {padding: 20px 0 40px;border-top: 2px solid #ddd;border-bottom: 2px solid #ddd;display: flex;justify-content: space-between}footer .col {width: 26%}footer .col ul {list-style: none;margin: 0;padding: 0}footer .col li a {color: #666;font-size: 13px;line-height: 14px;text-decoration: none;padding: 6px 0;display: block}footer .col li a:hover {text-decoration: underline}footer .footerCopy {display: flex;justify-content: space-between}footer .badge {padding: 10px 0}footer .copyright {text-align: right;margin: 10px 0}footer .ccpaFtrLnk {font-size: 12px;color: #2196f3}footer .copyright p {font-size: 12px;line-height: 15px;width: 430px;margin: 5px 0}footer .copyright p a {color: #232323;text-decoration: underline}/*** HP ***/.promoSearch:after,.news_hp:after,.topRx:after {content: "";position: absolute;width: 20px;height: 40px;left: 0;bottom: -40px;border-radius: 10px 0 0 0;box-shadow: 0 -20px 0 0 #d5edfc;background: transparent}.promoSearch:after {box-shadow: 0 -20px 0 0 #0171bb}.news_hp:before,.topRx:before {content: "";position: absolute;width: 20px;height: 40px;left: 0;top: -40px;border-radius: 0 0 0 10px;box-shadow: 0 20px 0 0 #d5edfc;background: transparent}.promoSearch,.shortcut,.news_hp,.AdWrapper,.topRx,.media {padding: 40px 5vw;text-align: center;position: relative}.news_hp h2,.topDrug h2,.topRx h2,.media h2 {font-size: 30px;padding-bottom: 15px;text-transform: uppercase}.shortcut a,.news_hp a,.topDrug a,.topRx a,.media a {color: #232323;transition: 250ms all}.promoSearch {background: #0171bb;border-radius: 0 0 10px 0}.promoSearch img {width: 300px;height: 200px;margin-bottom: 20px}.promoSearch .sc-searchbox .sc-searchbox-input-wrapper {position: relative;z-index: 51}.promoSearch .sc-searchbox input {font-size: 15px;padding: 0 45px 0 20px;border-radius: 10px;border: 0;outline: 0;height: 50px}.promoSearch .sc-searchbox button {font-size: 18px;color: #0171bb;background: transparent;border: 0;outline: 0;position: absolute;right: 15px;top: 16px}.promoSearch .sc-searchbox .sc-searchbox-list {position: absolute;top:45px;padding: 70px 10px 15px 10px;z-index: 50;background: #000;text-align: left;border-radius: 10px;border-top-left-radius: 0px;border-top-right-radius: 0px;}.promoSearch .sc-searchbox .sc-searchbox-list-item {color: #fff;padding: 10px}.promoSearch .sc-searchbox .sc-searchbox-list .sc-searchbox-list-item.sc-searchbox-item-active {background: #fff;color: #232323;cursor: pointer}.promoSearch p {color: #fff;font-size: 14px}.promoSearch p a {color: #adf;font-size: 14px;text-decoration: underline;transition: 250ms all}.promoSearch p a:after {content: ',';display: inline-block}.promoSearch p a:last-child:after {display: none}.promoSearch p a:hover {color: #fff}.shortcut {display: flex;flex-wrap: wrap;justify-content: center}.shortcut a {font-size: 16px;font-weight: 600;background: #d5edfc;border-radius: 10px;padding: 20px 15px 20px 50px;margin: 5px;width: 100px;height: 40px;text-align: left;position: relative;display: flex;align-items: center}.shortcut span {color: #2196f3;font-size: 25px;top: 28px;left: 14px;position: absolute;transition: 250ms all}.shortcut a:hover,.news_hp .wrapper a:hover,.topDrug .az li a:hover,.media .wrapper a:hover,#A_Z li a:hover {background: #000;color: #fff;text-decoration: none}.shortcut a:hover *,.news_hp .wrapper a:hover *,.media .wrapper a:hover * {color: #fff}.news_hp,.topRx {background: #d5edfc;border-radius: 0 10px 10px 0}.news_hp .wrapper a {text-align: left;border-radius: 10px;height: 85px;padding: 20px;margin-bottom: 14px;background: #fff;display: block}.news_hp .wrapper span {color: #2196f3;font-size: 12px;font-weight: bold;line-height: 12px;text-transform: uppercase;display: block;transition: 250ms all}.news_hp .wrapper h3 {font-size: 16px;line-height: 20px;margin: 10px 0}.news_hp .wrapper .timestamp {color: #999;font-size: 12px;transition: 250ms all}main#HP .AdWrapper #rightAd_rdr {position: absolute;right: 5vw;top: auto;bottom: 90px}.topDrug .az ul,#A_Z ul {list-style: none;padding: 0;display: flex;flex-wrap: wrap;justify-content: center}.topDrug .az li,#A_Z li {margin: 6px;padding: 0 !important}.topDrug .az li a,#A_Z li a {color: #fff;font-size: 24px;font-weight: 600;line-height: 40px;border-radius: 100%;padding: 5px;width: 40px;height: 40px;background: #e5e5e5;display: inline-block;transition: all 250ms}.topDrug .az li a.active,#A_Z li a.active {background: #2196f3}.topDrug .azList {height: 300px;width: calc(100% - 340px);margin: 40px 0;overflow-y: auto;position: relative}.topDrug .azList ul {display: none;list-style: none;margin: 20px;padding: 0;column-count: 2;column-gap: 30px;text-align: left;width: calc(100% - 40px);position: absolute}.topDrug .azList #list-azA {display: block}.topDrug .azList li {border-bottom: 1px dotted #ddd;padding: 0 !important;width: 100%;display: inline-block}.topDrug .azList li a {color: #2196f3;font-size: 16px;padding: 8px 0;display: block}.topRx ul {list-style: none;margin: 0;padding: 0;text-align: left;column-count: 2;column-gap: 50px}.topRx li {padding: 0 !important;border-bottom: 1px solid #f1f6f9;display: flex;align-items: center}.topRx li:before {content: "\e605";font-family: 'icomoon';color: #fff;font-size: 14px;line-height: 16px;width: 15px;height: 15px;background: #2196f3;border-radius: 100%}.topRx li a {font-size: 16px;padding: 8px;width: 100%;min-height: 38px;display: flex;align-items: center}.media #leftAd_rdr {position: absolute}.media .container {margin-left: 200px}.media .wrapper a {text-align: left;background: #d5edfc;border-radius: 10px;margin-bottom: 14px;display: block;height: 70px;padding: 10px}.media .wrapper img {border-radius: 10px;width: 70px;height: 70px;position: absolute}.media .wrapper h3 {font-size: 16px;line-height: 18px;margin: 10px 0 10px 80px}/*** Article ***/.rxArt main {display: flex;}.rxArt main#HP,.rxArt.imgcol main {display: table;width: 100%}.story {margin: 0;max-width: 950px;}.story .share {float: right;margin-top: -32px}.story article {font-size: 16px;padding: 5px 0}.story article a:hover {text-decoration: underline}.story article .alert {background: #ed1c24;font-size: 12px;color: #fff;padding: 5px 10px;border-radius: 30px;font-weight: 600;text-transform: uppercase;display: inline-block}.story article h3 {text-decoration: underline;text-transform: uppercase}.monograph_sum{width:auto;border: 2px solid #59A3DD;    border-radius: 6px;margin-bottom: 25px;}.monograph_header{background: #F1F8FC;    border-radius: 3px 3px 0px 0px;padding:1px 10px;font-size:17px;line-height:26px;}.monograph_header h2.monograph_source{line-height: 20px;}.monograph_date{float:right;}.monograph_cont{padding:15px;}.drug_fda{  padding-top: 15px;  padding-bottom:10px;  background-image: linear-gradient(to right, #232323 40%, rgba(255, 255, 255, 0) 20%);  background-position:bottom;  background-size: 17px 1px;  background-repeat: repeat-x;}.drug_review_btn{background: #0171BB;border-radius: 3px;}.story article ul {margin: 30px 0}.story article ul li,.story article ol li, .monograph_cont ul li {padding: 8px 0;line-height: 22px;break-inside: avoid}.story .pageSection {margin: 60px 0}.story .pageSection:first-child {margin-top: 20px}.story .pageSection .clear {clear: none}#apPage h5 {font-size: 15px}.bookmark {display: block;position: relative;top: -230px}#apPgNum {font-size: 18px;font-weight: 600;text-align: left;color: #333333;padding: 5px 10px;margin-bottom: 25px;border-left:5px solid #2196f3;}#apPgNum span{font-size:26px;line-height:30px;}.rxArt.pgcon #apPgNum {background: #92A74E}.rxArt.pgsideeffect #apPgNum {background: #F3614D}.slide-viewpoert {margin-bottom: 25px}.monomodmsg {font-size: 14px;text-align: right;margin: 10px 0}/**.rxArt .stickyColLeft,.rxArt .stickyColRight{padding:0px 20px}**/.rxArt #rxlistAD160,.rxArt #rightAd_rdr {position: sticky;position: -webkit-sticky;top: 182px}.story .driver {display: inline-block;font-size: 18px;font-weight: 600}.story .btn_driver a {display: inline-block;color: #fff;padding: 6px 40px;border-radius: 3px;background: #2196f3;transition: background 250ms}.story .btn_driver a:hover {text-decoration: none;background: #000}.story .Red,.story .final {color: #f00;text-transform: uppercase;font-size: 16px;font-weight: 600}#Disc_Warning {border-radius: 12px;padding: 15px 20px;margin: 20px 0 -40px 0;line-height: 17px;font-size: 16px;font-weight: 600;text-transform: uppercase;color: #fff;background: #da1b23}.pgContent .blackBorderBox_fmt {    border-radius: 6px;    padding: 25px;    background: #F9F4F4;margin:20px 0;}.blackBorderBox_fmt b{font-weight:400;line-height:26px;}.blackBorderBox_fmt p:nth-child(2)>b{color: #DB5757;    font-size: 20px;    font-weight: 600;    line-height: 30px;    text-align: center;}.mnvit_copy {margin: 20px 0;width: 100%;max-width: 470px}.pgContent center {overflow-x: auto}.pgContent .artTable,.pgContent .blacktbl,.pgContent .blackpic {width: 100%;margin-bottom: 10px;border-spacing: 0;text-align: center;table-layout: fixed}.pgContent .artTable tr td:nth-child(odd),.pgContent .blacktbl tr td:nth-child(odd) {background: #eee}.pgContent .artTable tr td:first-child,.pgContent .blacktbl tr td.EmphTd {border-left: 1px solid #989898;text-align: center;background: #555;color: #fff;font-weight: 600}.pgContent .artTable tr td,.pgContent .blacktbl tr td {font-size: 12px;padding: 5px;border-bottom: 1px solid #e0e0e0;border-top: none}.pgContent .blackpic img {width: auto;height: auto;max-width: 100%}#forPatients {margin: 20px 0}#forPatients .forPatientsHdr {margin: 0;padding: 5px;text-align: center;border-radius: 3px 3px 0 0;background: #92A74E;color: #fff;font-size: 18px}#forPatients .forPatientContent {padding: 0 25px 25px 25px;border: 1px solid #92a74e}#fdaWrapper {background: #003152;color: #fff;margin: 30px auto;max-width: 715px}#fdaWrapper img {padding: 25px;position: absolute}#fdaWrapper h3 {padding: 15px;margin: 0 0 0 190px;font-size: 19px;line-height: 24px;border-left: 1px solid #4d6f86;text-decoration: none}#fdaWrapper p {padding: 11px 15px;font-size: 12px;margin: 0 0 0 190px;border-left: 1px solid #4d6f86}#fdaWrapper p a {color: #fff;text-decoration: underline}.medianet {margin: 50px auto}.story .fdbTerms {border-radius: 5px;padding: 15px 20px;margin: 20px 0;background: #000}.story .fdbTerms a {font-size: 14px;display: inline-block;color: #fff}.consumerHeading {font-weight: 600;display: block;margin: 30px 0 5px}.continue_reading {font-weight: 600;color: #6cc2ff;margin: 50px auto;text-align: center;display: table}.continue_reading:before,.continue_reading:after {content: '.............';font-size: 15px;color: #ccc;top: -5px;letter-spacing: 2px;position: relative;display: table-cell}.story #sponsors .wrapper ul {column-count: 2}.apPageBottom {border-top: 1px solid #ccc;margin: 40px 0}.apPageBottom #refs {font-size: 14px;font-style: italic;margin: 10px 0;color: #2196f3}.apPageBottom #refs .icon-search {font-size: 12px;color: #F26522;padding: 0 4px;vertical-align: middle;display: inline-block}.apPageBottom #refs:hover {cursor: pointer;text-decoration: underline}.apPageBottom #refStash {display: none;background: #eee;padding: 20px;margin-bottom: 20px;font-size: 12px}.lastreviewed {margin: 10px 0;font-size: 14px;color: #777}.story .source,.story .credit,.story .disclaimer,.story .Sizeminus {font-size: 12px}.otherNames p {font-size: 14px}/*** Article (hero) ***/.wrapper-hero {padding: 30px 2% 10px;position: relative;margin: 0;}.wrapper-hero .hero h1,.pageWrapper h1 {text-transform: uppercase;margin: 45px 0 15px}.story .slideshow h1 {font-size: 42px}.wrapper-hero .hero ul {margin: 0;padding: 0}.wrapper-hero .hero ul li {list-style: none;line-height: 26px;padding: 2px 0;}.wrapper-hero .hero ul li[itemprop="name"] span {font-weight: 400}.wrapper-hero .hero ul li[itemprop="name"] a {color: #2196f3}.wrapper-hero .hero .drug_name {margin: 5px 0 10px -22px}.wrapper-hero .hero .drug_name [class^="drug"] {padding: 8px 12px;margin: 0 10px;display: inline-block;position: relative}.wrapper-hero .hero .drug_name [class^="drug"]:after {content: " | ";color: #aaa;position: absolute;right: -13px}.wrapper-hero .hero .drug_name span:last-of-type:after {display: none}.wrapper-hero .hero .drug_name [class^="drug"] a {color: #2196f3;font-size: 18px;line-height: 22px;text-decoration: none;display: inline-block}.wrapper-hero .hero .drug_name [class^="drug"] a:hover {text-decoration: underline}.wrapper-hero .monolastreviewed,.wrapper-hero .reviewer,.wrapper-hero .reviewdate {    line-height: 26px;padding: 5px 0 10px;}.wrapper-hero .monolastreviewed a {color: #232323;margin-right: 10px}.wrapper-hero .monolastreviewed i {font-style: normal}.wrapper-hero .hero ul+p {color: #fff;font-size: 14px;background: #333;text-align: center;padding: 5px 0;width: 150px}.author a {color: #2196f3;text-decoration: none}.author a:hover {text-decoration: underline}.breadcrumbs {color: #777777;font-size: 14px;line-height: 16px;width: 95%;top: 20px;position: absolute;text-transform: uppercase}.breadcrumbs a {color: #2196f3;font-size:14px;line-height:16px;}.breadcrumbs a:after {font-family: 'icomoon';content: "\e605";padding-left: 4px;display: inline-block;vertical-align: middle;color: #232323;}.trustBadge {color: #4CAF50;font-size: 14px;padding: 6px 10px 5px 35px;margin: 10px 0;border: 1px solid #4CAF50;position: relative;display: inline-block;transition: all 250ms;display:none;}.trustBadge .icon-shield {font-size: 19px;color: #4CAF50;position: absolute;left: 8px;top: 5px;transition: all 700ms}.trustBadge:hover {text-decoration: none;background: #000;color: #fff;border-color: #fff;cursor: pointer}.trustBadge:hover .icon-shield {color: #fff}.trustBadgeContent {text-align: center;padding: 30px}.trustBadgeContent ul {padding: 0;margin: 0;display: inline-block}.trustBadgeContent li {float: left;list-style: none}.trustBadgeContent .trustLink {margin: 20px 0}.trustBadgeContent .trustLink li:before {content: "|";padding: 0 10px}.trustBadgeContent .trustLink li:first-child:before {display: none}.trustBadgeContent .trustLink a {color: #2196f3;font-size: 16px;text-decoration: none}.trustBadgeContent .trustLink a:hover {text-decoration: underline}.trustBadgeContent .badge {display: block;margin: 15px auto;width: 340px;height: 60px}.trustBadgeContent p {font-size: 12px;margin: 5px 0}.trustBadgeContent p a {color: #2196f3}.drugDropdown {height: 30px;list-style: none;margin: 10px 0 16px;padding: 0}.drugDropdown li {float: left;}.drugDropdown li>a {text-decoration: none;background: #F1F5F7;margin-right: 15px;padding: 7px 10px;display: inline-block;position: relative;border-radius: 3px;    width: 160px;    color: #2196F3;white-space: nowrap;font-size: 15px;}.drug_review_btn a{background: none !important;color:#ffffff !important;}.drugDropdown .drugSelect {padding: 6px 25px 6px 10px;}.drugDropdown .drugSelect:after {font-family: 'icomoon';    content: "\e605";    font-size: 27px;    position: absolute;    top: -1px;    right: 1px;    transform: rotate(90deg);    background: #DBEBF8;    color: #2196F3;    width: 29px;    height: 31px;    text-align: center;}.drugDropdown a.prof:hover,.drugDropdown a.sideEffect:hover{background: #555;color: #fff}.drugDropdown .drugOption {display: none;position: absolute;border-radius: 0px 3px 3px 3px;    margin:0;background: #EAF4FC;z-index: 9;max-height: 40vh;width: 194px;overflow-y: auto;box-shadow: 0 6px 4px -4px #ccc;font-size: 15px;}.drugDropdown li:hover .drugSelect {background: #EAF4FC;border-radius: 3px 3px 0px 0px;}.drugDropdown li:hover .drugSelect:after{background: #2196F3;transform: rotate(270deg);color:#ffffff;line-height:35px;border-radius: 0px 0px 3px 3px;}.drugDropdown li:hover .drugOption {display: block;}.drugDropdown .drugOption a {display: block;line-height: 30px;text-decoration: none;padding: 8px 10px}.drugDropdown a.sideEffect {background: #F3614D;color: #fff;display:none;}.drugDropdown a.prof {background: #47638D;color: #fff;}.drugOption::-webkit-scrollbar-track {box-shadow: inset 0 0 6px rgba(0, 0, 0, 0.3);background: #fafafa}.drugOption::-webkit-scrollbar {width: 3px;background: #fafafa}.drugOption::-webkit-scrollbar-thumb {background: #000}.drugOption::-webkit-scrollbar-thumb:hover {background: #2196f3}/*** Article (submenu) ***/.submenu .icon-menu {display: none}.submenu .tab {border-bottom: 5px solid #eee}.submenu .tab a {color: #47638D;font-size: 18px;font-weight: 600;padding: 10px 12px;margin-bottom: -7px;text-decoration: none;height: 32px;border-bottom: 5px solid #eee;display: inline-block;opacity: .3;transition: all 250ms}.submenu .tab a.con {color: #92A74E}.submenu .tab a.sideEffect {color: #F3614D}.submenu .tab a.active {cursor: default}.submenu .tab a.prof.active,.submenu .tab a.prof:hover {border-bottom: 5px solid #47638D;opacity: 1}.submenu .tab a.con.active,.submenu .tab a.con:hover {border-bottom: 5px solid #92A74E;opacity: 1}.submenu .tab a.sideEffect.active,.submenu .tab a.sideEffect:hover {border-bottom: 5px solid #F3614D;opacity: 1}.submenu .tab a span {font-size: 32px;margin-right: 8px;vertical-align: -32%}.submenu .tab a .icon-pro {font-size: 26px}.submenu .toc.link {    background: #F1F8FC;    border-radius: 6px 6px 0px 0px;    padding: 0px 16px 0px 16px;}.submenu .icon-menu:before {margin-right:20px;}.submenu .icon-menu:after{content: url("https://images.rxlist.com/images/mobile/rxlist/logo-rxl.png");background-repeat: no-repeat;margin-left:20px;}.submenu .toc.link ul {padding: 0;margin: 5px 0 0px -6px;list-style: none;display: inline-block}.submenu .toc.link ul li {padding: 0;float: left;}/* .submenu .toc.link li.active a {    background: #2196F3;    color: #ffffff;    border-radius: 3px;} */.submenu .toc.link a {color: black;line-height: 25.5px;text-decoration: none;padding: 6px 6px;margin: 0 6px;display: inline-block;position: relative;}.submenu .toc.link a:hover {color: #2196f3;}.submenu .toc.link a:after {content: " | ";color: #aaa;position: absolute;right: -13px}.submenu .toc.link li:last-child a:after {display: none}.submenu .toc.link a:hover {text-decoration: underline}.miniMenu .masterSub {top: 50px}/*.miniTitle .hero h1 {position: fixed;top: -33px;left: 70px;font-size: 24px !important;line-height: 26px;width: calc(100% - 650px);white-space: nowrap;overflow: hidden;text-overflow: ellipsis;z-index: 9999999;transition: all 250ms}*/.submenu.stuck h2.drug_fda {    display: none;}/* .submenu.stuck {position: fixed;top: -150px;left: 0;right: 0;background: #fff;box-shadow: 0 1px 5px 0 #ccc;height: 50px;z-index: 999999}.submenu.stuck>span[class*="icon-"] {color: #2196f3;display: block;padding: 0 20px;font-size: 30px;cursor: pointer;line-height: 50px;position: absolute} */.submenu.stuck>span[class*="icon-"]:hover {color: #232323;}.submenu.stuck .tab {border: none;right: 10px;position: absolute}.submenu.stuck .tab a {display: none;font-size: 16px;line-height: 18px;height: auto;margin: 0;padding: 15px 35px 15px 20px;border-bottom: none !important;white-space: nowrap}.submenu.stuck .tab a span {font-size: 20px;vertical-align: text-bottom}.submenu.stuck .tab a.active {display: block;cursor: pointer;top: 0;right: 0;position: absolute}.submenu.stuck .tab a.active:after {font-family: 'icomoon';content: "\e605";color: #232323;font-size: 22px;position: absolute;right: 8px;z-index: -1;transform: rotate(90deg)}/* .submenu.stuck .tab.select:before {content: '';width: 100%;height: 50px;display: block;border-bottom: 2px solid #eee} */.submenu.stuck .tab a.option {display: block;background: #fff;box-shadow: inset 0px -1px 3px -1px #ccc;opacity: 1}.submenu.stuck .tab a.option:hover {color: #232323}.submenu.stuck .toc.link ul {bottom: 18px;  right: 100px;margin: 0;position: fixed;}.submenu.stuck .toc.link li {float: none;/* background:white; */}.submenu.stuck .toc.link a {font-size: 17px !important;line-height: 19px !important;margin: 0;padding: 10px 30px;white-space: nowrap}.submenu.stuck .toc.link a:after {display: none}.submenu.stuck .toc.link a:hover {text-decoration: none}/* .submenu.stuck .toc.link li.active a {display: block;color: #232323;top: 0;right: 0;position: absolute;background: none;} *//* .submenu.stuck .toc.link li.active:after {font-family: 'icomoon';content: "\e605";font-size: 22px;position: absolute;right: 0;top: 14px;z-index: -1;transform: rotate(90deg)} */.submenu.stuck li.active {display: block;background: #2196f3;border-radius: 10px;}.submenu.stuck li.active a {color: white;}.submenu.stuck li {display: none;}.submenu.stuck ul:hover li {display: block;}/* .submenu.stuck .toc.link .select:before {content: '';width: 100%;height: 50px;display: block;border-bottom: 2px solid #eee} *//* .submenu.stuck .toc.link a.option {display: block;padding: 15px 20px;background: #fff;box-shadow: inset 0px -1px 3px -1px #ccc;transition: all 250ms}.submenu.stuck .toc.link a.option:hover {color: #232323;} *//*** Article (right column) ***/aside {width: 310px}aside .sideBox {padding: 20px 0;z-index: 0;position: relative}aside .sideBox.promo {padding-top: 0}aside .dialog-activator:after{content:'Tools';font-weight: 700;    font-size:24px;line-height: 140%;color: #333333;text-align: center;display: flex;justify-content: center;}aside .sideBox.promo a {text-decoration: none;}aside .sideBox.promo .rrpromo:hover{background:#000;border-radius:3px;}aside .sideBox.promo .rrpromo {border-bottom: 1px solid #E3E6E8;}aside .sideBox.promo .rrpromo .icon-arrow-right2{   display: none;}aside .sideBox.promo .rrpromo p {font-size: 14px;line-height: 21px;font-weight: 700;margin: 16px 0 14px 5px;color: #2196F3;}aside .sideBox.promo .rrpromo span[class^="icon-"] {font-size: 25px;color: #2196F3;padding: 8px;margin: 1px 5px 1px 0;float: right;transition: all 250ms}aside .sideBox.promo .rrpromo span[class^="icon-arrow"] {background: none !important;color: #232323;font-size: 35px;float: right;margin: 0;padding: 0}aside .sideBox.promo .rrpromo span {font-size: 12px;color: #777777;display: inline-block;font-weight:400;line-height:18px;}aside .sideBox.slide h2,aside .featured_slideshow h3 {background: #777777;color: #fff;font-size: 16px;padding: 6px;margin: 0;text-align: center;text-decoration: none !important}aside .sideBox.slide .owl-carousel {width: 310px;min-height: 250px;display: inline-block;margin: 0 auto}aside .sideBox.slide .wrapper {text-align: center;background: #000;background: rgba(0, 0, 0, .3);position: absolute;top: 166px;height: 40px;display: table;width: 100%;transition: all 250ms;z-index: 1}aside .sideBox.slide .wrapper span {vertical-align: middle;padding: 11px 45px;color: #fff;width: 190px;white-space: nowrap;overflow: hidden;text-overflow: ellipsis;display: inline-block;font-size: 14px}aside .sideBox.slide .item img {height: 210px}aside .sideBox.slide .item p {font-size: 14px;font-style: italic;line-height: 17px;margin: 6px}aside .sideBox.slide .owl-nav [class*='owl-'] {color: #fff;font-size: 45px;opacity: 0.5;position: absolute;top: 158px}aside .sideBox.slide .owl-nav [class*='owl-']:hover {opacity: 1}aside .sideBox.slide .owl-nav .owl-prev {left: 0}aside .sideBox.slide .owl-nav .owl-next {right: 0}aside .sideBox.reviews {border-left: 5px solid #568a10;background: #e8f7b8;margin: 20px 0;padding: 0}aside .sideBox.reviews a {text-decoration: none;color: #568a10;font-weight: 600;font-size: 18px;text-transform: uppercase;padding: 16px 10px;width: calc(100% - 20px);display: inline-block;transition: all 250ms}aside .sideBox.reviews a:hover {color: #e8f7b8;background: #568a10}aside #rightAd_rdr {width: 310px;margin: 20px auto}aside .featured_slideshow {padding: 20px 0}aside .featured_slideshow .content {padding: 0;list-style: none}aside .featured_slideshow .content li {border-top: 1px solid #ccc;padding: 10px 0}aside .featured_slideshow .content li:first-child {border: none;padding-top: 0}aside .featured_slideshow .content img {width: 79px;height: 79px;float: left;transition: opacity 400ms}aside .featured_slideshow .content p {color: #777777;display: inline-block;width: calc(100% - 90px);height: 73px;margin: 6px 0 0 10px;font-size: 16px;line-height: 18px}aside .featured_slideshow .content p span {display: block;font-size: 13px;line-height: 15px;color: #777777;padding-top: 8px}aside .featured_slideshow .content li:hover * {color: #2196f3;cursor: pointer}aside #rightAd_rdr.sidebox:after {display: none}aside .sideBox ul {padding: 0;list-style-type: none;display: inline;}aside .sideBox ul li {display: inline;}aside .sideBox ul li a:after {content: ", ";}aside .sideBox ul li a:last-child:after {content: ""}/*** Article (lite TOC $ vitTOC) ***/.apPage .toc_lite, .vitTOC{background-color: #F1F8FC;padding:10px;}.apPage .toc_lite .owl-carousel,.vitTOC {margin: 0px !important;list-style: none;display: inline-block;column-count: 1 !important;padding:0px;}.apPage .toc_lite .owl-carousel>li,.vitTOC>li {padding: 0 !important;float: left}.apPage .toc_lite .owl-carousel>li>a,.vitTOC>li>a {font-size: 18px;line-height: 22px;padding: 8px 12px;margin: 0 10px;border-radius: 5px;display: inline-block;position: relative}.apPage .toc_lite .owl-carousel>li>a:hover,.apPage .toc_lite .owl-carousel .open,.vitTOC>li>a:hover {background: #2196f3;color: #fff;text-decoration: none}.apPage .toc_lite .owl-carousel>li>a:after,.vitTOC>li>a:after {content: " | ";color: #aaa;position: absolute;right: -13px}.apPage .toc_lite .owl-carousel>li:last-child a:after,.vitTOC>li:last-child a:after {display: none}.apPage .toc_lite .sub {display: none;border: 2px solid #2196f3;border-radius: 0 0 5px 5px;list-style: none;margin: -5px 0 0 10px;padding: 3px;width: auto;max-width: 26vw;background: #fff;position: absolute;z-index: 1}.apPage .toc_lite .sub li {padding: 0 !important;line-height: 22px !important}.apPage .toc_lite .sub li a {color: #232323;font-weight: 400;padding: 4px 0;display: block}.apPage .toc_lite .sub li span[class^="icon-"] {color: #f7941d;background: #fff;position: absolute;left: 10px;margin-top: 12px}/*** Article (interval) ***/.mediaPrmo {border-radius: 10px;height: 300px;max-width: 800px;margin: 50px auto;display: block;position: relative;clear: both;background: #999;transition: all 250ms;}.mediaPrmo {border-radius: 10px;height: 300px;max-width: 800px;margin: 50px auto;display: block;position: relative;clear: both;background: #999;transition: all 250ms}.mediaPrmo img {border-radius: 10px;object-fit: cover;width: 45%;height: 300px;position: absolute;transition: all 250ms}.mediaPrmo .skew {position: absolute;left: 38%;width: 150px;height: 300px;background: #999;transform: skew(-10deg);transition: all 250ms}.mediaPrmo [class^="icon-"] {position: absolute;right: 10px;top: 10px;color: #fff;opacity: .8;transition: all 250ms}.mediaPrmo .label,.mediaPrmo .caption,.mediaPrmo .desc,.mediaPrmo .btn {display: block;color: #fff;margin: 25px 20px 25px 45%;text-align: center;position: relative;transition: all 250ms}.mediaPrmo .label {font-size: 15px;padding-top: 30px}.mediaPrmo .label:before,.mediaPrmo .label:after {content: "";border: .5px solid #fff;width: 20px;margin: 5px 10px;display: inline-block}.mediaPrmo .caption {font-size: 20px;font-weight: 600;line-height: 24px}.mediaPrmo .desc {font-size: 14px}.mediaPrmo .btn {color: #777777;padding: 10px;font-weight: 600;border-radius: 5px;background: #fff;transition: all 250ms}.mediaPrmo:hover {text-decoration: none !important;background: #eee}.mediaPrmo:hover img {width: 33%;filter: grayscale(100%)}.mediaPrmo:hover .skew {background: #eee;left: 25%}.mediaPrmo:hover [class^="icon-"] {color: #232323;}.mediaPrmo:hover .label,.mediaPrmo:hover .caption,.mediaPrmo:hover .desc,.mediaPrmo:hover .btn {margin-left: 30%;color: #232323;}.mediaPrmo:hover .label:before,.mediaPrmo:hover .label:after {border-color: #000}.mediaPrmo:hover .btn {background: #000;color: #fff}.article-promo {margin: 50px 0;padding: 20px 0;border: 0 solid #f2f2f2;border-width: 5px 0;text-align: center}.article-promo .item {padding: 0 15px;width: calc(33% - 30px);max-width: 150px;height: 230px;display: inline-table}.article-promo a img {width: 100%;max-width: 150px;transition: opacity 250ms}.article-promo a span {font-size: 14px;font-weight: 600;color: #232323;margin: 20px 0;text-align: left;width: 100%;display: inline-block}.article-promo .icon-slideshow:before {content: 'SLIDESHOW'}.article-promo .icon-quiz:before {content: 'QUIZ'}.article-promo .icon-image:before {content: 'IMAGE'}.article-promo a p {font-size: 14px;margin-top: -10px;line-height: 16px !important;text-align: left}.article-promo a:hover img {opacity: .6}.pgContent .learn_more_zomig {background: #f7941d;color: #fff;font-size: 16px;padding: 5px 55px 5px 15px;border-radius: 3px;margin-top: 15px;display: inline-block;position: relative;transition: background 250ms}.pgContent .learn_more_zomig span {font-weight: 600;font-size: 18px}.pgContent .learn_more_zomig .icon-arrow-right2 {position: absolute;right: 0;top: 0;border-left: 1px solid rgba(255, 255, 255, 0.30)}.pgContent .learn_more_zomig .icon-arrow-right2:before {border-left: 1px solid rgba(0, 0, 0, 0.15);font-size: 38px}.pgContent .learn_more_zomig:hover {text-decoration: none;background: #000}#crsprm-2081-assmnt {max-width: 748px;border-color: #eee;border-style: solid;border-width: 5px 0;clear: both;margin: 50px auto;overflow: hidden;padding: 18px 0}#crsprm-2081-assmnt .cross-promo__hero {float: left;margin-right: 40px}#crsprm-2081-assmnt .cross-promo__content {padding-top: 10px}#crsprm-2081-assmnt .cross-promo__subheading {color: #3a6d69;font-size: 12px;font-weight: 600;text-transform: uppercase}#crsprm-2081-assmnt .cross-promo__subheading img.logoTitle {margin: 6px 0 10px 5px}#crsprm-2081-assmnt a:hover {text-decoration: none}#crsprm-2081-assmnt .cross-promo__heading {color: #232323;font-size: 30px;font-weight: 600;line-height: 32px;margin-bottom: 20px}#crsprm-2081-assmnt .cross-promo__cta {color:#232323;font-size: 17px}#crsprm-2081-assmnt .cross-promo__cta::after {content: '';display: inline-block;width: 30px;height: 30px;margin: 0 0 -5px 8px;vertical-align: bottom;background-image: url(https://images.medicinenet.com/images/ads/btn-blue-arrow.png)}.webmd_lab_ad {margin: 40px 0}.webmd_lab_testing {border: 1px solid #eee;margin: 0 auto;background: #fafeff;padding: 0 40px;max-width: 550px}.webmd_lab_testing h4 {font-size: 26px;color: #232323;line-height: 28px;margin: 30px 0 -5px 0}.webmd_lab_testing p {color: #777777;line-height: 18px !important}.webmd_lab_testing .webmd_lab_testing_btn {background: #f26522;width: 300px;border-radius: 3px;padding: 6px;color: #fff;text-align: center;font-size: 18px}.webmd_lab_testing a:hover {text-decoration: none !important}.webmd_lab_testing span.icon-arrow-right2:before {position: absolute;font-size: 29px}.webmd_lab_testing .webmd_lab_logo {font-size: 10px;color: #aaa;margin: 25px 0}.webmd_lab_ad:after {content: '';background: url(https://images.medicinenet.com/images/ads/rightad_toptransparent.gif) no-repeat center 0;height: 10px;display: block}.webmdrx_coup .webmdrx p {text-align: left;padding-right: 100px;width: 140px;white-space: nowrap;overflow: hidden;text-overflow: ellipsis;position: relative}.webmdrx_coup .webmdrx .webmdrx_img {position: absolute;right: 0}.webmdrx_coup h3 {margin: 5px 0;font-size: 14px;line-height: 16px;text-decoration: none !important}.webmdrx_coup .wrapper {margin: 10px 0;padding: 10px 10px 20px;box-shadow: 0 0 4px 0 #ddd;max-width: 600px;position: relative}.webmdrx_coup .wrapper img {width: 40px;padding: 0 20px 2px}.webmdrx_coup .wrapper .pharmName {position: absolute;font-size: 10px;text-align: center;width: 80px;white-space: nowrap;overflow: hidden;text-overflow: ellipsis}.webmdrx_coup .wrapper .reg {position: absolute;top: 20px;left: 20%;color: #777777;font-size: 13px}.webmdrx_coup .wrapper .reg span {text-decoration: line-through}.webmdrx_coup .wrapper .reg p {margin: 0}.webmdrx_coup .wrapper .cou {position: absolute;top: 17px;left: 45%}.webmdrx_coup .wrapper .cou span {font-size: 15px;font-weight: 600}.webmdrx_coup .wrapper .cou p {margin: -3px 0;font-size: 13px;color: #777777;}.webmdrx_coup .wrapper a {position: absolute;top: 18px;right: 5%;color: #fff !important;font-size: 14px;font-weight: 600;background: #02c96a;padding: 8px 25px;transition: all 250ms}.webmdrx_coup .wrapper a:hover {text-decoration: none !important;background: #000}/*** Article (landing) ***/#Drugs_AZlist ul,.quizAtoZ,.sc_az ul {padding: 0;display: inline-block}#Drugs_AZlist ul li,.quizAtoZ li,.sc_az li {list-style: none;padding: 0;margin: 6px;float: left}#Drugs_AZlist li a,.quizAtoZ li a,.sc_az li a {text-decoration: none;display: inline-block;padding: 10px;color: #6896da;font-size: 24px;font-weight: 600;line-height: 30px;border-radius: 3px;width: 30px;height: 30px;text-align: center;background: #f5f5f5;transition: all 250ms}#Drugs_AZlist li a:hover,.quizAtoZ li a:hover,.sc_az li a:hover {background: #000;color: #fff;text-decoration: none}.Rxl_landing_DC,.Rxl_landing_feat,.sc_common_ss {margin: 50px 0;clear: both}.Rxl_landing_DC ul,.sc_common_ss ul,.sc_popular_sym ul {margin: 0;font-size: 18px}.Rxl_landing_feat img {margin-right: 20px}.Rxl_landing_feat .feat_quiz {text-decoration: underline}#Drugs_AZlist .roundtop {padding: 20px 0;text-transform: uppercase;font-size: 19px;font-weight: 600;text-decoration: underline}.contentstyle h4,.AZ_results h4 {font-size: 20px;margin: 20px 0}.contentstyle h4 a,.AZ_results h4 a {margin: 4px 2px;padding: 5px 15px;border-radius: 20px;background: #f5f5f5;display: inline-block;transition: all 250ms}.contentstyle h4 a:hover,.AZ_results h4 a:hover {background: #000;color: #fff;text-decoration: none}.contentstyle h5,.AZ_results h5 {background: #6896DA;margin: 30px 0 0 0;padding: 5px 10px;color: #6896DA}.contentstyle h5 a,.AZ_results h5 a {color: #fff;font-size: 24px;cursor: default;pointer-events: none}.contentstyle ul,.AZ_results ul {list-style-type: none;margin: 0;padding: 0;display: block !important}.contentstyle li,.AZ_results li,.drugChecker_Page .drug_A-Z_list li {padding: 0 !important;position: relative}.contentstyle li a,.AZ_results li a,.drugChecker_Page .drug_A-Z_list li a {padding: 10px !important;font-size: 16px;display: block;transition: all 250ms}.contentstyle li:nth-child(even) *,.AZ_results li:nth-child(even) *,.drugChecker_Page .drug_A-Z_list li:nth-child(even) * {background: #f5f5f5}.contentstyle li:hover *,.AZ_results li:hover *,.drugChecker_Page .drug_A-Z_list li:hover * {background: #000 !important;color: #fff;text-decoration: none !important}.contentstyle li span,.AZ_results li span {position: absolute;right: 10px;top: 13px;font-size: 14px;background: #fff;transition: all 250ms}#imageCategories:first-child a {border: none}#imageCategories a {text-decoration: none;padding: 20px 0;min-height: 180px;display: inline-block;border-top: 1px solid #eee}#imageCategories img {width: auto;position: absolute;transition: all 250ms}#imageCategories h4 {color: #232323;margin: 10px 0 10px 200px;font-size: 20px;line-height: 22px;transition: color 250ms}#imageCategories p {font-size: 16px;line-height: 22px;color: #777777;margin: 10px 0 10px 200px;display: inline-block;transition: color 250ms}#imageCategories a:hover * {color: #2196f3}#imageCategories a:hover img {filter: grayscale(100%)}.quizLinks_fmt {margin: 30px 0}.quizLinks_fmt .alpha {color: #fff;font-weight: 600;background: #6896da;font-size: 24px;padding: 8px 20px;margin-top: 30px;position: relative}.quizLinks_fmt .alpha .top {visibility: hidden}.quizLinks_fmt .alpha .top:after {content: "\e605";font-family: 'icomoon' !important;font-size: 40px;color: #fff;padding: 0 10px;position: absolute;right: 0;top: -6px;visibility: visible;transform: rotate(-90deg)}.quizLinks_fmt .alpha .top:hover:after {color: #aac7f3}.quizLinks_fmt .quizLink_fmt {padding: 20px;min-height: 79px;width: calc(100% - 40px);display: inline-block;transition: all 250ms}.quizLinks_fmt .quizLink_fmt:nth-child(odd) {background: #f5f5f5}.quizLinks_fmt .quizLink_fmt img {border-radius: 3px;position: absolute}.quizLinks_fmt .quizLink_fmt h3 {margin: 0 0 0 90px;color: #2196f3;line-height: 20px;text-decoration: none;text-transform: capitalize;transition: all 250ms}.quizLinks_fmt .quizLink_fmt p {color: #232323;margin: 10px 0 0 90px;font-size: 14px;line-height: 18px;transition: all 250ms}.quizLinks_fmt .quizLink_fmt:hover {background: #000;text-decoration: none}.quizLinks_fmt .quizLink_fmt:hover * {color: #fff}#accordion h3 {margin: 5px 0;text-decoration: none}#accordion h3 a {color: #fff;background: #6896da;font-size: 20px;line-height: 26px;padding: 10px 60px 10px 15px;text-transform: capitalize;display: block;text-decoration: none;position: relative;transition: all 250ms}#accordion h3 a:after {content: "\e605";font-family: 'icomoon' !important;font-size: 40px;padding: 0 10px;position: absolute;top: 50%;right: 0;transform: translateY(-50%) rotate(90deg)}#accordion h3 a:hover {background: #000}#accordion .fold {display: none;position: relative}#accordion h3:first-child+.fold {display: block}#accordion .fold ul {list-style: none;padding: 0;display: block;column-count: 2}#accordion .fold ul li {padding: 0}#accordion .fold a {padding: 20px;height: 260px;width: calc(100% - 40px);max-width: 200px;text-align: center;display: inline-block;transition: background 250ms}#accordion .fold a img {border-radius: 3px}#accordion .fold a h4 {color: #232323;font-size: 20px;line-height: 22px;text-align: left;margin: 20px 0 10px;transition: color 250ms}#accordion .fold a p {color: #232323;font-size: 16px;line-height: 20px;text-align: left;margin: 0;transition: color 250ms}#accordion .fold a:hover {text-decoration: none;background: #000 !important}#accordion .fold a:hover * {color: #fff}#centering_area .breadcrumb {margin: 30px auto 0;font-size: 14px;width: 1100px}#centering_area .breadcrumb a:after {font-family: 'icomoon';content: "\e605";padding-left: 4px;display: inline-block;vertical-align: middle;color: #232323;}#symptom_checker {width: 1100px;margin: 0 auto}#symptom_checker .sc_content_well {margin: 50px 0}#symptom_checker .sc_content_well h3 {text-decoration: underline;text-transform: uppercase}#symptom_checker .sc_common_ss ul li,#symptom_checker .sc_popular_sym ul li {padding: 5px 0}#symptom_checker .sc_common_ss ul li a,#symptom_checker .sc_popular_sym ul li a {color: #2196f3;text-decoration: none;cursor: pointer}#symptom_checker .sc_common_ss ul li a:hover,#symptom_checker .sc_popular_sym ul li a:hover {text-decoration: underline}#centering_area .medianet,#centering_area .from_webmd {width: 1100px}#search {max-width: 1265px;margin: 0 auto;padding: 0 20px;grid-template-columns: 0 auto 350px}#search .story {margin: 0;padding: 0 20px 30px 20px;width:100%;max-width: 1400px;}#search .breadcrumbs {display: none}#search .story article {padding: 25px 0}#search .searchresults {width: auto;padding: 0;text-align: left;position: relative;margin: 70px 0}#search .searchresults.main {margin-top: 30px}#search .searchresults h3 {color: #fff;font-size: 20px;background: #6896da;text-decoration: none !important;padding: 5px 10px;margin: 10px 0}#search .searchresults ul {padding: 0;margin: 0;list-style: none;overflow: hidden;display: block !important}#search .searchresults li {padding: 0 !important;border-top: 1px solid #eee}#search .searchresults li:first-child {border: none}#search .searchresults li a {font-weight: 600;font-size: 18px;line-height: 22px;padding: 15px;display: block;transition: all 250ms}#search .searchresults li img {margin-right: 15px;float: left}#search .searchresults li .brand {font-size: 18px;color: #2196f3;font-weight: 600;line-height: 22px}#search .searchresults li .generic {color: #232323;font-size: 15px;font-weight: 400;line-height: 19px}#search .searchresults li span {font-size: 12px;color: #777777;line-height: 14px;display: block;transition: all 250ms}#search .searchresults li p {font-size: 14px;color: #232323;line-height: 18px;font-style: italic;transition: all 250ms}#search .searchresults li a:hover {background: #000;color: #fff;text-decoration: none}#search .searchresults li a:hover * {color: #fff}#search .searchresults .gradient,#ForumCenter_fmt .sideBox[class$=List] .gradient {width: 100%;height: 30px;position: absolute;bottom: 0;background: -moz-linear-gradient(top, rgba(255, 255, 255, 0) 0%, rgba(255, 255, 255, 0) 1%, rgba(255, 255, 255, 1) 100%);background: -webkit-linear-gradient(top, rgba(255, 255, 255, 0) 0%, rgba(255, 255, 255, 0) 1%, rgba(255, 255, 255, 1) 100%);background: linear-gradient(to bottom, rgba(255, 255, 255, 0) 0%, rgba(255, 255, 255, 0) 1%, rgba(255, 255, 255, 1) 100%);filter: progid:DXImageTransform.Microsoft.gradient(startColorstr='#00ffffff', endColorstr='#ffffff', GradientType=0)}#search .searchresults .more,#ForumCenter_fmt .sideBox[class$=List] .more {border-top: 1px solid #DCDCDC;position: relative}#search .searchresults .more span,#ForumCenter_fmt .sideBox[class$=List] .more span {border: 1px solid #dcdcdc;border-radius: 3px;border-top: 1px solid #fff;padding: 3px 20px;margin-top: -1px;position: absolute;top: 50%;left: calc(50% - 42px);cursor: pointer;font-size: 40px;line-height: 20px;color: #2196f3;-webkit-transition: color 200ms;transition: color 200ms}#search .searchresults .more span:before,#ForumCenter_fmt .sideBox[class$=List] .more span:before {transform: rotate(90deg);display: block}#search .searchresults .more span:hover,#ForumCenter_fmt .sideBox[class$=List] .more span:hover {color: #ccc;background: #fff;background: -moz-linear-gradient(top, #fff 0%, #eee 100%);background: -webkit-linear-gradient(top, #fff 0%, #eee 100%);background: linear-gradient(to bottom, #fff 0%, #eee 100%);filter: progid:DXImageTransform.Microsoft.gradient(startColorstr='#fff', endColorstr='#eee', GradientType=0)}#search .searchresults .more span.active:before,#ForumCenter_fmt .sideBox[class$=List] .more span.active:before {transform: rotate(-90deg)}#search #noresult {margin: 50px 0}/*** Article (user reviews) ***/.pgContent .related .relMono {font-size: 22px}#patientComments_fmt {padding: 30px;margin: 30px 0;background: #f5f5f5;border: 1px solid #d9d9d9;border-radius: 5px;position: relative}#patientComments_fmt:before,#patientComments_fmt:after {content: "";position: absolute;width: 0;height: 0;border-style: solid;border-color: transparent;border-top: 0}#patientComments_fmt:before {top: -8px;left: 25px;border-bottom-color: #D9D9D9;border-width: 8px}#patientComments_fmt:after {top: -7px;left: 26px;border-bottom-color: #f5f5f5;border-width: 7px}#patientComments_fmt .commentTop {font-style: italic}#patientComments_fmt .patComment {padding: 40px 20px;position: relative}#patientComments_fmt .patComment:before {content: open-quote;font-size: 100px;position: absolute;color: #e4e4e4;margin: -55px 0 0 -35px}#patientComments_fmt .patComment:after {content: close-quote;font-size: 100px;position: absolute;color: #e4e4e4;margin: -55px -15px 0 0;right: 0}#patientComments_fmt .suggReading a {text-transform: capitalize}/*** Article (FAQ) ***/#faqContent #faq-top,#faqContent h2 {display: none}#faqContent .faq-reviewed p {font-size: 14px;line-height: 16px}#faqContent #faqPromo {margin: 20px 0;padding: 20px;border: 1px solid #dedede;border-radius: 10px}#faqContent #faqPromo .faqContImg img {margin-right: 8px;float: left}#faqContent #faqPromo .faqContTitle {font-size: 16px;font-weight: 600;display: block}#faqContent #faqPromo .faqContTag {font-size: 13px;margin: 10px 0;display: block}#faqContent .faqAnswers img {width: 100%;height: auto;border-radius: 5px;max-width: 800px;margin: 10px auto;display: block}#faqContent .faqAnswers img.spec {max-width: 180px}#faqContent .faqAnswers .q,#faqContent .faqAnswers .a {font-size: 22px;font-weight: 600;color: #6896DA;padding-right: 5px}#faqContent .faqAnswers .ques {font-size: 22px;font-style: italic;line-height: 24px}#faqContent .faqAnswers .faqHead+p {padding: 20px;margin: 15px 0;background: #f5f5f5;border: 1px solid #d9d9d9;border-radius: 3px;position: relative}#faqContent .faqAnswers .faqHead+p:before,#faqContent .faqAnswers .faqHead+p:after {content: "";position: absolute;width: 0;height: 0;border-style: solid;border-color: transparent;border-top: 0}#faqContent .faqAnswers .faqHead+p:before {top: -8px;left: 25px;border-bottom-color: #D9D9D9;border-width: 8px}#faqContent .faqAnswers .faqHead+p:after {top: -7px;left: 26px;border-bottom-color: #f5f5f5;border-width: 7px}#faqContent .faqAnswers .backToTop {font-size: 15px;text-align: right;margin: -10px 0 40px 0;display: block}#faqContent .faq-source {border-top: 1px solid #ccc;font-size: 14px;font-style: italic;line-height: 16px;margin: 40px 0;padding: 10px 0;display: block}#faqContent .starCont .faqHead {font-size: 18px;text-decoration: underline;text-transform: uppercase}/*** Article (secondary) ***/.rxlsecondary .toc,.RXLSyndicated .toc {position: relative;border-bottom: 1px solid #ccc;margin: 20px 0}.rxlsecondary .toc ul li,.RXLSyndicated .toc ul li {list-style: none}.rxlsecondary .toc ul li:before,.RXLSyndicated .toc ul li:before {font-family: 'icomoon';content: "\e909";font-size: 15px;vertical-align: text-bottom;position: absolute;left: 12px;transition: transform 250ms}.rxlsecondary .toc ul li a,.RXLSyndicated .toc ul li a {color: #2196f3;text-decoration: none}.rxlsecondary .toc ul li:hover,.RXLSyndicated .toc ul li:hover {cursor: pointer}.rxlsecondary .toc ul li:hover a,.RXLSyndicated .toc ul li:hover a {text-decoration: underline}.rxlsecondary .toc ul li:hover:before,.RXLSyndicated .toc ul li:hover:before {transform: rotate(90deg)}.authEditorWrap {padding: 10px 15%;max-width: 1100px}.authEditorWrap .authEditorCont {list-style: none;font-size: 16px;color: #e0f0ff;line-height: 18px;text-align: center;padding: 4px 0}.authEditorWrap .authEditorCont * {display: inline}.authEditorWrap .authEditorCont a {color: #fff}.authEditorWrap .authEditorCont .magOnOff,.authEditorWrap .authEditorCont .authEditorPopOut {display: none}/*** Article (syndicated) ***/.RXLSyndicated .wrapper h3 {font-size: 26px;line-height: 30px;text-decoration: none}.RXLSyndicated .apPage {clear: both}.RXLSyndicated .wrapper p {line-height: 32px}.RXLSyndicated .wrapper ul {display: block}.RXLSyndicated .wrapper ul li,.RXLSyndicated .wrapper ol li {padding: 8px 0;line-height: 26px}.RXLSyndicated .AP-wrapper {width: 340px;margin: 0 40px 30px 0;float: left}#lrgArtImg {margin: 20px auto;max-width: 650px}#lrgArtImg img {width: 100% !important}#lrgArtImg .lrgArtImgCap {font-size: 13px;color: #777777;line-height: 15px;display: inline-block;padding: 5px 0}.RXLSyndicated .AP-wrapper .slide span {font-size: 12px}.forum_symptom_checker {margin: 50px auto;max-width: 600px}.forum_symptom_checker a {background: #fafafa;border: 5px solid #eee;border-radius: 10px;height: 223px;display: block;transition: all 250ms}.forum_symptom_checker a:hover {border-color: #ddd;background: #fff;text-decoration: none !important}.forum_symptom_checker .sym_image {float: left}.forum_symptom_checker .sym_text {margin: 0 20px 0 165px}.forum_symptom_checker .sym_h3 {font-size: 30px;font-weight: 600;text-decoration: none}.forum_symptom_checker .sym_h3 .green {color: #588527}.forum_symptom_checker .sym_h3 .blue {color: #2196f3}.RXLSyndicated .aia_rdr {width: 420px;float: right;border: 1px solid #ddd;margin: 0 0 20px 20px;clear: both}.RXLSyndicated .aia_title_bar_fmt {background: #5385b5;padding: 8px;text-align: center;color: #fff}.RXLSyndicated .aia_rdr h4 {margin: 0;font-size: 18px}.RXLSyndicated .aia_content_fmt {font-size: 15px;padding: 0 15px}.RXLSyndicated .aia_rdr li {padding: 10px 0;line-height: 17px}.separator {display: none}.article-extra .thumbnails h3,#ForumCenter_fmt .sideBox h3 {font-size: 24px}.article-extra .thumbnails ul {padding: 0;margin: 0;display: block}.article-extra .thumbnails .relCondImageQuizContent li,.article-extra .thumbnails .mainart li {padding: 0 !important;list-style: none}.article-extra .thumbnails .relCondImageQuizContent li:nth-child(even),.article-extra .thumbnails .mainart li:nth-child(even) {background: #f5f5f5}.article-extra .thumbnails .relCondImageQuizContent li a,.article-extra .thumbnails .mainart li a {padding: 14px;min-height: 79px;width: calc(100% - 28px);transition: all 250ms;display: inline-block;color: #777777;}.article-extra .thumbnails .relCondImageQuizContent li img,.article-extra .thumbnails .mainart li img {border-radius: 3px;float: left;margin-right: 15px}.article-extra .thumbnails .relCondImageQuizContent li h2,.article-extra .thumbnails .mainart li h2 {margin: 0 0 0 90px;font-size: 18px;line-height: 20px;color: #2196f3}.article-extra .thumbnails .relCondImageQuizContent li p,.article-extra .thumbnails .mainart li p {margin: 10px 0 0 90px;font-size: 16px;line-height: 18px !important}.article-extra .thumbnails .relCondImageQuizContent li a:hover,.article-extra .thumbnails .mainart li a:hover {color: #fff;background: #2196f3;text-decoration: none}.article-extra .thumbnails .relCondImageQuizContent li a:hover h2,.article-extra .thumbnails .mainart li a:hover h2 {color: #fff}.article-extra .thumbnails .Tab_Items ul {padding-left: 30px}#A_Z ul {justify-content: left;text-align: center}/*** Article (ForumCenter) ***/#ForumCenter_fmt .sideBox[class$=List] {margin-bottom: 50px}#ForumCenter_fmt .sideBox[class$=List] .wrapper {margin: 0;position: relative;overflow: hidden}#ForumCenter_fmt .sideBox[class$=List] .wrapper ul {margin: 0;padding: 0;list-style: none;display: block}#ForumCenter_fmt .sideBox[class$=List] .wrapper ul li {padding: 0}#ForumCenter_fmt .sideBox[class$=List] .wrapper ul li:nth-child(even) {background: #f5f5f5}#ForumCenter_fmt .sideBox[class$=List] .wrapper ul li:last-child {margin-bottom: 20px}#ForumCenter_fmt .sideBox[class$=List] .wrapper ul li a {padding: 20px;min-height: 79px;width: calc(100% - 40px);display: inline-block;transition: all 250ms}#ForumCenter_fmt .sideBox[class$=List] .wrapper ul li a:hover {color: #fff;background: #2196f3;text-decoration: none}#ForumCenter_fmt .sideBox[class$=List] .wrapper ul li a:hover p {color: #fff}#ForumCenter_fmt .sideBox[class$=List] .wrapper ul li a img {border-radius: 3px;position: absolute}#ForumCenter_fmt .sideBox[class$=List] .wrapper ul li a h2 {margin: 0 0 0 100px;font-size: 18px;line-height: 18px}#ForumCenter_fmt .sideBox[class$=List] .wrapper ul li a p {color: #232323;margin: 10px 0 0 100px;font-size: 15px;line-height: 18px;transition: all 250ms}#ForumCenter_fmt .sideBox[class$=List] .more span:before {content: "\e605"}/*** Slideshows ***/.slideshow #apPage:before {content: "";border-top: 4px dotted #ddd;margin: 10% auto;padding-bottom: 25px;display: block;text-align: center;width: 150px}.slideshow #apPage:first-child:before {display: none}.slideshow .apPage {text-align: center}.slideshow .apPage h3 {font-size: 26px;text-decoration: none}.slideshow .apPage img {width: 100%;max-width: 493px;border-radius: 5px}.slideshow .apPage .content {text-align: justify;margin: 25px auto 80px;max-width: 493px}#slideshow_resources {margin: 60px 5%}#slideshow_resources .resources_left {border-top: 1px solid #ccc;border-bottom: 1px solid #ccc;padding: 10px 0}#slideshow_resources .copyright p {float: right;font-size: 13px;line-height: 16px;text-align: right}#slideshow_resources p {margin: 5px 0}#slideshow_resources p a {font-style: italic}#slideshow_resources p a:hover {text-decoration: underline}#slideshow_resources p a:after {font-family: 'icomoon' !important;content: "\e612";font-size: 12px;color: #F26522;padding: 0 4px;vertical-align: middle;font-style: normal;display: inline-block}#slideshow_resources h4,#slideshow_resources p a img {display: none}#slideshow_resources #sources_fmt,#slideshow_resources #disclaimer_fmt {background: #eee;padding: 10px 20px 20px 20px;margin-bottom: 20px;font-size: 13px}#slideshow_resources #sources_fmt .heading {font-weight: 600;margin: 15px 0}#slideshow_resources #sources_fmt p,#slideshow_resources #disclaimer_fmt p {margin: 10px 0}.pageWrapper #headline .author {list-style: none;padding: 0;margin: -10px 0 0 0;font-size: 14px}.pageWrapper #headline .author a {color: #000}.pageWrapper #headline .reviewdate {font-size: 14px}/*** Images ***/.imgcath{    font-size: 50px;    line-height: 54px;    margin:32px 0 0 0;    font-weight: 600;    font-style: normal;    display: inline-block;    font-family: 'Raleway', sans-serif;}.imagecol.content {display: flex;justify-content: space-between}.imagecol .pageWrapper {padding: 40px 0}.imagecol .apPage {text-align: center}.imagecol .apPage h1 {line-height: 28px;margin: 40px auto;font-size: 18px;color: #fff;padding: 5px 10px;background: #000;text-decoration: none;text-transform: none}.imagecol .apPage img {max-width: 493px;width: 100%;margin-bottom: 20px}.imagecol .apPage .content {text-align: justify}.imagecol .apPage .source {text-align: left;font-style: italic}body.imgcol footer,body.imgcol #sponsors {display: none}/*** Quizzes ***/.wrapper-hero.quiz .reviewer {margin: 10px 0}.wrapper-hero.quiz .reviewer a {text-decoration: none;color: #2196f3}.wrapper-hero.quiz .reviewer a:hover {text-decoration: underline}article#quizWrapper {max-width: 800px !important;margin: 0 auto;padding: 0}#quiz-wrapper .instream-ad {text-align: center}#quizWrapper .question {background: #6896DA;margin: 30px 0;width: 100%;border-radius: 5px;display: table}#quizWrapper .question-header {position: absolute}#quizWrapper .question-number {color: #fff;font-size: 16px;font-weight: 600;position: absolute;z-index: 0;padding: 10px}#quizWrapper .question-number i {width: 0;height: 0;border-style: solid;border-width: 70px 70px 0 0;border-color: #000 transparent transparent transparent;position: absolute;left: 0;top: 0;z-index: -1}#quizWrapper .question-message.show {color: #fff;font-size: 20px;font-weight: 600;text-transform: uppercase;background: #ed1c24;width: calc(100vw - 431px);max-width: 736px;padding: 19px 0;border-radius: 0 5px 0 0;text-align: center}#quizWrapper .question img {width: 100%;border-radius: 5px 5px 0 0}#quizWrapper .question-content {padding: 50px 30px 30px 30px;min-height: 380px}#quizWrapper .question-content h2 {font-size: 26px;line-height: 34px;color: #fff;margin: 20px 0 30px 0}#quizWrapper .question-content .answer {margin: 6px 0;background: #fff;cursor: pointer;width: 100%;min-height: 55px;display: table;transition: all 250ms}#quizWrapper .question-content .answer:hover {background: #f26522;color: #fff}#quizWrapper .question-content .answer-letter {background: #000;color: #fff;font-size: 20px;font-weight: 600;padding: 0 20px;vertical-align: middle;width: 15px;display: table-cell}#quizWrapper .question-content .answer-text {font-size: 17px;padding: 10px 15px;vertical-align: middle;display: table-cell}#quizWrapper .question-content .image-type {border: 5px solid #000;background: #000;color: #fff;width: calc(100% - 10px)}#quizWrapper .question-content .image-type img {border-radius: 0}#quizWrapper .question-content .image-type .answer-text {text-align: center;padding: 10px 15px;display: block}#quizWrapper .question-content .image-type:hover {border: 5px solid #f26522}#quizWrapper .question-content .correct,#quizWrapper .question-content .correct:hover {background: #dff0d8;color: #598527;cursor: auto}#quizWrapper .question-content .correct .answer-letter {background: #598527}#quizWrapper .question-content .correct:after {font-family: 'icomoon' !important;content: "\e628";font-size: 20px;color: #63bf71;vertical-align: middle;text-align: center;width: 55px;display: table-cell}#quizWrapper .question-content .incorrect,#quizWrapper .question-content .incorrect:hover {background: #f2dede;color: #a94442;cursor: auto}#quizWrapper .question-content .incorrect .answer-letter {background: #9e0b0f}#quizWrapper .question-content .incorrect:after {font-family: 'icomoon' !important;content: "\e629";font-size: 20px;color: #ff6363;vertical-align: middle;text-align: center;width: 55px;display: table-cell}#quizWrapper .question-content .image-type.correct {border-color: #598527;background: #598527;color: #fff}#quizWrapper .question-content .image-type.incorrect {border-color: #9e0b0f;background: #9e0b0f;color: #fff}#quizWrapper .question-content .explanation.hide {visibility: hidden;display: block}#quizWrapper .question-content .explanation.show {visibility: visible;background: #fff;margin-top: -6px}#quizWrapper .question-content .explanation-heading {font-weight: 600;padding: 20px}#quizWrapper .question-content .explanation-correct-answer {display: block;color: #598527;font-size: 150%}#quizWrapper .question-content .explanation-content {padding: 20px;border-top: 1px solid #ddd}#quizWrapper .question-content .explanation-content>span {font-weight: 600}#quizWrapper .question-content .notselected,#quizWrapper .question-content .image-type.correct:after,#quizWrapper .question-content .image-type.incorrect:after {display: none}#quizWrapper .question .question-next-button {visibility: hidden;color: #fff;border: 1px solid rgba(255, 255, 255, 0.5);padding: 10px 0;margin: 0 40% 30px 40%;font-size: 16px;text-transform: capitalize;text-align: center;display: block;border-radius: 5px;cursor: pointer;transition: background 250ms}#quizWrapper .question.answered .question-next-button.show {visibility: visible}#quizWrapper .question.answered .question-next-button:hover {background: rgba(255, 255, 255, 0.2)}#quizWrapper .quiz-check-button {background: #f26522;color: #fff;font-size: 24px;text-transform: uppercase;text-align: right;border-radius: 5px;padding: 20px 60px;position: relative;cursor: pointer;transition: background 250ms}#quizWrapper .quiz-check-button:after {font-family: 'icomoon' !important;content: "\e605";font-size: 50px;position: absolute;top: 0}#quizWrapper .quiz-check-button:hover {background: #000}#quizWrapper #quizResources {border-top: 1px solid #ccc;margin: 40px 0;padding: 10px 0;font-size: 14px}#quizWrapper #quizResources p {margin: 5px 0}#quizWrapper #quizResources p a {font-style: italic}#quizWrapper #quizResources p a:hover {text-decoration: underline}#quizWrapper #quizResources p a:after {font-family: 'icomoon' !important;content: "\e612";font-size: 12px;color: #F26522;padding: 0 4px;vertical-align: middle;font-style: normal;display: inline-block}#quizWrapper #quizResources p a img {display: none}#quizWrapper #sources_fmt,#quizWrapper #disclaimer_fmt {background: #eee;padding: 10px 20px 20px 20px;margin-bottom: 20px;font-size: 13px}#quizWrapper #sources_fmt .heading {font-weight: 600;margin: 15px 0}#quizWrapper #sources_fmt p,#quizWrapper #disclaimer_fmt p {margin: 10px 0}#quizWrapper .quiz-status {position: fixed;top: 0;right: 0;left: 0;z-index: 999999;background: rgba(80, 114, 165, 0.95);padding: 12px 20px;height: 26px;display: none}#quizWrapper .quiz-status h1 {color: #fff;font-size: 20px !important;line-height: 24px;margin: 0;max-width: calc(100% - 125px);white-space: nowrap;overflow: hidden;text-overflow: ellipsis}#quizWrapper .quiz-status .quiz-progressbar {background: #fbc98e;margin: 14px -20px 0 -20px}#quizWrapper .quiz-status .quiz-progress-indicator {background: #f26522;height: 6px;transition: width 1s}#quizWrapper .quiz-status .quiz-status-right {position: absolute;right: 20px;top: 11px;font-size: 20px;color: #fff;line-height: 25px}#quizWrapper .quiz-status .quiz-correct-num {float: left;margin-right: 10px}#quizWrapper .quiz-status .quiz-incorrect-num {float: right}#quizWrapper .quiz-status .quiz-correct-num:before {font-family: 'icomoon' !important;content: "\e628";font-size: 20px;color: #63bf71;margin: 0 5px;vertical-align: text-bottom}#quizWrapper .quiz-status .quiz-incorrect-num:before {font-family: 'icomoon' !important;content: "\e629";font-size: 20px;color: #ff6363;margin: 0 5px;vertical-align: text-bottom}#quizWrapper .quiz-modal-overlay {background: rgba(0, 0, 0, 0.8);position: fixed;top: 0;left: 0;right: 0;height: 100%;z-index: 999999}#quizWrapper .quiz-modal {background: #fff;width: 60%;border-radius: 3px 3px 0 0;position: absolute;top: 50%;left: 50%;transform: translate(-50%, -50%)}#quizWrapper .quiz-modal-header {background: #f26522;color: #fff;font-size: 20px;font-weight: 600;padding: 13px 20px;border-radius: 3px 3px 0 0;text-align: center;position: relative}#quizWrapper .quiz-modal-header .facebook-like {background: #4267b2;border: 1px solid #4267b2;color: #fff;font-size: 14px;text-decoration: none;border-radius: 5px;padding: 4px 7px 3px 1px;position: absolute;right: 12px;top: 12px}#quizWrapper .quiz-modal-header .facebook-like:before {font-family: 'icomoon' !important;content: "\e608";font-size: 14px;color: #fff;margin: 0 6px;vertical-align: text-bottom}#quizWrapper .quiz-modal-header .facebook-like:hover {background: #000;border: 1px solid #000}#quizWrapper .quiz-modal-content {padding: 40px}#quizWrapper .quiz-modal-content .quiz-modal-message {font-size: 18px}#quizWrapper .quiz-modal-content .quiz-result {border-top: 1px solid #ddd;border-bottom: 1px solid #ddd;margin: 50px 0;padding: 15px 0}#quizWrapper .quiz-modal-content .quiz-result-text {font-size: 18px;font-weight: 600;line-height: 26px}#quizWrapper .quiz-modal-content .quiz-result-text:before {font-family: 'icomoon' !important;content: "\e605";font-size: 20px;font-weight: bold;margin-right: 4px;vertical-align: text-bottom}#quizWrapper .quiz-modal-content .quiz-result-text-bold {color: #f26522}#quizWrapper .quiz-modal-content .quiz-related-text {font-size: 18px;font-weight: 600;padding-bottom: 8px}#quizWrapper .quiz-modal-content .quiz-related a {display: block;line-height: 26px;font-size: 18px}#quizWrapper .quiz-modal-content .quiz-button {background: #4e6d9f;color: #fff;font-size: 18px;font-weight: 600;line-height: 21px;padding: 15px 50px;border-radius: 3px;width: 140px;text-align: center;margin: 50px auto 0 auto;transition: background 250ms}#quizWrapper .quiz-modal-content .quiz-button.startover:before {font-family: 'icomoon' !important;content: "\e630";font-size: 20px;color: #fff;margin-right: 10px;vertical-align: text-bottom}#quizWrapper .quiz-modal-bottom:after {font-family: 'icomoon' !important;content: "\e605";font-size: 40px;color: #fff;position: absolute;right: 10px;bottom: -55px}#quizWrapper .quiz-modal-bottom a {color: #fff;font-size: 18px;background: #6896da;padding: 15px 70px 15px 15px;position: absolute;bottom: -51px;right: 0;left: 0;border-radius: 0 0 3px 3px;text-align: right;white-space: nowrap;overflow: hidden;text-overflow: ellipsis;transition: background 250ms}#quizWrapper .quiz-modal-bottom .next-quiz-bold {font-weight: 600;padding: 0 10px}#quizWrapper .quiz-modal-content .quiz-button:hover,#quizWrapper .quiz-modal-bottom a:hover {text-decoration: none;background: #000;cursor: pointer}@media screen and (-ms-high-contrast: active),screen and (-ms-high-contrast: none) {article#quizWrapper {width: 100%;padding: 0 10%}}/*** Pill Identifier ***/#srch-drug-pillid,.PillId_fmt,#imageSlider,#PillID_fmt .sc-searchbox,.nav-search.sc-searchbox.drug-search {width: calc(100% - 52px);max-width: 600px;margin: 50px auto;border: 1px solid #ccc;padding: 25px;background: #fafafa}#pill_identifier_fmt .frmPillIdentifier-field-fmt {padding: 10px;position: relative}#srch-drug-pillid label,.PillId_fmt .HighlightedMsg {float: left;color: #888;font-size: 16px;font-weight: 600;line-height: 30px}#pill_identifier_fmt .frmPillIdentifier-field-fmt img {float: left;margin: 9px 10px 0 7px}#simprint,#scolor,#sshape {border: 1px solid #ccc;padding: 5px 10px;outline: none;border-radius: 3px}form#frmPillIdentifier #drug-pill-imprints-wrap {position: absolute;left: 177px;top: 39px;z-index: 1}#drug-pill-imprints-suggest {border: 1px solid #ccc;background: #fff;padding: 5px;border-radius: 3px;margin-top: -1px}#drug-pill-imprints-suggest p {margin: 0;padding: 5px 10px}#drug-pill-imprints-suggest .selected p {background: #000;color: #fff;cursor: pointer;border-radius: 3px}#pill_identifier_fmt .overlay,#pill_identifier_fmt .radio-color,#pill_identifier_fmt .jawsonly,#pill_identifier_fmt .shim {display: none}#pill_identifier_fmt #colorSwatch,#pill_identifier_fmt #shapeSwatch {border: 1px solid #ccc;background: #fff;width: 460px;padding: 15px;border-radius: 5px;margin-top: -1px;position: absolute;z-index: 10000}#pill_identifier_fmt .colorContent ul,#pill_identifier_fmt .shapeContent ul {display: block;margin: 0;padding: 0}#pill_identifier_fmt .colorContent li {float: left;background: url(https://img.webmd.com/dtmcms/live/webmd/consumer_assets/site_images/miscellaneous/pill_identifier/pill_id_color_solid_sprite.gif) no-repeat top left;height: 78px;width: 92px;padding: 0;list-style: none}#pill_identifier_fmt li.pc-solid-white {background-position: -1px -2px}#pill_identifier_fmt li.pc-solid-offwhite {background-position: -87px -2px}#pill_identifier_fmt li.pc-solid-clear {background-position: -174px -2px}#pill_identifier_fmt li.pc-solid-black {background-position: -1px -76px}#pill_identifier_fmt li.pc-solid-gray {background-position: -87px -76px}#pill_identifier_fmt li.pc-solid-brown {background-position: -174px -76px}#pill_identifier_fmt li.pc-solid-tan {background-position: -1px -149px}#pill_identifier_fmt li.pc-solid-red {background-position: -87px -149px}#pill_identifier_fmt li.pc-solid-pink {background-position: -174px -149px}#pill_identifier_fmt li.pc-solid-orange {background-position: -1px -220px}#pill_identifier_fmt li.pc-solid-peach {background-position: -87px -220px}#pill_identifier_fmt li.pc-solid-yellow {background-position: -173px -220px}#pill_identifier_fmt li.pc-solid-green {background-position: 0px -293px}#pill_identifier_fmt li.pc-solid-blue {background-position: -87px -293px}#pill_identifier_fmt li.pc-solid-purple {background-position: -173px -293px}#pill_identifier_fmt .pillcolor-solid a {display: block;height: 76px}#pill_identifier_fmt .pillcolor-solid a:hover,#pill_identifier_fmt .pillshape a:hover {background: rgba(0, 114, 188, 0.2);border-radius: 5px}#pill_identifier_fmt .shapeContent li {float: left;background: url(https://img.webmd.com/dtmcms/live/webmd/consumer_assets/site_images/miscellaneous/pill_identifier/pill_id_shape_sprite.gif) no-repeat top left;height: 70px;width: 75px;padding: 0;list-style: none}#pill_identifier_fmt li.ps-circle {background-position: 0px 0px}#pill_identifier_fmt li.ps-oblong {background-position: -78px 0px}#pill_identifier_fmt li.ps-oval {background-position: -155px 0px}#pill_identifier_fmt li.ps-square {background-position: -227px 0px}#pill_identifier_fmt li.ps-rectangle {background-position: -1px -63px}#pill_identifier_fmt li.ps-diamond {background-position: -78px -63px}#pill_identifier_fmt li.ps-triangle {background-position: -153px -63px}#pill_identifier_fmt li.ps-pentagon {background-position: -226px -63px}#pill_identifier_fmt li.ps-hexagon {background-position: -1px -130px}#pill_identifier_fmt li.ps-heptagon {background-position: -80px -130px}#pill_identifier_fmt li.ps-octagon {background-position: -152px -130px}#pill_identifier_fmt li.ps-other {background-position: -226px -130px}#pill_identifier_fmt .pillshape a {display: block;height: 68px}#PillID_fmt .submit_button {background: #6896da;border: 0;outline: 0;color: #fff;text-transform: uppercase;border-radius: 3px;padding: 10px;margin: 30px;width: calc(100% - 60px);transition: all 250ms}#PillID_fmt .submit_button:hover {background: #000}#PillID_fmt .sc-searchbox-input,.nav-search.sc-searchbox.drug-search .sc-searchbox-input {border: 1px solid #ccc;border-right: none;outline: none;border-radius: 3px 0 0 3px}#PillID_fmt .sc-searchbox-input:focus,.nav-search.sc-searchbox.drug-search .sc-searchbox-input:focus {border-color: #000}#PillID_fmt .sc-searchbox-button,.nav-search.sc-searchbox.drug-search .sc-searchbox-button {background: #6896da}#PillID_fmt .sc-searchbox-list {max-width: calc(100% - 50px)}.PillId_fmt .search {border: 1px solid #ccc;padding: 5px 10px;margin-left: 10px;outline: none}#PillID_fmt .PillId_fmt .submit_button {margin-bottom: 10px}#imageSlider {text-align: center;z-index: 0;position: relative}#imageSlider .sliderwrapper {min-height: 355px;position: relative}#imageSlider .contentdiv {position: absolute;top: 50%;left: 50%;transform: translate(-50%, -50%)}#imageSlider .contentdiv h1 {font-size: 20px;line-height: 22px}#imageSlider .contentdiv img {border-radius: 5px}#imageSlider .contentdiv p {font-size: 16px;line-height: 20px}.pagination2 a {background: #ccc;font-size: 18px;color: #fff !important;border-radius: 5px;border: none !important;padding: 5px 14px;margin: 4px 2px !important;display: inline-block;transition: all 250ms}.pagination2 a.selected {background: #6896da}.pagination2 a:hover {text-decoration: none !important;background: #000}.drugSearchResult {padding: 0;margin: 0;list-style: none;width: calc(100vw - 407px)}.drugSearchResult li {padding: 25px !important;margin: 10px 0;background: #fafafa;border: 1px solid #ccc;display: inline-block;width: calc(100% - 50px)}.drugSearchResult .drug_img img {width: auto;height: 125px;border-radius: 5px;transition: 250ms all}.drugSearchResult .drug_img a:hover img {opacity: .8}.drugSearchResult .drug_info .drug_name {margin: 15px 0}.drugSearchResult .drug_info .drug a:hover {text-decoration: underline}.drugSearchResult.fdbdrug {overflow-x: auto;display: inline-flex;min-height: 300px}.drugSearchResult.fdbdrug::-webkit-scrollbar-track {box-shadow: inset 0 0 3px rgba(0, 0, 0, 0.2);background-color: #F5F5F5}.drugSearchResult.fdbdrug::-webkit-scrollbar {height: 15px;background-color: #F5F5F5}.drugSearchResult.fdbdrug::-webkit-scrollbar-thumb {background-color: #000}.drugSearchResult.fdbdrug::-webkit-scrollbar-thumb:hover {background: #2196f3}.drugSearchResult.fdbdrug li {width: 167px;margin: 10px 5px;padding: 15px !important}.drugSearchResult.fdbdrug .drug_info .drug_name {font-size: 12px}h3.drugheader {font-size: 18px;text-align: center;color: #333;text-decoration: none !important;text-transform: capitalize;padding: 5px 10px;margin: 60px 0 25px 0;background: #ddd}/*** Drug Checker ***/.drugChecker_Page ul {margin: 0 0 -3px !important;padding: 0;list-style-type: none}.drugChecker_Page .drug_header img.pillimage {float: right;width: 276px;height: 228px}.drugChecker_Page .drug_header .drugresults.p2 li {position: relative;list-style: none;padding: 10px 0}.drugChecker_Page .drug_header .drugresults.p2 li:before {top: 2px !important}.drugChecker_Page .drug_header .drugresults.p2 li a {margin-left: 40px}.drugChecker_Page .drug_A-Z_list {border-bottom: 1px solid #ccc;padding-bottom: 20px}.drugChecker_Page .drug_A-Z_list h4 {color: #fff;border-bottom: 1px solid #ccc;padding: 40px 0;margin: 0 0 20px}.drugChecker_Page .drug_A-Z_list h4 a {display: inline-block;padding: 10px;margin: 5px 0;color: #6896DA;font-size: 24px;font-weight: 600;line-height: 30px;border-radius: 3px;width: 30px;height: 30px;text-align: center;background: #f5f5f5;transition: all 250ms}.drugChecker_Page .drug_A-Z_list h4 a:hover {background: #000;color: #fff;text-decoration: none}.drugChecker_Page .drug_A-Z_list h4 a.disabled {color: #ddd;pointer-events: none}.drugChecker_Page .drug_A-Z_list h4 a:last-child {font-size: 17px;vertical-align: bottom}.drugChecker_Page #drugNameInput {padding: 30px 0}.drugChecker_Page #drugNameInput h3 {float: left;color: #888;font-size: 16px;margin: 5px 10px 5px 0;text-decoration: none;text-transform: capitalize}.drugChecker_Page #txtAutoComplete {width: 395px;height: 30px}.drugChecker_Page #drugNameOutput {margin: 20px 0;display: none}.drugChecker_Page #drugNameOutput .listresult {border: 1px solid #ccc;border-radius: 10px;padding: 20px}.drugChecker_Page #drugNameOutput .listresult li {font-size: 14px;background: #000;color: #fff;margin: 5px 0;padding: 5px 35px 5px 10px;position: relative}.drugChecker_Page #drugNameOutput .listresult li .remove:before {font-family: 'icomoon';content: "\e624";font-size: 15px;color: #fff;position: absolute;right: 6px;top: 5px}.drugChecker_Page #drugNameOutput .listresult .buttons input {background: #6896da;border: 0;outline: 0;color: #fff;text-transform: uppercase;border-radius: 3px;padding: 10px;margin-right: 5px;transition: all 250ms}.drugChecker_Page #drugNameOutput .listresult .buttons input:hover {background: #000}.drugChecker_Page #foundCount {font-weight: 600;color: #f00;margin: 20px 0;display: block}.drugChecker_Page #resultSevUrl li {margin: 10px 0;line-height: 16px;font-size: 13px}.drugChecker_Page .tabWrap {margin: 20px 0}.drugChecker_Page .tabList li {display: inline-block;margin-right: 3px;padding: 9px 0;z-index: 1;position: relative}.drugChecker_Page .tabList li a {color: #fff;padding: 10px 25px;background: #6896DA;border: 1px solid #6896DA;border-radius: 3px 3px 0 0;transition: all 250ms}.drugChecker_Page .tabList li a:hover {text-decoration: none;background: #000;border-color: #000}.drugChecker_Page .tabList li.active a {color: #232323;background: #fff;border-color: #ccc;border-bottom-color: #fff}.drugChecker_Page .tabContent {border: 1px solid #ccc;margin: -2px 0 40px;padding: 20px;position: relative}.drugChecker_Page .tabContent .sevdesctitle {font-size: 19px;font-weight: 600;margin-left: 40px}.drugChecker_Page .tabContent .sevdesc {display: inline-block;font-size: 15px;line-height: 17px;margin-left: 40px}.drugChecker_Page .tabContent .intsource,.drugChecker_Page .tabContent .intcopyright,.drugChecker_Page .drug_disclaimer {font-size: 13px}.drugChecker_Page .divider {border-top: 1px dotted #ddd;margin: 30px 0}.drugChecker_Page .pillIcon:before,.drugChecker_Page .drug_header .drugresults.p2 ul li:before {font-family: 'icomoon';content: "\e905";font-size: 26px;position: absolute;top: 15px}.drugChecker_Page .serious.pillIcon:before,.drugChecker_Page .drug_header .drugresults.p2 ul li.serious:before {color: #cc0000}.drugChecker_Page .significant.pillIcon:before,.drugChecker_Page .drug_header .drugresults.p2 ul li.significant:before {color: #ff6600}.drugChecker_Page .minor.pillIcon:before,.drugChecker_Page .drug_header .drugresults.p2 ul li.minor:before {color: #ffaf00}.drugChecker_Page .drugexplained {border: 1px solid #ccc;padding: 20px}.drugChecker_Page .drugexplained h3 {margin: 0}.drugChecker_Page .drugexplaindetail {padding: 5px 0;position: relative}.drugChecker_Page .drugexplaindetail h3 {font-size: 16px;margin: 16px 0 2px 40px;text-decoration: none}.drugChecker_Page .drugexplaindetail p {line-height: 20px;margin: 0 0 0 40px}.drugChecker_Page .drug_content {margin: 30px 0}.drugChecker_Page .intChkDriverText {text-align: center;margin: 40px 0 0 0}.drugChecker_Page .intChkDriverBtn {text-align: center;margin: 20px 0 40px}.drugChecker_Page .intChkDriverBtn a {background: #6896da;color: #fff;text-transform: uppercase;border-radius: 3px;padding: 10px 30px;transition: all 250ms}.drugChecker_Page .intChkDriverBtn a:hover {background: #000;color: #fff;text-decoration: none}/*** Pharmacy Locater ***/.cityAlphaDiv h3 {color: #6896da;font-size: 24px;background: #6896DA;margin: 0;padding: 5px 10px;text-decoration: none !important;position: relative}.cityAlphaDiv h3 span {position: absolute;left: 16px;color: #fff}.cityAlphaDiv ul {list-style-type: none;margin: 0;padding: 0;display: block !important}.cityAlphaDiv li {padding: 0 !important}.cityAlphaDiv li a {padding: 10px !important;font-size: 16px;display: block;transition: all 250ms}.cityAlphaDiv li:nth-child(even) a {background: #f5f5f5}.cityAlphaDiv li a:hover {background: #000;color: #fff;text-decoration: none}.cityAlphaDiv .noCityLetter {color: #ec4747;font-size: 18px}#divCityAZ table {width: 100% !important;table-layout: fixed}#divCityAZ table ul {list-style-type: none;margin: 0 5px;padding: 0;display: block}#divCityAZ table li {padding: 0;border-bottom: 1px solid #ddd}#divCityAZ table li a {padding: 10px 15px;font-size: 16px;display: block;white-space: nowrap;overflow: hidden;text-overflow: ellipsis;transition: all 250ms}#divCityAZ table li a:hover {background: #000;color: #fff;text-decoration: none}#divCityAZ table img {margin-right: 10px}#localTopicsPharm .legend,#tabcontentcontainer .tabcontent {display: none}#map_canvas_pharmacy,#map_canvas_hospital {width: 100% !important;margin: 15px 0}#localTopicsPharmTabs {margin: 20px 0;position: relative}#localTopicsPharmTabs #tablist {margin: 0;padding: 0;width: 100%}#localTopicsPharmTabs #tablist li {float: left;list-style: none;padding: 0;margin-right: 10px}#localTopicsPharmTabs #tablist li a {color: #fff;font-weight: 600;text-transform: uppercase;text-decoration: none;padding: 10px 20px;background: #ec4747 !important;display: inline-block;border-radius: 3px 3px 0 0;transition: all 250ms}#localTopicsPharmTabs #tablist li a.current {background: #2196f3 !important}#localTopicsPharmTabs #tablist li a:hover {background: #000 !important}#localTopicsPharmTabs #tabcontentcontainer,#localTopicsHospitalsContent {background: #fff !important;height: 400px;overflow-y: auto;clear: both}#tabcontentcontainer .tabcontent:before {content: "";width: 100%;position: absolute;border-top: 3px solid #2196f3;margin-top: -3px}#tabcontentcontainer .tabcontent:last-child:before {border-color: #ec4747}#localTopicsPharmDiv,#localTopicsHospitalsDiv {padding: 15px;margin-right: 15px;position: relative}#localTopicsPharmDiv:nth-child(even),#localTopicsHospitalsDiv:nth-child(even) {background: #f2f2f2}#localTopicsPharmDiv img,#localTopicsHospitalsDiv img {position: absolute}#localTopicsPharmDiv p,#localTopicsHospitalsDiv p {margin: -3px 90px 0 26px}#localTopicsPharmDiv .pharmacy a,#localTopicsHospitalsDiv .hospital a {font-weight: 600;text-decoration: underline}#localTopicsPharmDiv h2 {position: absolute;font-size: 12px;color: #ec4747;right: 10px;top: 3px}#hospitalTerms {font-size: 11px;padding: 30px 0}#hospitalTerms span {font-weight: 600}#pharm,#emerg,#hospitals {margin-top: 70px}/*** Responsive ***/@media (min-width:768px) {.story {width: calc(100% - 352px);padding: 0 50px 0 0;}.masterhead,.rxArt .adTopWrapper.hide,.wrapper-hero,.submenu.stuck {max-width: calc(100vw - 80px);margin: 0 auto;}.masterSub.on,.masterSub {max-width: calc(100vw - 80px);margin: 0 auto;left: 0;right: 0;}.miniTitle .hero h1 {left: 150px;}}@media (max-width:1023px) {.topDrug .azList ul {column-count: 1}}@media (min-width:1024px) and (max-width:1199px) {.submenu .tab a {font-size: 13px;padding: 10px;height: 22px}.submenu .tab a span,.submenu .tab a .icon-pro {font-size: 20px}.submenu .toc.link a {font-size: 16px;line-height: 18px;padding: 6px 10px}.webmdrx_coup .wrapper .reg {display: none}.webmdrx_coup .wrapper .cou {left: 26%}}@media (min-width:1024px) {.stickyColLeft {display: block}#quiz-wrapper .story {width: 100%;padding: 0 20px 30px 20px}.article-promo .item {padding: 0 2px;width: calc(33% - 6px)}.drugChecker_Page .drug_A-Z_list li a {width: calc(100vw - 645px)}.drugSearchResult {width: calc(100vw - 597px)}}@media (min-width:1200px) {.wrapper-sponsors {padding: 40px 5%}.wrapper-sponsors h2 {font-size: 30px}.wrapper-sponsors .sponsors ul li a {font-size: 18px}.wrapper-sponsors .sponsors ul {margin: 16px 0}footer nav a {padding: 0 15px}footer nav .network a:after {padding: 0 20px}footer nav .network a {font-size: 16px}main section>.wrapper {max-width: 1100px}.story header h2 {font-size: 30px;margin: 20px 190px 10px 0;line-height: 30px}.story article .alert {font-size: 16px;padding: 8px 16px}.share a {font-size: 22px;width: 40px;height: 40px;margin: 0 2px}.share span {padding: 9px;line-height: 39px}#accordion .fold ul {column-count: 3}.article-promo .item {padding: 0 20px}#quizWrapper .question-message.show {min-width: 758px}}@media (min-width:1300px) {main#HP .container {column-count: 2;column-gap: 14px}.masterhead .wrapper {}.breadcrumbs {width: calc(95% - 375px)}#quiz-wrapper .story {padding: 0 20px 30px 0}#quizWrapper .question-message.show {width: calc(100vw - 557px)}.Rxl_landing_DC ul,.sc_common_ss ul,.sc_popular_sym ul,.drugCentRelatedDrugs ul {column-count: 2;column-gap: 50px;list-style-position: inside;display: block !important}.Rxl_landing_DC ul li,.sc_common_ss ul li,.sc_popular_sym ul li,.drugCentRelatedDrugs ul li {break-inside: avoid}.drugSearchResult {width: 100%}.drugSearchResult .drug_img {float: left;margin: 0 30px 5px 0}.drugSearchResult .drug_info .drug_name {margin: 0 0 15px 0}}@media (min-width:1350px) {.masterhead,.rxArt .adTopWrapper.hide,.wrapper-hero,.submenu.stuck {max-width: 1250px;}.masterSub.on,.masterSub {width: 1250px;left: 0;right: 0;}}@media (min-width:1400px) {main section>.wrapper {max-width: 1200px}.submenu.stuck .tab {width: 190px}.submenu.stuck .tab a {font-size: 16px}.submenu.stuck .toc.link a {font-size: 15px}.story header h2 {font-size: 42px;line-height: 42px}.story article {font-size: 17px}.pgContent #artPromoCunk .artPCLinks {width: 72%}#accordion .fold ul {column-count: 4}.slideshow .apPage h3 {font-size: 30px}.slideshow .apPage .content {font-size: 18px;max-width: 800px}/**.mediaPrmo img{width:60%}**/.mediaPrmo .skew {left: 55%}.mediaPrmo .label,.mediaPrmo .caption,.mediaPrmo .desc,.mediaPrmo .btn {margin-left: 60%}.miniTitle .hero h1 {left: 200px;}}@media (min-width:1500px) {main#HP .promoSearch {display: flex;align-items: center}.promoSearch{padding:40px 12vw;}main#HP .promoSearch img {margin: 0 80px 0;}main#HP .sc-searchbox {width: 100%}main#HP .promoSearch .sc-searchbox .sc-searchbox-list {width: calc(60vw - 350px)}.article-promo .item {padding: 0 10px;height: 125px;width: calc(33% - 20px);max-width: 350px}.article-promo a img {position: absolute}.article-promo a span,.article-promo a p {margin-left: 160px;font-size: 15px}.story #sponsors .wrapper ul {column-count: 3}#lrgArtImg {float: right;clear: both;margin: 20px 0 20px 20px !important;width: 500px !important}.miniTitle .hero h1 {left: 250px;}/**.story{margin:0 6%;width: calc(76% - 240px)}**//**.masterhead .wrapper{margin:0 4%}**//**.wrapper-hero{margin:0 4%}**//**.masterSub nav{margin:0 3%}**/}@media (min-width:1600px) {.miniTitle .hero h1 {left: 300px;}/**.wrapper-hero{margin:0 4%}.story{margin:0 6%;width: calc(86% - 400px)}**//**.masterhead .wrapper{margin:0 5%}**//**.masterSub nav{margin:0 5%}**/}@media (min-width:1800px) {.miniTitle .hero h1 {left: 400px;}}/*** Print ***/@media print {*,*:before,*:after {background: transparent !important;color: #000 !important;box-shadow: none !important;text-shadow: none !important}a,a:visited {text-decoration: underline}abbr[title]:after {content: " (" attr(title) ")"}a[href^="#"]:after,a[href^="javascript:"]:after {content: ""}pre,blockquote {border: 1px solid #999;page-break-inside: avoid;padding: 20px}thead {display: table-header-group}tr,img {page-break-inside: avoid}img {max-width: 100% !important}p,h2,h3 {orphans: 3;widows: 3}h2,h3 {page-break-after: avoid}#backTop,.adTopWrapper,header,.sticky-wrapper,.stickyColLeft,.stickyColRight,.toc,.webmdrx,.driver,.btn_driver,.medianet,.article-promo,#crsprm-2081-assmnt,#fdaWrapper,.from_webmd,.aia_rdr,.forum_symptom_checker,.article-extra,#footerAd_rdr,#sponsors,footer {display: none !important}.wrapper-hero {padding: 0 !important}}</style>
<style>.moduleSpacer_rdr{background:url(https://images.medicinenet.com/images/sponsorbox/spacer.gif) 0 0;clear:both;font-size:1%;height:4px}.sponsorBox_right_rdr{width:470px;background-color:#fff;padding-right:4px;clear:both}.sponsorBox_right_rdr a:link,.sponsorBox_right_rdr a:visited{color:#069!important;text-decoration:none}.sponsorBox_right_rdr a:hover,.sponsorBox_right_rdr a:active{color:#24a2dd!important;text-decoration:underline}.sponsorBox_right_rdr.sponsorBoxCenterArea{padding-right:0}.sponsorBox_header_fmt{background:url(https://images.medicinenet.com/images/sponsorbox/sponsorBoxBorderTop.gif) repeat-x;height:33px;padding:1px 0 0}.sponsorBox_topLeft_fmt{float:left;margin:-1px 0 0 0;padding:0}.sponsorBox_topRight_fmt{float:right;margin:-1px 0 0 0}.sponsorBox_mainLinks_fmt{background:url(https://images.medicinenet.com/images/sponsorbox/sponsorBoxBorderRight.gif) repeat-y 100% 0;clear:both}.sponsorBox_mainLinksContent_fmt{padding:0;background:url(https://images.medicinenet.com/images/sponsorbox/sponsorBoxBorderLeft.gif) repeat-y}* html .sponsorBox_mainLinksContent_fmt{height:0}.sponsorBox_sponsorText_fmt{background:url(https://images.medicinenet.com/images/sponsorbox/SponsorBoxText.gif) no-repeat;float:left;width:13px;margin:0}.sponsorBox_links_fmt{float:left;width:350px}.sponsorBox_links_wide_fmt{float:left;width:350px}.sponsorBox_links_fmt ul,.sponsorBox_links_wide_fmt ul,.sponsorBox_linksRightAligned_fmt ul,.sponsorBox_center_links_fmt ul,.sponsorBox_center_linksRightAligned_fmt ul{clear:left;list-style:none;margin:0;padding:0 0 0 9px}.sponsorBox_links_fmt li,.sponsorBox_links_wide_fmt li,.sponsorBox_linksRightAligned_fmt li,.sponsorBox_center_links_fmt li,.sponsorBox_center_linksRightAligned_fmt li{background:url(https://images.medicinenet.com/images/sponsorbox/sponsorBoxListBullet.gif) no-repeat 0 3px;font-size:90%;list-style-image:none!important;margin:4px 0 0;padding:0 0 0 15px}* html .sponsorBox_links_fmt li,* html .sponsorBox_links_wide_fmt li,* html .sponsorBox_linksRightAligned_fmt li,* html .sponsorBox_center_links_fmt li,* html .sponsorBox_center_linksRightAligned_fmt li{background-position:0 5px;margin:2px 0 0}#middleContent_fmt .sponsorBox_links_fmt li,#middleContent_fmt .sponsorBox_links_wide_fmt li,#middleContent_fmt .sponsorBox_linksRightAligned_fmt li,#middleContent_fmt .sponsorBox_center_links_fmt li,#middleContent_fmt .sponsorBox_center_linksRightAligned_fmt li{font-size:90%}*+html .sponsorBox_mainLinksContent_fmt{min-height:0}*+html .sponsorBox_links_fmt li,*+html .sponsorBox_links_wide_fmt li,*+html .sponsorBox_linksRightAligned_fmt li,*+html .sponsorBox_center_links_fmt li,*+html .sponsorBox_center_linksRightAligned_fmt li{background-position:0 5px;margin:2px 0 0}*+html .sponsorBox_links_fmt{font-size:100%}.sponsorBox_photo_fmt{float:right;padding:7px 8px 6px 0}.sponsorBox_linksRightAligned_fmt{float:right;width:210px}.sponsorBox_photoLeftAligned_fmt{float:left;padding:7px 0 0 8px}.sponsorBox_bottom_fmt{background:url(https://images.medicinenet.com/images/sponsorbox/sponsorBoxBkg.gif) no-repeat 100% 100%}.sponsorBox_bottomBorder_fmt{background:#fff url(https://images.medicinenet.com/images/sponsorbox/sponsorBoxBkg.gif) no-repeat 0 100%;font-size:1%;height:10px;width:20px}* html .sponsorBox_bottomBorder_fmt{height:7px}.sponsorBox_clear_fmt{clear:both}.sponsorBox_header_fmt .sponsorBox_headerTbl_fmt{float:left;width:93%}.sponsorBoxCenterArea .sponsorBox_headerTbl_fmt{float:left;width:95%}.sponsorBox_header_fmt .dottedLineSP{background:url(https://images.medicinenet.com/images/sponsorbox/sponsorBoxDottedLine.gif) no-repeat right top;padding-left:5px;padding-right:8px}.sponsorBox_header_fmt .topLogoSP{padding-left:8px;padding-top:1px}.sponsorBox_bottomLinks_fmt{clear:both;font-size:80%;padding:3px 0 0 20px}.sponsorBox_bottomLinks_fmt a{padding-right:8px}.sponsorBox_right_rdr.sponsorBoxCenterArea .sponsorBox_bottomLinks_fmt a{padding-right:15px}.sponsorBox_header_fmt h1{color:#6C340A!important;font-size:90%;line-height:1em;margin:0;padding:0}.sponsorBox_header_fmt h1 a:link,.sponsorBox_header_fmt h1 a:visited{color:#6C340A!important}.sponsorBox_clearingDiv_fmt{clear:both;font-size:0;height:0}#mainContent_ctr .sponsorBox_right_rdr{padding-right:0}#mainContent_ctr .sponsorBox_headerTbl_fmt{width:93%}#mainContent_ctr .sponsorBox_links_fmt{float:left;width:350px}#mainContent_ctr .sponsorBox_bottomLinks_fmt a{padding-right:15px}#mainContent_ctr .sponsorBox_header_fmt h1{font-size:90%}#mainContent_ctr .sponsorBox_links_fmt li,#mainContent_ctr .sponsorBox_links_wide_fmt li,#mainContent_ctr .sponsorBox_linksRightAligned_fmt li,#mainContent_ctr .sponsorBox_center_links_fmt li,#mainContent_ctr .sponsorBox_center_linksRightAligned_fmt li{background:url(https://images.medicinenet.com/images/sponsorbox/sponsorBoxListBullet.gif) no-repeat 0 5px}#thirdCol_area .sponsorBox_header_fmt h1{font-size:80%}#thirdCol_area .sponsorBox_links_fmt li,#thirdCol_area .sponsorBox_links_wide_fmt li,#thirdCol_area .sponsorBox_linksRightAligned_fmt li,#thirdCol_area .sponsorBox_center_links_fmt li,#thirdCol_area .sponsorBox_center_linksRightAligned_fmt li{font-size:85%}#MiddleCol .sponsorBox_links_fmt{float:left;font-size:90%;width:350px}#MiddleCol .sponsorBox_links_fmt li,#MiddleCol .sponsorBox_links_wide_fmt li,#MiddleCol .sponsorBox_linksRightAligned_fmt li,#MiddleCol .sponsorBox_center_links_fmt li,#MiddleCol .sponsorBox_center_linksRightAligned_fmt li{font-size:110%}#MiddleCol .sponsorBox_header_fmt h1{font-size:100%}td.topPad .sponsorBox_links_fmt{float:left;font-size:90%;width:350px}td.topPad .sponsorBox_links_fmt li,td.topPad.sponsorBox_links_wide_fmt li,td.topPad .sponsorBox_linksRightAligned_fmt li,td.topPad .sponsorBox_center_links_fmt li,td.topPad .sponsorBox_center_linksRightAligned_fmt li{font-size:12px}#sponsorBox_frame_fmt{border:1px solid #000;clear:both;margin:0 0 0 25px;overflow:auto;padding:3px}#sponsorBox_frame_fmt a{color:#069}#sponsorBox_frame_fmt a:hover{text-decoration:underline}#sponsorBox_frame_fmt h1{font-size:11px;margin:1px 0 2px;padding:0}#sponsorBox_frame_fmt h2{color:#00539F;font-size:130%;line-height:1.1em;margin:1px 0 2px}#sponsorBox_frame_fmt h3{color:#00539F;font-size:90%;line-height:1.1em;margin:1px 0 2px}#sponsorBox_frame_fmt p{color:#000;font-size:11px;margin:0 0 5px;padding:0}#sponsorBox_frame_fmt ul{color:#000;margin:10px 0 0 20px;padding:0}#sponsorBox_frame_fmt li{background:#fff;color:#000;font-size:11px;list-style-type:dot;margin:0 0 5px;padding:0}#sponsorBox_frame_fmt{background-color:#fff;border:1px solid #999;height:85px;margin:0 5px 0 17px;overflow:auto;position:relative}#sponsorBox_frame_fmt sup{font-size:90%;vertical-align:text-top}#sponsorBox_bottomLinks_fmt{clear:left;font-size:11px;padding:3px 0 0 20px}.sponsorBox494_rdr{background:#fff;font-family:Arial,Verdana,Helvetica,sans-serif;font-size:10pt;padding-right:4px;position:relative;width:100%}.sponsorBox_bottomLinks_fmt{clear:both;font-size:80%;padding:0 0 0 1px}.sponsorBox_bottomLinks_fmt a.infolnk{padding:0 0 0 15px}.sponsorBox_popupHidden{display:none!important}.sponsorBox494_rdr .sponsorBox_popupVisible{background:#fff;border:2px solid #000;left:16px;display:block!important;position:absolute;top:37px;width:454px}.sponsorBox494_rdr .sponsorBox_PopupContent{background:#fff;height:67px;overflow:auto;padding:2px 5px 0 2px;width:447px}.sponsorBox494_rdr .sponsorBox_PopupClose{font-size:80%;text-align:right;width:454px}.sponsorBox_PopupContent h1,.sponsorBox_PopupContent h2,.sponsorBox_PopupContent h3,.sponsorBox_PopupContent h4,.sponsorBox_PopupContent h5{font-size:90%;line-height:12px;margin:0;padding:0 0 2px}.sponsorBox_PopupContent p{font-size:90%;line-height:12px;margin:0;padding:0 0 2px}.sponsorBox_PopupContent strong{font-size:110%;font-weight:700}.sponsorBox_PopupContent ol,.sponsorBox_PopupContent ul{font-size:90%;line-height:12px;margin:0;padding:0 0 2px}.sponsorBox_PopupContent li{margin:0;padding:0}.sponsorBox494_rdr .sponsorBox_PopupClose a,.sponsorBox494_rdr .sponsorBox_PopupClose a:link,.sponsorBox494_rdr .sponsorBox_PopupClose a:hover,.sponsorBox494_rdr .sponsorBox_PopupClose a:visited{color:#069}.sponsorBox494_rdr .sponsorBox_PopupClose a,.sponsorBox494_rdr .sponsorBox_PopupClose a:link{text-decoration:none}.sponsorBox494_rdr .sponsorBox_PopupClose a:hover,.sponsorBox494_rdr .sponsorBox_PopupClose a:visited{text-decoration:underline}.sponsorBox_bottomLinks_fmt{clear:both;font-size:80%;padding:3px 0 0;margin-left:20px}.sponsorBox_title_fmt{padding:0 0 0 5px;float:left}* html .sponsorBox_title_fmt{float:left;margin-left:8px;padding-left:0}.sponsorBox_attribution_fmt{background:url(https://images.medicinenet.com/images/sponsorbox/SponsorBoxDottedLine.gif) no-repeat;float:right;height:32px;margin:0 0 0 4px;padding:0 3px 0 27px}.sponsorBox_title_fmt a:link,.sponsorBox_title_fmt a:visited{color:#6C340A!important;text-decoration:none}.sponsorBox_title_fmt a:hover,.sponsorBox_title_fmt a:active{text-decoration:underline}.sponsorBox_links_fmt a:link,.sponsorBox_links_fmt a:visited{color:#069!important;text-decoration:none}.sponsorBox_links_fmt a:hover,.sponsorBox_links_fmt a:active{color:#24a2dd!important;text-decoration:underline}.video_container{width:300px;border:1px #ddd solid;background-color:#fff;border-radius:5px;-webkit-border-radius:5px;-moz-border-radius:5px}.video_container .video_header{background-color:#f0f0ee;padding:5px 0 5px 6px}.video_container .video_container_links{border-top:1px #ddd solid}.video_container .video_container_links h3{margin:7px 0 0 6px;padding:0;font-size:100%;font-weight:700}.video_container .video_container_links ul{list-style:none;margin:3px 0 17px 12px;padding:0}.video_container .video_container_links ul li{background:url(https://images.medicinenet.com/images/webmd/li_purple.gif) no-repeat 0 9px;line-height:18px;padding-left:8px;font-size:13px!important}</style>
<style>.cookie-consent-ctr .close,.cookie-consent-ctr .legal{box-sizing:border-box;position:relative;vertical-align:middle}.cookie-consent-ctr{background-color:#EDEFEF;box-sizing:border-box;color:#666;font:14px/1.4 Lato,Arial,sans-serif;min-width:1052px;overflow:hidden;padding:1em;position:relative;text-align:center;z-index:1000}.cookie-consent-ctr .close{background:url(data:image/png;base64,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) no-repeat #EDEFEF;cursor:pointer;display:block;float:right;height:28px;width:28px}.cookie-consent-ctr .legal{display:inline-block;max-width:90%}#colorbox,#webmdHoverClose{position:absolute;z-index:999}.thin .cookie-consent-ctr{min-width:790px}.thin.harmony .cookie-consent-ctr{min-width:768px}.ua_type_mobile .cookie-consent-ctr{min-width:100%}.ua_type_mobile .cookie-consent-ctr .legal{float:left;max-width:80%;text-align:left}#webmdHoverOverlay{background:#fefefe;height:100%;position:fixed;width:100%;z-index:999}#colorbox{background:#fff;-moz-box-shadow:0 0 15px 2px #7f7f7f;-webkit-box-shadow:0 0 15px 2px #7f7f7f;box-shadow:0 0 15px 2px #7f7f7f;-moz-border-radius:10px;border-radius:10px;width:550px;overflow:visible!important;padding:0!important}.browserIE #colorbox{border:1px solid #7f7f7f}#webmdHoverContent{background:#fff;-moz-border-radius:12px;border-radius:12px}.browserIE #webmdHoverContent{border:1px solid #999}.browserIE_7 #colorbox,.browserIE_8 #colorbox{border-color:#DADADA;padding-bottom:2px!important;padding-right:2px!important}.browserIE_7 #webmdHoverContent,.browserIE_8 #webmdHoverContent{border-color:#B9B9B9}#webmdHoverClose{background:url(https://img.webmd.com/dtmcms/live/webmd/consumer_assets/site_images/modules/webmd_overlay_close_x.png) no-repeat;cursor:pointer;display:block;height:34px;text-indent:-5000px;width:34px;top:-15px;right:-15px}#webmdHoverTitle,.app_view #adLabel,.app_view .logo_AdChoices{display:none}#webmd_confirm{text-align:center;padding:28px}#webmd_confirm .webmd_confirm_content{text-align:left}#webmd_confirm .webmd_confirm_buttons{margin-top:10px}#webmd_confirm_false_button{margin-left:12px}</style>

<link href="https://images.rxlist.com/oocommon/css/oo-ui.css" rel="stylesheet">

<script type="text/javascript">
var s_account="webmdcom";
var s_pagename="rxlist.com/rocephin-drug.htm";
var s_bu="cns";
var s_siteclass="od";
var s_site="rxlist";
var s_server_type="MN";
var s_channel_health="rxlist";
var s_refpath="rxlist";
var s_server_number="MA4-NET";
var s_asset="66600rdesc";
var s_template_name="RXL_Drug";
var s_channel="4286";
var s_asset_class="rx-mono";
var s_asset_type="content";
var s_articletype="rx-mono";
var s_pagenum="1";
var s_pub="rxlist";
var s_user_group="unregistered";
</script>
<script type="text/javascript" src="https://img.wbmdstatic.com/webmd_static_vue/webmd-share-static-files/webmd/PageBuilder_Assets/JS/api/oo_shim_head.min.js"></script>
<script async src="https://preferences.trustarc.com/webservices/js?domain=webmd&amp;type=webmd_popnew&amp;js=responsive"></script>
<script src="//assets.adobedtm.com/2c8c1e17b98c/bd8b7ed95b8d/launch-a2e2197ecad5.min.js"></script>

<title>Rocephin (Ceftriaxone): Side Effects, Uses, Dosage, Interactions, Warnings</title>
<meta NAME="Description" CONTENT="Rocephin (Ceftriaxone) may treat, side effects, dosage, drug interactions, warnings, patient labeling, reviews, and related medications including drug comparison and health resources." />
<meta NAME="KeyWords" CONTENT="Rocephin Ceftriaxone drug description chemical structure black box warning medications drugs generic fda approved patient labeling reviews professionals clinicians clinical" />



        
<script async src="https://images.rxlist.com/rxlist/js/all.min.js"></script>
<meta name="y_key" content="11fe84c14ab87627" /> 

<meta http-equiv="X-UA-Compatible" content="IE=Edge">
<meta http-equiv="content-type" content="text/html; charset=iso-8859-1" />
<link rel="alternate" type="application/rss+xml" title="RxList - Updated and New Drug Monographs" href="https://www.rxlist.com/rss/rxlist_drugs.xml"/>
<link rel="alternate" type="application/rss+xml" title="RxList - News and Features" href="https://www.rxlist.com/rss/rxlist_news.xml"/>
<link rel="alternate" type="application/rss+xml" title="RxList - Health and Medical Slideshows" href="https://www.rxlist.com/rss/rxlist_slideshows.xml" />

<link rel="canonical" href="https://www.rxlist.com/rocephin-drug.htm" />
<meta property="og:title" content="Rocephin (Ceftriaxone): Side Effects, Uses, Dosage, Interactions, Warnings" />
<meta property="og:description" content="Rocephin (Ceftriaxone) may treat, side effects, dosage, drug interactions, warnings, patient labeling, reviews, and related medications including drug comparison and health resources." />
<meta property="og:site_name" content="RxList" />
<meta property="og:image" content="https://images.rxlist.com/images/facebook/rxlist/fb-rxlist-default-2.jpg" /><meta property="fb:page_id" content="131322716913673" />
<meta property="og:type" content="article" />
<meta property="og:url" content="https://www.rxlist.com/rocephin-drug.htm" />
<meta property="topicid" content="4286" />
<script type="application/ld+json">
[
{
"@context":"https://schema.org",
"@type":"Drug",
"mainEntityOfPage":"https://www.rxlist.com/rocephin-drug.htm",
"lastReviewed":"9/14/2021",

"warning":"https://www.rxlist.com/rocephin-drug.htm#warnings",
"name":"ceftriax",
"drugClass":"Cephalosporins, 3rd Generation",
"isAvailableGenerically":"true",
"relatedDrug":"Ceftriaxone",
"reviewedBy":{"@type":"Person","name":"John P. Cunha, DO, FACOEP"},
"about":"Rocephin (Ceftriaxone) may treat, side effects, dosage, drug interactions, warnings, patient labeling, reviews, and related medications including drug comparison and health resources.",
"datePublished":"9/14/2021",
"headline":"Rocephin (Ceftriaxone): Side Effects, Uses, Dosage, Interactions, Warnings",
"publisher":{
    "@type":"Organization",
    "name":"RxList",
    "logo": {
        "@type":"ImageObject",
        "url":"https://images.rxlist.com/images/oologos/rxlist-logo.jpg"
        }
    }
}
]
</script></head>
<body class="rxArt pgprof">
<div id="backTop">
    <span class="icon-arrow-right2"></span>
</div>    <script type="module" async src="https://images.rxlist.com/oocommon/js/oo-ui.js"></script>
<svg hidden width="240.12" height="37.437" viewBox="0 0 63.533 9.9052"
  xmlns="https://www.w3.org/2000/svg">
  <symbol id="mni-logo-svg">
  <g transform="translate(-32.677 -80.098)">
    <path d="m34.663 81.236 2.6238 6.5484 2.6238-6.5484h1.3725v8.0257h-1.0583v-3.1254l0.09922-3.3734-2.6348 6.4988h-0.81029l-2.6293-6.4823 0.10473 3.3569v3.1254h-1.0583v-8.0257zm10.804 8.1359q-1.2127 0-1.9734-0.79375-0.76068-0.79926-0.76068-2.1332v-0.18741q0-0.88746 0.33624-1.582 0.34175-0.70004 0.94809-1.0914 0.61185-0.39688 1.3229-0.39688 1.1631 0 1.808 0.76619 0.64492 0.76619 0.64492 2.1938v0.42444h-4.0404q0.02205 0.88194 0.51263 1.4276 0.49609 0.54019 1.2568 0.54019 0.54019 0 0.91502-0.22049 0.37483-0.22049 0.65595-0.58429l0.62287 0.48507q-0.74965 1.152-2.249 1.152zm-0.12678-5.3468q-0.61736 0-1.0363 0.452-0.41892 0.44648-0.51814 1.2568h2.9876v-0.07717q-0.0441-0.77721-0.41892-1.2016-0.37483-0.42995-1.0142-0.42995zm3.3845 2.2049q0-1.3725 0.65044-2.2049 0.65043-0.83785 1.7033-0.83785 1.0473 0 1.6592 0.71658v-3.1089h1.0198v8.4667h-0.93707l-0.04961-0.63941q-0.61185 0.74965-1.7033 0.74965-1.0363 0-1.6922-0.84887-0.65044-0.84887-0.65044-2.2159zm1.0197 0.11576q0 1.0142 0.41892 1.5875 0.41892 0.57326 1.1576 0.57326 0.97014 0 1.4166-0.87092v-2.7395q-0.45751-0.84336-1.4056-0.84336-0.74965 0-1.1686 0.57878-0.41892 0.57878-0.41892 1.7143zm6.7028 2.9159h-1.0198v-5.9642h1.0198zm-1.1024-7.5461q0-0.24805 0.14883-0.41892 0.15434-0.17088 0.452-0.17088 0.29766 0 0.452 0.17088 0.15434 0.17088 0.15434 0.41892t-0.15434 0.41341q-0.15434 0.16536-0.452 0.16536-0.29766 0-0.452-0.16536-0.14883-0.16536-0.14883-0.41341zm5.1263 6.8241q0.5457 0 0.9536-0.33073 0.4079-0.33073 0.452-0.82682h0.96463q-0.02756 0.51263-0.35278 0.97565t-0.87092 0.73863q-0.54019 0.27561-1.1465 0.27561-1.2182 0-1.9403-0.81029-0.71658-0.8158-0.71658-2.2269v-0.17088q0-0.87092 0.31971-1.5489 0.3197-0.678 0.91502-1.0528 0.60082-0.37483 1.4166-0.37483 1.0032 0 1.6647 0.60083 0.66697 0.60082 0.71107 1.5599h-0.96463q-0.0441-0.57878-0.44097-0.94809-0.39136-0.37483-0.97014-0.37483-0.77722 0-1.2072 0.56224-0.42444 0.55673-0.42444 1.6151v0.19292q0 1.0308 0.42444 1.5875t1.2127 0.55673zm4.6247 0.72209h-1.0197v-5.9642h1.0197zm-1.1024-7.5461q0-0.24805 0.14883-0.41892 0.15434-0.17088 0.452-0.17088 0.29766 0 0.452 0.17088t0.15434 0.41892-0.15434 0.41341-0.452 0.16536q-0.29766 0-0.452-0.16536-0.14883-0.16536-0.14883-0.41341zm3.6987 1.582 0.03307 0.74965q0.68351-0.8599 1.7859-0.8599 1.8907 0 1.9072 2.1332v3.9412h-1.0197v-3.9467q-0.0055-0.64492-0.29766-0.9536-0.28663-0.30868-0.89848-0.30868-0.4961 0-0.87092 0.26458-0.37483 0.26458-0.58429 0.69453v4.2499h-1.0197v-5.9642zm7.7391 6.0744q-1.2127 0-1.9734-0.79375-0.76068-0.79926-0.76068-2.1332v-0.18741q0-0.88746 0.33624-1.582 0.34175-0.70004 0.94809-1.0914 0.61185-0.39688 1.3229-0.39688 1.1631 0 1.808 0.76619 0.64492 0.76619 0.64492 2.1938v0.42444h-4.0404q0.02205 0.88194 0.51263 1.4276 0.49609 0.54019 1.2568 0.54019 0.54019 0 0.91502-0.22049 0.37483-0.22049 0.65595-0.58429l0.62287 0.48507q-0.74965 1.152-2.249 1.152zm-0.12678-5.3468q-0.61736 0-1.0363 0.452-0.41892 0.44648-0.51814 1.2568h2.9876v-0.07717q-0.0441-0.77721-0.41892-1.2016-0.37483-0.42995-1.0142-0.42995zm9.9605 5.2366h-1.0638l-4.0404-6.1846v6.1846h-1.0638v-8.0257h1.0638l4.0514 6.2122v-6.2122h1.0528zm4.1948 0.11024q-1.2127 0-1.9734-0.79375-0.76068-0.79926-0.76068-2.1332v-0.18741q0-0.88746 0.33624-1.582 0.34175-0.70004 0.94809-1.0914 0.61185-0.39688 1.3229-0.39688 1.1631 0 1.808 0.76619 0.64492 0.76619 0.64492 2.1938v0.42444h-4.0404q0.02205 0.88194 0.51263 1.4276 0.4961 0.54019 1.2568 0.54019 0.54019 0 0.91502-0.22049 0.37483-0.22049 0.65595-0.58429l0.62287 0.48507q-0.74965 1.152-2.249 1.152zm-0.12678-5.3468q-0.61736 0-1.0363 0.452-0.41892 0.44648-0.51814 1.2568h2.9876v-0.07717q-0.0441-0.77721-0.41892-1.2016-0.37483-0.42995-1.0142-0.42995zm5.0161-2.1718v1.4442h1.1135v0.78824h-1.1135v3.6987q0 0.35829 0.14883 0.54019 0.14883 0.17639 0.50712 0.17639 0.17639 0 0.48507-0.06615v0.82682q-0.40239 0.11024-0.78273 0.11024-0.68351 0-1.0308-0.41341t-0.34727-1.1741v-3.6987h-1.0859v-0.78824h1.0859v-1.4442z" stroke-width=".26458" aria-label="RxList"/>
  </g>
</symbol>
</svg><svg hidden><symbol id="magnifying-glass-icon" width="30px" height="30px" viewBox="0 0 24 24" fill="none"><g stroke="currentColor" stroke-linecap="round" stroke-linejoin="round"/><g><path d="M15 15L21 21" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"/><path d="M17 10C17 13.866 13.866 17 10 17C6.13401 17 3 13.866 3 10C3 6.13401 6.13401 3 10 3C13.866 3 17 6.13401 17 10Z" stroke="currentColor" stroke-width="2"/></g></symbol></svg>
<svg hidden><symbol id="arrow-down-icon" viewBox="0 0 512 512" width="512px" height="512px"><polygon points="396.6,160 416,180.7 256,352 96,180.7 115.3,160 256,310.5 "/></symbol></svg>
<svg hidden><symbol id="arrow-up-icon" viewBox="0 0 512 512" width="512px" height="512px"><polygon points="396.6,352 416,331.3 256,160 96,331.3 115.3,352 256,201.5 "/></symbol></svg>
<svg hidden><symbol id="open-icon" viewBox="0 0 100 100" width="100" height="100"><rect width="100" height="10" y="20"></rect><rect width="100" height="10" y="50"></rect><rect width="100" height="10" y="80"></rect></symbol></svg>
<svg hidden><symbol id="close-icon" viewBox="0 0 100 100" width="100" height="100"><line style="stroke:currentColor;stroke-width:10;" x1="5" y1="5" x2="95" y2="95"></line><line style="stroke:currentColor;stroke-width:10;" x1="95" y1="5" x2="5" y2="95"></line></symbol></svg>
<div tw class="max-w-screen-xl mx-auto sticky w-full bg-white z-[10000] top-0 transition-[top] duration-500">
	<nav id="menu" class="w-full flex justify-between items-center box-border px-4 h-12 lg:h-16 border-b border-slate-400 group">
		<div class="hamburger-icon lg:hidden px-2.5 hover:text-sky-400 cursor-pointer">
			<svg class="open-icon fill-current self-center group-[.open-hamburger]:hidden" viewBox="0 0 100 100" width="20" height="20"><use xlink:href="#open-icon"/></svg>
			<svg class="close-icon fill-current self-center hidden group-[.open-hamburger]:inline-block" viewBox="0 0 100 100" width="20" height="20"><use xlink:href="#close-icon"/></svg>
		</div>
		<div class="bg-white z-10 h-full flex justify-between items-center lg:min-w-[200px] lg:max-w-[200px]">
			<a onclick="wmdTrack('tn-home');" itemprop="url" href="https://www.rxlist.com/">
        <img src="https://images.rxlist.com/images/mobile/rxlist/logo-rxl.png" alt="RxList Logo" title="RxList Logo">
    </a>
		</div>
		<div class="grow"></div>
		<div class="menu-center absolute flex flex-col-reverse justify-end lg:flex-row top-12 lg:top-auto lg:relative w-full h-[calc(100vh-128px)] lg:h-full overflow-y-scroll lg:overflow-initial -left-full lg:left-auto transition-all group-[.open-hamburger]:left-0 bg-black lg:bg-white bg-opacity-80 lg:bg-opacity-100">
		<ul class="menu-items flex lg:flex-col-auto flex-col lg:flex-row flex-nowrap w-full max-h-full h-auto lg:h-full overflow-y-scroll lg:overflow-initial p-0 list-none lg:group-[.open-search]:hidden bg-white">
      <li class="relative justify-around flex flex-col px-2 lg:px-0 whitespace-nowrap group/item border-b border-white lg:hover:border-sky-400 cursor-pointer">
        <div class="menu-item flex bg-white z-10 h-full peer group lg:px-3.5 lg:hover:text-sky-400">
					<div class="pointer-events-none lg:pointer-events-auto flex-grow lg:flex-grow-auto whitespace-nowrap self-center pl-3.5 py-2 group-[.show]:text-sky-400 lg:group-[.show]:text-black group-hover/item:text-sky-400 text-lg lg:text-base text-left hover:no-underline">
						<span>Drugs & Vitamins</span>
					</div>
					<div class="icon-button flex self-center">
						<svg class="icon-down self-center lg:group-hover/item:hidden group-[.show]:hidden" viewBox="0 0 512 512" width="30" height="20"><use xlink:href="#arrow-down-icon"/></svg>
						<svg class="icon-up self-center hidden lg:group-hover/item:inline-block lg:group-hover/item:fill-sky-400 group-[.show]:inline-block" viewBox="0 0 512 512" width="30" height="20"><use xlink:href="#arrow-up-icon"/></svg>
					</div>
				</div>
        <ul class="overflow-visible lg:absolute min-w-full hidden lg:flex lg:opacity-0 peer-[.show]:flex flex-col px-3.5 py-1 gap-y-1 top-16 lg:shadow-md lg:bg-neutral-100 group-focus:flex lg:-z-10 lg:transition lg:ease-in-out lg:-translate-y-[120%] lg:group-hover/item:opacity-100 lg:group-hover/item:-translate-y-0 lg:duration-300 border-t lg:border-t-0 border-sky-400">
          <li class="pl-2 lg:pl-0 lg:py-2 hover:text-sky-400 text-lg lg:text-base"><a class="hover:no-underline" onclick="wmdTrack('tn-drug');" href="https://www.rxlist.com/drugs/alpha_a.htm">Drugs A-Z</a></li>
          <li class="pl-2 lg:pl-0 lg:py-2 hover:text-sky-400 text-lg lg:text-base"><a class="hover:no-underline" onclick="wmdTrack('tn-drug');" href="https://www.rxlist.com/script/main/alphaidx.asp?p=a_rx-mcon">Generic Drugs A-Z</a></li>
          <li class="pl-2 lg:pl-0 lg:py-2 hover:text-sky-400 text-lg lg:text-base"><a class="hover:no-underline" href="https://www.rxlist.com/drug_classification/article.htm">Drugs by Classification</a></li>
          <li class="pl-2 lg:pl-0 lg:py-2 hover:text-sky-400 text-lg lg:text-base"><a class="hover:no-underline" href="https://www.rxlist.com/drugs_comparison/article.htm">Drugs Comparison (Drug Vs. Drug)</a></li>
          <li class="pl-2 lg:pl-0 lg:py-2 hover:text-sky-400 text-lg lg:text-base"><a class="hover:no-underline" onclick="wmdTrack('tn-vit');" href="https://www.rxlist.com/supplements/article.htm">Vitamins & Supplements</a></li>
          <li class="pl-2 lg:pl-0 lg:py-2 hover:text-sky-400 text-lg lg:text-base"><a class="hover:no-underline" onclick="wmdTrack('tn-drugint');" href="https://www.rxlist.com/drug-interaction-checker.htm">Drug Interaction Checker</a></li>
	        <li class="pl-2 lg:pl-0 lg:py-2 hover:text-sky-400 text-lg lg:text-base"><a class="hover:no-underline" onclick="wmdTrack('tn-pillid');" href="https://www.rxlist.com/pill-identification-tool/article.htm">Pill Identifier</a></li>
        </ul>
      </li>
      <li  class="relative justify-around flex flex-col px-2 lg:px-0 whitespace-nowrap group/item border-b border-white lg:hover:border-sky-400 cursor-pointer">
        <div class="menu-item flex bg-white z-10 h-full peer group lg:px-3.5 lg:hover:text-sky-400">
					<div class="pointer-events-none lg:pointer-events-auto flex-grow lg:flex-grow-auto whitespace-nowrap self-center pl-3.5 py-2 group-[.show]:text-sky-400 lg:group-[.show]:text-black group-hover/item:text-sky-400 text-lg lg:text-base text-left hover:no-underline">
						<span>Tools & Resources</span>
					</div>
					<div class="icon-button flex self-center">
					<svg class="icon-down self-center lg:group-hover/item:hidden group-[.show]:hidden" viewBox="0 0 512 512" width="30" height="20"><use xlink:href="#arrow-down-icon"/></svg>
					<svg class="icon-up self-center hidden lg:group-hover/item:inline-block lg:group-hover/item:fill-sky-400 group-[.show]:inline-block" viewBox="0 0 512 512" width="30" height="20"><use xlink:href="#arrow-up-icon"/></svg>
					</div>
				</div>
        <ul class="overflow-visible lg:absolute min-w-full hidden lg:flex lg:opacity-0 peer-[.show]:flex flex-col px-3.5 py-1 gap-y-1 top-16 lg:shadow-md lg:bg-neutral-100 group-focus:flex lg:-z-10 lg:transition lg:ease-in-out lg:-translate-y-[120%] lg:group-hover/item:opacity-100 lg:group-hover/item:-translate-y-0 lg:duration-300 border-t lg:border-t-0 border-sky-400">
          <li class="pl-2 lg:pl-0 lg:py-2 hover:text-sky-400 text-lg lg:text-base"><a class="hover:no-underline" onclick="wmdTrack('tn-dict');" href="https://www.rxlist.com/drug-medical-dictionary/article.htm">Medical Dictionary</a></li>
					<li class="pl-2 lg:pl-0 lg:py-2 hover:text-sky-400 text-lg lg:text-base"><a class="hover:no-underline" onclick="wmdTrack('tn-ss');" href="https://www.rxlist.com/drug-slideshows-all/article.htm">Slideshows</a></li>
					<li class="pl-2 lg:pl-0 lg:py-2 hover:text-sky-400 text-lg lg:text-base"><a class="hover:no-underline" onclick="wmdTrack('tn-ic');" href="https://www.rxlist.com/image_gallery_collection/article.htm">Images</a></li>
					<li class="pl-2 lg:pl-0 lg:py-2 hover:text-sky-400 text-lg lg:text-base"><a class="hover:no-underline" onclick="wmdTrack('tn-qz');" href="https://www.rxlist.com/quizzes_a-z_listing/article.htm">Quizzes</a></li>
					<!-- <li class="pl-2 lg:pl-0 lg:py-2 hover:text-sky-400 text-lg lg:text-base"><privacy-button text="Privacy &amp; Other Trust Info"></privacy-button></li> -->
        </ul>
      </li>
			<li class="relative justify-around flex flex-col px-2 lg:px-0 whitespace-nowrap group/item border-b border-white lg:hover:border-sky-400 cursor-pointer">
					<div class="menu-item flex bg-white z-10 h-full peer group">
						<div class="pointer-events-none lg:pointer-events-auto flex-grow lg:flex-grow-auto whitespace-nowrap self-center pl-3.5 py-2 group-[.show]:text-sky-400 lg:group-[.show]:text-black group-hover/item:text-sky-400 text-lg lg:text-base text-left hover:no-underline">
							<span>Privacy & Other Trust Info</span>
						</div>	
						<div class="icon-button flex self-center">
							<svg class="icon-down self-center lg:group-hover/item:hidden group-[.show]:hidden" viewBox="0 0 512 512" width="30" height="20"><use xlink:href="#arrow-down-icon"/></svg>
							<svg class="icon-up self-center hidden lg:group-hover/item:inline-block lg:group-hover/item:fill-sky-400 group-[.show]:inline-block" viewBox="0 0 512 512" width="30" height="20"><use xlink:href="#arrow-up-icon"/></svg>
							</div>
					</div>
					<ul class="overflow-visible lg:absolute min-w-full hidden lg:flex lg:opacity-0 peer-[.show]:flex flex-col px-3.5 py-1 gap-y-1 top-16 lg:shadow-md lg:bg-neutral-100 group-focus:flex lg:-z-10 lg:transition lg:ease-in-out lg:-translate-y-[120%] lg:group-hover/item:opacity-100 lg:group-hover/item:-translate-y-0 lg:duration-300 border-t lg:border-t-0 border-sky-400">
					<li class="pl-2 lg:pl-0 lg:py-2 hover:text-sky-400 text-lg lg:text-base"><a class="hover:no-underline" href="https://www.rxlist.com/script/main/art.asp?articlekey=64474" target="_blank">Privacy Policy</a></li>
					<li class="pl-2 lg:pl-0 lg:py-2 hover:text-sky-400 text-lg lg:text-base"><a class="hover:no-underline" href="https://www.rxlist.com/script/main/art.asp?articlekey=64467" target="_blank">About Us</a></li>
					<li class="pl-2 lg:pl-0 lg:py-2 hover:text-sky-400 text-lg lg:text-base"><a class="hover:no-underline" href="https://www.rxlist.com/contact_us/article.htm" target="_blank">Contact Us</a></li>
					<li class="pl-2 lg:pl-0 lg:py-2 hover:text-sky-400 text-lg lg:text-base"><a class="hover:no-underline" href="https://www.rxlist.com/script/main/art.asp?articlekey=64473" target="_blank">Terms of Use</a></li>
					<li class="pl-2 lg:pl-0 lg:py-2 hover:text-sky-400 text-lg lg:text-base"><a class="hover:no-underline" href="https://www.rxlist.com/script/main/art.asp?articlekey=77768" target="_blank">Advertising Policy</a></li>
					</ul>
			</li>
    </ul>
		<ce-search-box class="nav-search self-center block w-full h-auto lg:h-11 p-2 lg:p-0 lg:w-1/2 lg:absolute lg:right-0 lg:hidden lg:group-[.open-search]:block bg-white" 
			search-api="/rxl/api/search" 
			submit-api="/search/rxl" 
			show-search-button="True" 
			search-button-text="Search" 
			placeholder="Search RxList..." 
			wrapper-class="nav-search"></ce-search-box>
	</div>
		<div class="search-icon flex px-2 lg:p-2 relative box-content border-l lg:border-l-0 border-black hover:text-sky-400 cursor-pointer">
			<svg class="icon fill-current" viewBox="0 0 30 30" width="30" height="30"><use xlink:href="#magnifying-glass-icon"/></svg>
		</div>
	</div>
</nav>
</div>
    <div class="adTopWrapper">
        <!-- Start 728x90 Ad Tag -->
        <!-- Start 728x90 Ad Tag -->     
<div id="bannerAdContainer">
    <div id="bannerAd_ctr">
        <div id="bannerAd_rdr">
            <div id="bannerAd_fmt"> 
                <script>
var ooAdTarget={targets:{'pvid': window.s_pageview_id || '','tug': window.s_tug || '','pug': window.s_pug || '','art': '66600','pt': '4286','uri': '%2Frocephin-drug.htm','app': '8','cc': '9993','oohc': '61'},'blockCodes': '_vac_t886_sex3_sex2_sex1_r529_r05_o92_o8_n97_n46_m32_k80_k7_k591_k51_j30_j10_i_h53_h52_h16_h10_gen2_gen1_g473_g00_food_fit_f65_f10_diet_cust9_cust4_bty21_age234_age123_age122_age121_age11_a55_a54_a49_a403_n952_cust017_cust022_a047_supplements_cust031_nn1_disx12_cust048_cust056_cust063_par_cust084_cust091_cust097_b962_n390_b972_cust126_n898_'}
</script>
<div id="ads2-pos-101" class="ad_placeholder ad"
    data-is-mobile="false" 
    data-block-codes="_vac_t886_sex3_sex2_sex1_r529_r05_o92_o8_n97_n46_m32_k80_k7_k591_k51_j30_j10_i_h53_h52_h16_h10_gen2_gen1_g473_g00_food_fit_f65_f10_diet_cust9_cust4_bty21_age234_age123_age122_age121_age11_a55_a54_a49_a403_n952_cust017_cust022_a047_supplements_cust031_nn1_disx12_cust048_cust056_cust063_par_cust084_cust091_cust097_b962_n390_b972_cust126_n898_" 
    data-pos="101" 
    data-sizes="[[728,90],[970, 90]]">
</div>

            </div>
            <div style="clear:both"></div>
        </div>
    </div>
</div>			
<!-- End 728x90 Ad Tag -->

        <!-- End 728x90 Ad Tag -->
    </div>
    <section class="wrapper-hero">
        <div class="hero" itemscope itemtype="https://schema.org/CreativeWork">
            <h1>
                Rocephin 
            </h1>
            <ul>
   <li itemprop="name">Generic Name: <span><a href="https://www.rxlist.com/ceftriaxone/generic-drug.htm">ceftriaxone</a></span></li>                   <li itemprop="name">Brand Name: <span>Rocephin</span></li>
                    <li itemprop="name">Drug Class: <span><a href="https://www.rxlist.com/how_do_third-generation_cephalosporins_work/drug-class.htm">Cephalosporins, 3rd Generation</a></span></li>
            </ul>
        </div>
        <div class="monolastreviewed">
Medical Editor: 
    <!--START HREFPOPOUT-->
    <a onclick="wmdTrack('art-auth');" href="/script/main/art.asp?articlekey=81326" target="_blank">John P. Cunha, DO, FACOEP</a>
    <!--END HREFPOPOUT-->
    
            <i>Last updated on RxList: <span>9/14/2021</span></i>
        </div>
            <div id="breadcrumbs" itemscope itemtype="https://schema.org/WebPage">
                <p class="breadcrumbs" itemprop="breadcrumb">
                    <a href="https://www.rxlist.com">home</a>
                    <a href="https://www.rxlist.com/drugs/alpha_a.htm">drugs a-z list</a>
                    rocephin (ceftriaxone) drug
                </p>
            </div>
            <!--social icons inserted here from the JS after id=breadcrumb div via append-->
        <ul class="drugDropdown">
            <!-- RELATED CENTER -->
    <!-- RELATED DRUGS -->
    <li>
        <a class="drugSelect">Related Drugs</a>
        <div class="drugOption">
            <a onclick="wmdTrack('lr-reldrug_0');" href="https://www.rxlist.com/cedax-drug.htm" title="Cedax">Cedax</a>
<a onclick="wmdTrack('lr-reldrug_1');" href="https://www.rxlist.com/cefotetan-drug.htm" title="Cefotetan">Cefotetan</a>
<a onclick="wmdTrack('lr-reldrug_2');" href="https://www.rxlist.com/cefzil-drug.htm" title="Cefzil">Cefzil</a>
<a onclick="wmdTrack('lr-reldrug_3');" href="https://www.rxlist.com/duricef-drug.htm" title="Duricef">Duricef</a>
<a onclick="wmdTrack('lr-reldrug_4');" href="https://www.rxlist.com/keflex-drug.htm" title="Keflex">Keflex</a>
<a onclick="wmdTrack('lr-reldrug_5');" href="https://www.rxlist.com/omnicef-drug.htm" title="Omnicef">Omnicef</a>
<a onclick="wmdTrack('lr-reldrug_6');" href="https://www.rxlist.com/recarbrio-drug.htm" title="Recarbrio">Recarbrio</a>
<a onclick="wmdTrack('lr-reldrug_7');" href="https://www.rxlist.com/spectracef-drug.htm" title="Spectracef">Spectracef</a>
<a onclick="wmdTrack('lr-reldrug_8');" href="https://www.rxlist.com/vantin-drug.htm" title="Vantin">Vantin</a>
<a onclick="wmdTrack('lr-reldrug_9');" href="https://www.rxlist.com/xerava-drug.htm" title="Xerava">Xerava</a>

        </div>
    </li>
    <!-- END RELATED DRUGS -->
    
    
<!-- END RELATED CENTER -->
                <li class="drug_review_btn">
                    <!--START DRUG REVIEWS-->
                    <a onclick="wmdTrack('mono-review');" href="https://www.rxlist.com/fdb/drugs/9768/ceftriaxone-drugreviews.htm" rel="nofollow">Rocephin User Reviews</a>
                    <!--END DRUG REVIEWS-->
                </li>
        </ul>
    </section>
    <main class="content">
        <section class="story">
	    <div id="apPage" class="apPage">
		 <div class="monograph_sum">
		 <div class="monograph_header">
                      <h2 class="monograph_source">Drug Summary</h2>
                 </div>
		 <div class="monograph_cont"><h4>What Is Rocephin?</h4>
<p>Rocephin (<a href="https://www.rxlist.com/consumer_ceftriaxone_rocephin/drugs-condition.htm" rel="rx-art" onclick="wmdTrack('embd-lnk');">ceftriaxone</a> sodium) for Injection is a cephalosporin <a href="https://www.rxlist.com/antibiotic/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">antibiotic</a> used to treat many kinds of bacterial infections, including severe or life-threatening forms such as <a href="https://www.rxlist.com/meningitis/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">meningitis</a>. Rocephin is available in <a href="https://www.rxlist.com/generic/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">generic</a> form.</p> 

<h4>What Are Side Effects of Rocephin?</h4>
<p>Common side effects of Rocephin include: 
<ul>
<li>injection site reactions (swelling, redness, pain, a hard lump, or soreness),</li> 
<li>loss of appetite, </li>
<li>nausea, </li>
<li>vomiting, </li>
<li>upset stomach, </li>
<li>diarrhea, </li>
<li>headache, </li>
<li>dizziness, </li>
<li>overactive reflexes, </li>
<li>pain or swelling in your tongue, </li>
<li>sweating, or </li>
<li>vaginal itching or <a href="https://www.rxlist.com/discharge/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">discharge</a>.</li>
</ul>


<h4>Dosage for Rocephin</h4>
<p>The usual adult daily dose is 1 to 2 grams given once a day (or in equally divided doses twice a day) depending on the type and severity of infection. Pediatric dosing depends on the condition being treated and the child's weight.</p> 


<h4>What Drugs, Substances, or Supplements Interact with Rocephin?</h4>
<p>Other drugs may interact with Rocephin. Tell your doctor all prescription and over-the-counter medications and supplements you use.</p> 

<h4>Rocephin During Pregnancy and Breastfeeding</h4>
<p>During pregnancy, Rocephin should be used only if prescribed. This medication passes into breast milk and may have undesirable effects on a nursing infant. Consult your doctor before breast-feeding. </p>

<h4>Additional Information</h4>
<p>Our Rocephin (ceftriaxone sodium) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
</div>
            </div>
	    </div>	
            <nav class="submenu" visibility="hide">
            <span class="icon-menu"></span>
 
            <!--START PROFESSIONAL MENU-->
            <div class="toc link">
		<h2 class="drug_fda">FDA Drug Information</h2>
                <ul class="fda_toc">
                <li><a href="/rocephin-drug.htm#description" id="mnuDESC">Drug Description</a></li>
                    <li><a href="/rocephin-drug.htm#indications" id="mnuIDS1">Indications</a></li>
                    <li><a href="/rocephin-drug.htm#dosage" id="mnuIDS2">Dosage</a></li>
                
                    <li><a href="/rocephin-drug.htm#side_effects" id="mnuAD1">Side Effects</a></li>
                    <li><a href="/rocephin-drug.htm#interactions" id="mnuAD2">Drug Interactions</a></li>

                    <li><a href="/rocephin-drug.htm#warnings" id="mnuWCP1">Warnings</a></li>                        
                    <li><a href="/rocephin-drug.htm#precautions" id="mnuWCP2">Precautions</a></li>         

                        <li><a href="/rocephin-drug.htm#overdosage" id="mnuOD1">Overdose & Contraindications</a></li>
                    
                <li><a href="/rocephin-drug.htm#clinpharm" id="mnuCP">Clinical Pharmacology</a></li>
                <li><a href="/rocephin-drug.htm#medguide" id="mnuPI">Medication Guide</a></li>
                </ul>
            </div>
            <!--END PROFESSIONAL MENU-->
            </nav>

                <article class="pageContainer">	
                    <div>
                    	
<section class="pageSection">
    <div id="apPage" class="apPage">
        <div class="wrapper">
            <a class="bookmark" name="description"></a>
            <div class="pgContent">
                

                </p>
<a name="D"></a>

<h2>Description for Rocephin</h2>

<p>Rocephin is a sterile, semisynthetic, broad-spectrum cephalosporin <a href="https://www.rxlist.com/antibiotic/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">antibiotic</a> for intravenous or <a href="https://www.rxlist.com/intramuscular_im/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">intramuscular</a> administration. Ceftriaxone sodium is (6<i>R</i>,7<i>R</i>)-7-[2-(2Amino-4-thiazolyl)glyoxylamido]-8-oxo-3-[[(1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-<i>as</i>triazin-3-yl)thio]methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7<sup>2</sup>-(<i>Z</i>)(<i>O</i>-methyloxime), disodium salt, sesquaterhydrate.</p>

<p>The chemical formula of ceftriaxone sodium is C<sub>18</sub>H<sub>16</sub>N<sub>8</sub>Na<sub>2</sub>O<sub>7</sub>S<sub>3</sub>&bull;3.5H<sub>2</sub>O. It has a calculated molecular weight of 661.59 and the following structural formula:</p>

<p></p>

<center>
<table cellspacing="0" class="blackpic" width="447">
	<tbody>
		<tr>
			<td><img alt="ROCEPHIN&reg; (ceftriaxone sodium) Structural Formula Illustration" height="136" src="https://images.rxlist.com/images/rxlist/ceftriax1.gif" width="447" /></td>
		</tr>
	</tbody>
</table>
</center>

<p></p>

<p>Rocephin is a white to yellowish-orange crystalline powder which is readily soluble in water, sparingly soluble in methanol and very slightly soluble in ethanol. The pH of a 1% aqueous solution is approximately 6.7. The color of Rocephin solutions ranges from light yellow to amber, depending on the length of storage, concentration and diluent used.</p>

<p>Rocephin contains approximately 83 mg (3.6 mEq) of sodium per gram of ceftriaxone activity.</p>

            </div>
            
<div id="667441035-1" class="medianet"><script type="text/javascript">try { window._mNHandle.queue.push(function () { window._mNDetails.loadTag("667441035-1", "510x175", "667441035"); }); } catch (error) { }</script></div>

        </div>
    </div>
</section>
<section class="pageSection">
    <div id="apPage" class="apPage">
        <div class="wrapper">
            <a class="bookmark" name="indications"></a>
            <div class="pgContent">
                

                
<a name="I"></a><h2>Uses for Rocephin</h2>
<p>Before instituting treatment with Rocephin, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing.</p>
<p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of Rocephin and other antibacterial drugs, Rocephin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p>
<p>Rocephin is indicated for the treatment of the following infections when caused by susceptible organisms:</p>
<p><i>LOWER RESPIRATORY TRACT INFECTIONS</i> caused by <i>Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis or Serratia marcescens.</i></p>
<p><i>ACUTE BACTERIAL OTITIS MEDIA</i> caused by <i>Streptococcus pneumoniae, Haemophilus influenzae</i> (including beta-lactamase producing strains) or <i>Moraxella catarrhalis</i> (including beta-lactamase producing strains).</p>
<p>NOTE: In one study lower clinical cure rates were observed with a single dose of Rocephin compared to 10 days of oral therapy. In a second study comparable cure rates were observed between single dose Rocephin and the comparator. The potentially lower clinical cure rate of Rocephin should be balanced against the potential advantages of parenteral therapy (see <a href="/rocephin-drug.htm#CS"><b>Clinical Studies</b></a>).</p>
<p><i>SKIN AND SKIN STRUCTURE INFECTIONS</i> caused by <i>Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes,</i> Viridans group streptococci, <i>Escherichia coli, Enterobacter cloacae, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Morganella morganii,* Pseudomonas aeruginosa, Serratia marcescens, Acinetobacter calcoaceticus, Bacteroides fragilis*</i> or <i>Peptostreptococcus</i> species.</p>
<p><i>URINARY TRACT INFECTIONS (complicated and uncomplicated)</i> caused by <i>Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii</i> or <i>Klebsiella pneumoniae.</i></p>
<p><i>UNCOMPLICATED GONORRHEA (cervical/urethral and rectal)</i> caused by <i>Neisseria gonorrhoeae,</i> including both penicillinase-and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase-producing strains <i>of Neisseria gonorrhoeae.</i></p>
<p><i>PELVIC INFLAMMATORY DISEASE</i> caused by <i>Neisseria gonorrhoeae.</i> Rocephin, like other cephalosporins, has no activity against <i>Chlamydia trachomatis.</i> Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and <i>Chlamydia trachomatis</i> is one of the suspected pathogens, appropriate antichlamydial coverage should be added.</p>
<p><i>BACTERIAL SEPTICEMIA</i> caused by <i>Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae</i> or <i>Klebsiella pneumoniae.</i></p>
<p><i>BONE AND JOINT INFECTIONS</i> caused by <i>Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae</i> or <i>Enterobacter</i> species.</p>
<p><i>INTRA-ABDOMINAL INFECTIONS</i> caused by <i>Escherichia coli, Klebsiella pneumoniae, Bacteroides fragilis, Clostridium species</i> (Note: most strains of <i>Clostridium difficile are resistant)</i> or <i>Peptostreptococcus</i> species.</p>
<p><i>MENINGITIS</i> caused by <i>Haemophilus influenzae, Neisseria meningitidis</i> or <i>Streptococcus pneumoniae.</i> Rocephin has also been used successfully in a limited number of cases of meningitis and shunt infection caused by <i>Staphylococcus epidermidis*</i> and <i>Escherichia coli.*</i></p>
<p>*Efficacy for this organism in this organ system was studied in fewer than ten infections.</p>
<p><i>SURGICAL PROPHYLAXIS:</i> The preoperative administration of a single 1 gm dose of Rocephin may reduce the incidence of postoperative infections in patients undergoing
surgical procedures classified as contaminated or potentially contaminated (eg, vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high-risk patients, such as those over 70 years of age, with acute cholecystitis not requiring therapeutic antimicrobials, obstructive jaundice or common duct bile stones) and in surgical patients for whom infection at the operative site would present serious risk (eg, during coronary artery bypass surgery). Although Rocephin has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo-controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery.</p>
<p>When administered prior to surgical procedures for which it is indicated, a single 1 gm dose of Rocephin provides protection from most infections due to susceptible organisms throughout the course of the procedure.</p>

            </div>
            
        </div>
    </div>
</section>
<section class="pageSection">
    <div id="apPage" class="apPage">
        <div class="wrapper">
            <a class="bookmark" name="dosage"></a>
            <div class="pgContent">
                

                <a name="DAA"></a><h2>Dosage for Rocephin</h2>
<p>Rocephin may be administered intravenously or intramuscularly.</p>
<p>Do not use diluents containing calcium, such as Ringer&rsquo;s solution or Hartmann&rsquo;s solution, to reconstitute Rocephin vials or to further dilute a reconstituted vial for IV administration because a precipitate can form. Precipitation of ceftriaxone-calcium can also occur when Rocephin is mixed with calcium-containing solutions in the same IV administration line. Rocephin must not be administered simultaneously with calcium-containing IV solutions, including continuous calcium-containing infusions such as parenteral nutrition via a Y-site. However, in patients other than neonates, Rocephin and calcium-containing solutions may be administered sequentially of one another if the infusion lines are thoroughly flushed between infusions with a compatible fluid (see <a href="/rocephin-drug.htm#W"><b>WARNINGS</b></a>).</p>
<p>There have been no reports of an interaction between ceftriaxone and oral calcium-containing products or interaction between intramuscular ceftriaxone and calcium-containing products (IV or oral).</p>
<h4>Neonates</h4>
<p>Hyperbilirubinemic neonates, especially prematures, should not be treated with Rocephin. Rocephin is contraindicated in premature neonates (see <a href="/rocephin-drug.htm#CI"><b>CONTRAINDICATIONS</b></a>).</p>
<p>Rocephin is contraindicated in neonates (&le; 28 days) if they require (or are expected to require) treatment with calcium-containing IV solutions, including continuous calcium-containing infusions such as parenteral nutrition because of the risk of precipitation of ceftriaxone-calcium (see <a href="/rocephin-drug.htm#CI"><b>CONTRAINDICATIONS</b></a>).</p>
<p>Intravenous doses should be given over 60 minutes in neonates to reduce the risk of bilirubin encephalopathy.</p>
<h4>Pediatric Patients</h4>
<p>For the treatment of skin and skin structure infections, the recommended total daily dose is 50 to 75 mg/kg given once a day (or in equally divided doses twice a day). The total daily dose should not exceed 2 grams.</p>
<p>For the treatment of acute bacterial otitis media, a single intramuscular dose of 50 mg/kg (not to exceed 1 gram) is recommended (see <b>INDICATIONS</b>).
For the treatment of serious miscellaneous infections other than meningitis, the recommended total daily dose is 50 to 75 mg/kg, given in divided doses every 12 hours. The total daily dose should not exceed 2 grams.</p>
<p>In the treatment of meningitis, it is recommended that the initial therapeutic dose be 100 mg/kg (not to exceed 4 grams). Thereafter, a total daily dose of 100 mg/kg/day (not to exceed 4 grams daily) is recommended. The daily dose may be administered once a day (or in equally divided doses every 12 hours). The usual duration of therapy is 7 to 14 days.</p>
<h4>Adults</h4>
<p>The usual adult daily dose is 1 to 2 grams given once a day (or in equally divided doses twice a day) depending on the type and severity of infection. The total daily dose should not exceed 4 grams.</p>
<p>If <i>Chlamydia trachomatis</i> is a suspected pathogen, appropriate antichlamydial coverage should be added, because ceftriaxone sodium has no activity against this organism.</p>
<p>For the treatment of uncomplicated gonococcal infections, a single intramuscular dose of 250 mg is recommended.</p>
<p>For preoperative use (surgical prophylaxis), a single dose of 1 gram administered intravenously 1/2 to 2 hours before surgery is recommended.</p>
<p>Generally, Rocephin therapy should be continued for at least 2 days after the signs and symptoms of infection have disappeared. The usual duration of therapy is 4 to 14 days; in complicated infections, longer therapy may be required.</p>
<p>When treating infections caused by <i>Streptococcus pyogenes</i>, therapy should be continued for at least 10 days.</p>
<p>No dosage adjustment is necessary for patients with impairment of renal or hepatic function (see <a href="/rocephin-drug.htm#P"><b>PRECAUTIONS</b></a>).</p>
<p>The dosages recommended for adults require no modification in elderly patients, up to 2 gm per day, provided there is no severe renal and hepatic impairment (see <a href="/rocephin-drug.htm#P"><b>PRECAUTIONS</b></a>).</p>
<h4>Directions For Use</h4>
<h5>Intramuscular Administration</h5>
<p>Reconstitute Rocephin powder with the appropriate diluent (see <b>Compatibility And Stability</b>).</p>
<p>Inject diluent into vial, shake vial thoroughly to form solution. Withdraw entire contents of vial into syringe to equal total labeled dose.</p>
<p>After reconstitution, each 1 mL of solution contains approximately 250 mg or 350 mg equivalent of ceftriaxone according to the amount of diluent indicated below. If required, more dilute solutions could be utilized.</p>
<p>As with all intramuscular preparations, Rocephin should be injected well within the body of a relatively large muscle; aspiration helps to avoid unintentional injection into a blood vessel.</p>
<p><center><table class="blacktbl" width="450" cellspacing="0">
  <tr>
    <td class="EmphTd" width="40%" rowspan="2">Vial Dosage Size</td>
    <td class="EmphTd" colspan="2">Amount of Diluent to be Added</td>
  </tr>
  <tr>
    <td class="EmphTd" width="30%" align="center">250 mg/mL</td>
    <td class="EmphTd" width="30%" align="center">350 mg/mL</td>
  </tr>
  <tr>
    <td align="center">500 mg</td>
    <td align="center">1.8 mL</td>
    <td align="center">1.0 mL</td>
  </tr>
  <tr>
    <td align="center">1 gm</td>
    <td align="center">3.6 mL</td>
    <td align="center">2.1 mL</td>
  </tr>
</table>
</center></p>
<h5>Intravenous Administration</h5>
<p>Rocephin should be administered intravenously by infusion over a period of 30 minutes, except in neonates where administration over 60 minutes is recommended to reduce the risk of bilirubin <a href="https://www.rxlist.com/encephalopathy/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">encephalopathy</a>. Concentrations between 10 mg/mL and 40 mg/mL are recommended; however, lower concentrations may be used if desired. Reconstitute vials with an appropriate IV diluent (see <b>Compatibility And Stability</b>).</p>
<p><center><table class="blacktbl" width="450" cellspacing="0">
  <tr>
    <td class="EmphTd" width="50%">Vial Dosage Size</td>
    <td class="EmphTd" width="50%">Amount of Diluent to be Added</td>
  </tr>
  <tr>
    <td align="center">500 mg</td>
    <td align="center">4.8 mL</td>
  </tr>
  <tr>
    <td align="center">1 gm</td>
    <td align="center">9.6 mL</td>
  </tr>
</table>
</center></p>
<p>After reconstitution, each 1 mL of solution contains approximately 100 mg equivalent of ceftriaxone. Withdraw entire contents and dilute to the desired concentration with the appropriate IV diluent.</p>
<h4>Compatibility And Stability</h4>
<p>Do not use diluents containing calcium, such as Ringer&rsquo;s solution or Hartmann&rsquo;s solution, to reconstitute Rocephin vials or to further dilute a reconstituted vial for IV administration. Particulate formation can result.</p>
<p>Ceftriaxone has been shown to be compatible with Flagyl<sup>&reg;</sup> IV (metronidazole hydrochloride). The concentration should not exceed 5 to 7.5 mg/mL metronidazole hydrochloride with ceftriaxone 10 mg/mL as an admixture. The admixture is stable for 24 hours at room temperature only in 0.9% sodium chloride injection or 5% dextrose in water (D5W). No compatibility studies have been conducted with the Flagyl<sup>&reg;</sup> IV RTU<sup>&reg;</sup> (metronidazole) formulation or using other diluents. Metronidazole at concentrations greater than 8 mg/mL will precipitate. Do not refrigerate the admixture as precipitation will occur.</p>
<p>Vancomycin, amsacrine, aminoglycosides, and fluconazole are incompatible with ceftriaxone in admixtures. When any of these drugs are to be administered concomitantly with ceftriaxone by intermittent intravenous infusion, it is recommended that they be given sequentially, with thorough flushing of the intravenous lines (with one of the compatible fluids) between the administrations.</p>
<p>Rocephin solutions should <i>not</i> be physically mixed with or piggybacked into solutions containing other <a href="https://www.rxlist.com/antimicrobial/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">antimicrobial</a> drugs or into diluent solutions other than those listed above, due to possible incompatibility (see <a href="/rocephin-drug.htm#W"><b>WARNINGS</b></a>).</p>
<p>Rocephin sterile powder should be stored at room temperature&mdash;77&deg;F (25&deg;C)&mdash;or below and protected from light. After reconstitution, protection from normal light is not necessary. The color of solutions ranges from light yellow to amber, depending on the length of storage, concentration and diluent used.</p>
<p>Rocephin <i>intramuscular</i> solutions remain stable (loss of potency less than 10%) for the following time periods:</p>
<p><center><table class="blacktbl" width="450" cellspacing="0">
  <tr>
  	<td width="40%" class="EmphTd">&nbsp;</td>
    <td class="EmphTd" colspan="3">Storage</td>
  </tr>
  <tr>
    <td class="EmphTd">Diluent</td>
    <td class="EmphTd" width="20%">Concentration<br /> mg/ml</td>
    <td class="EmphTd" width="20%">Room Temp.<br />(25&deg;C)</td>
    <td class="EmphTd" width="20%">Refrigerated<br /> (4&deg;C)</td>
  </tr>
  <tr>
    <td rowspan="2">Sterile Water for Injection</td>
    <td align="center">100</td>
    <td align="center">2 days</td>
    <td align="center">10 days</td>
  </tr>
  <tr>
    <td align="center">250, 350</td>
    <td align="center">24 hours</td>
    <td align="center">3 days</td>
  </tr>
  <tr>
    <td rowspan="2">0.9% Sodium Chloride<br />
	 &nbsp;&nbsp;Solution</td>
    <td align="center">100</td>
    <td align="center">2 days</td>
    <td align="center">10 days</td>
  </tr>
  <tr>
    <td align="center">250, 350</td>
    <td align="center">24 hours</td>
    <td align="center">3 days</td>
  </tr>
  <tr>
    <td rowspan="2">5% Dextrose Solution</td>
    <td align="center">100</td>
    <td align="center">2 days</td>
    <td align="center">10 days</td>
  </tr>
  <tr>
    <td align="center">250, 350</td>
    <td align="center">24 hours</td>
    <td align="center">3 days</td>
  </tr>
  <tr>
    <td rowspan="2">Bacteriostatic Water + 0.9%<br />
	 &nbsp;&nbsp;Benzyl Alcohol</td>
    <td align="center">100</td>
    <td align="center">24 hours</td>
    <td align="center">10 days</td>
  </tr>
  <tr>
    <td align="center">250, 350</td>
    <td align="center">24 hours</td>
    <td align="center">3 days</td>
  </tr>
  <tr>
    <td>1% Lidocaine Solution</td>
    <td align="center">100</td>
    <td align="center">24 hours</td>
    <td align="center">10 days</td>
  </tr>
  <tr>
    <td>&nbsp;&nbsp;(without epinephrine)</td>
    <td align="center">250, 350</td>
    <td align="center">24 hours</td>
    <td align="center">3 days</td>
  </tr>
</table>
</center></p>
<p>Rocephin <i>intravenous</i> solutions, at concentrations of 10, 20 and 40 mg/mL, remain stable (loss of potency less than 10%) for the following time periods stored in glass or PVC containers:</p>
<p><center><table class="blacktbl" width="450" cellspacing="0">
  <tr>
    <td width="40%" class="EmphTd">&nbsp;</td>
    <td class="EmphTd" colspan="2">Storage</td>
  </tr>
  <tr>
    <td class="EmphTd">Diluent</td>
    <td class="EmphTd" width="30%">Room Temp. <br />(25&deg;C)</td>
    <td class="EmphTd" width="30%">Refrigerated <br />(4&deg;C)</td>
  </tr>
  <tr>
    <td>Sterile Water</td>
    <td align="center">2 days</td>
    <td align="center">10 days</td>
  </tr>
  <tr>
    <td>0.9% Sodium Chloride Solution</td>
    <td align="center">2 days</td>
    <td align="center">10 days</td>
  </tr>
  <tr>
    <td>5% Dextrose Solution</td>
    <td align="center">2 days</td>
    <td align="center">10 days</td>
  </tr>
  <tr>
    <td>10% Dextrose Solution</td>
    <td align="center">2 days</td>
    <td align="center">10 days</td>
  </tr>
  <tr>
    <td>5% Dextrose + 0.9% Sodium Chloride Solution*</td>
    <td align="center">2 days</td>
    <td align="center">Incompatible</td>
  </tr>
  <tr>
    <td>5% Dextrose + 0.45% Sodium Chloride Solution</td>
    <td align="center">2 days</td>
    <td align="center">Incompatible</td>
  </tr>
  <tr>
    <td class="credit" colspan="3">*Data available for 10 to 40 mg/mL concentrations in this diluent in PVC containers only.</td>
  </tr>
</table>
</center></p>
<p>The following intravenous Rocephin solutions are stable at room temperature (25&deg;C) for 24 hours, at concentrations between 10 mg/mL and 40 mg/mL: Sodium Lactate (PVC
container), 10% Invert Sugar (glass container), 5% Sodium Bicarbonate (glass container), Freamine III (glass container), Normosol-M in 5% Dextrose (glass and PVC containers), Ionosol-B in 5% Dextrose (glass container), 5% Mannitol (glass container), 10% Mannitol (glass container).</p>
<p>After the indicated stability time periods, unused portions of solutions should be discarded.</p>
<h4>Note</h4>
<p>Parenteral drug products should be inspected visually for particulate matter before administration.</p>
<p>Rocephin reconstituted with 5% Dextrose or 0.9% Sodium Chloride solution at concentrations between 10 mg/mL and 40 mg/mL, and then stored in frozen state (-20&deg;C) in PVC or polyolefin containers, remains stable for 26 weeks.</p>
<p>Frozen solutions of Rocephin should be thawed at room temperature before use. After thawing, unused portions should be discarded. <b>DO NOT REFREEZE.</b></p>
<a name="HS"></a><h2>HOW SUPPLIED</h2>
<p><b>Rocephin</b> is supplied as a sterile crystalline powder in glass vials. The following packages are available:</p>
<p class="EmphText">Vials containing 500 mg equivalent of ceftriaxone. Box of 1 (<b>NDC</b> 0004-1963-02) and box of 10 (<b>NDC</b> 0004-1963-01).</p>
<p class="EmphText">Vials containing 1 gm equivalent of ceftriaxone. Box of 1 (<b>NDC</b> 0004-1964-04) and box of 10 (<b>NDC</b> 0004-1964-01).</p>
<h4>Note</h4>
<p>Rocephin sterile powder should be stored at room temperature, 77&deg;F (25&deg;C) or below, and protected from light.</p>
<p class="credit">Distributed by: <b>Genentech USA, Inc.</b> A Member of the Roche Group, 1 DNA Way, South San Francisco, CA 94080-4990. Revised: July 2018</p>
            </div>
            <div id="667441035-3" class="medianet"><script type="text/javascript">try { window._mNHandle.queue.push(function () { window._mNDetails.loadTag("667441035-3", "510x175", "667441035"); }); } catch (error) { }</script></div>

        </div>
    </div>
</section>
<section class="pageSection">
    <div id="apPage" class="apPage">
        <div class="wrapper">
            <a class="bookmark" name="side_effects"></a>
            <div class="pgContent">
                

                
<a name="AR"></a><h2>Side Effects for Rocephin</h2>
<p>Rocephin is generally well tolerated. In clinical trials, the following adverse reactions, which were considered to be related to Rocephin therapy or of uncertain etiology, were observed:</p>
<p><i><b>Local Reactions</b> - </i>pain, induration and tenderness was 1% overall. Phlebitis was reported in &lt;1% after IV administration. The incidence of warmth, tightness or induration was 17% (3/17) after IM administration of 350 mg/mL and 5% (1/20) after IM administration of 250 mg/mL.</p>
<p><i><b>General Disorders And Administration Site Conditions</b> - </i> injection site pain (0.6%).</p>
<p><i><b>Hypersensitivity</b> - </i> rash (1.7%). Less frequently reported (&lt;1%) were pruritus, fever or chills.</p>
<p><i><b>Infections And Infestations</b> - </i> genital fungal infection (0.1%).</p>
<p><i><b>Hematologic</b> - </i>eosinophilia (6%), thrombocytosis (5.1%) and leukopenia (2.1%). Less frequently reported (&lt;1%) were anemia, hemolytic anemia, neutropenia, lymphopenia, thrombocytopenia and prolongation of the prothrombin time.</p>
<p><i><b>Blood And Lymphatic Disorders</b> - </i>granulocytopenia (0.9%), coagulopathy (0.4%).</p>
<p><i><b>Gastrointestinal</b> - </i>diarrhea/loose stools (2.7%). Less frequently reported (&lt;1%) were nausea or vomiting, and dysgeusia. The onset of pseudomembranous colitis symptoms may occur during or after antibacterial treatment (see <a href="/rocephin-drug.htm#W"><b>WARNINGS</b></a>).</p>
<p><i><b>Hepatic</b> - </i>elevations of aspartate aminotransferase (AST) (3.1%) or alanine aminotransferase (ALT) (3.3%). Less frequently reported (&lt;1%) were elevations of alkaline phosphatase and bilirubin.</p>
<p><i><b>Renal</b> - </i>elevations of the BUN (1.2%). Less frequently reported (&lt;1%) were elevations of creatinine and the presence of casts in the urine.</p>
<p><i><b>Central Nervous System</b> - </i>headache or dizziness were reported occasionally (&lt;1%).</p>
<p><i><b>Genitourinary</b> - </i>moniliasis or vaginitis were reported occasionally (&lt;1%).</p>
<p><i><b>Miscellaneous</b> - </i>diaphoresis and flushing were reported occasionally (&lt;1%).</p>
<p><i><b>Investigations</b> - </i>blood creatinine increased (0.6%).</p>
<p>Other rarely observed adverse reactions (&lt;0.1%) include abdominal pain, agranulocytosis, allergic pneumonitis, anaphylaxis, basophilia, biliary lithiasis, bronchospasm, colitis, dyspepsia, epistaxis, flatulence, gallbladder sludge, glycosuria, hematuria, jaundice, leukocytosis, lymphocytosis, monocytosis, nephrolithiasis, palpitations, a decrease in the prothrombin time, renal precipitations, seizures, and serum sickness.</p>
<h4>Postmarketing Experience</h4>
<p>In addition to the adverse reactions reported during clinical trials, the following adverse experiences have been reported during clinical practice in patients treated with Rocephin. Data are generally insufficient to allow an estimate of incidence or to establish causation.</p>
<p>A small number of cases of fatal outcomes in which a crystalline material was observed in the lungs and kidneys at autopsy have been reported in neonates receiving Rocephin and calcium-containing fluids. In some of these cases, the same intravenous infusion line was used for both Rocephin and calcium-containing fluids and in some a precipitate was observed in the intravenous infusion line. At least one fatality has been reported in a neonate in whom Rocephin and calcium-containing fluids were administered at different time points via different intravenous lines; no crystalline material was observed at autopsy in this neonate. There have been no similar reports in patients other than neonates.</p>
<p><i><b>Gastrointestinal</b> &ndash;</i> pancreatitis, stomatitis and glossitis.</p>
<p><i><b>Genitourinary</b> &ndash;</i> oliguria, ureteric obstruction, post-renal acute renal failure.</p>
<p><i><b>Dermatologic</b> &ndash;</i> exanthema, allergic dermatitis, urticaria, edema; acute generalized exanthematous pustulosis (AGEP) and isolated cases of severe cutaneous adverse reactions (erythema multiforme, Stevens-Johnson syndrome or Lyell&rsquo;s syndrome/toxic epidermal necrolysis) have been reported.</p>
<h5>Hematological Changes</h5>
<p>Isolated cases of agranulocytosis (&lt; 500/mm<sup>3</sup>) have been reported, most of them after 10 days of treatment and following total doses of 20 g or more.</p>
<h5>Nervous System Disorders</h5>
<p>convulsion</p>
<h5>Other, Adverse Reactions</h5>
<p>symptomatic precipitation of ceftriaxone calcium salt in the gallbladder, kernicterus, oliguria, and anaphylactic or anaphylactoid reactions.</p>
<h4>Cephalosporin Class Adverse Reactions</h4>
<p>In addition to the adverse reactions listed above which have been observed in patients treated with ceftriaxone, the following adverse reactions and altered laboratory test results have been reported for cephalosporin class antibiotics:</p>
<h5>Adverse Reactions</h5>
<p>Allergic reactions, drug fever, serum sickness-like reaction, renal dysfunction, toxic nephropathy, reversible hyperactivity, hypertonia, hepatic dysfunction including cholestasis, aplastic anemia, hemorrhage, and superinfection.</p>
<h5>Altered Laboratory Tests</h5>
<p>Positive direct Coombs&rsquo; test, false-positive test for urinary glucose, and elevated LDH (see <a href="/rocephin-drug.htm#P"><b>PRECAUTIONS</b></a>).</p>
<p>Several cephalosporins have been implicated in triggering seizures, particularly in patients with renal impairment when the dosage was not reduced (see <a href="/rocephin-drug.htm#DAA"><b>DOSAGE AND ADMINISTRATION</b></a>). If seizures associated with drug therapy occur, the drug should be discontinued. Anticonvulsant therapy can be given if clinically indicated.</p>

            </div>
            
        </div>
    </div>
</section>
<section class="pageSection">
    <div id="apPage" class="apPage">
        <div class="wrapper">
            <a class="bookmark" name="interactions"></a>
            <div class="pgContent">
                

                <a name="DI"></a><h2>Drug Interactions for Rocephin</h2>
<p>Patients that are administered local anesthetics may be at increased risk of developing methemoglobinemia when concurrently exposed to the following oxidizing agents:</p>
<p><center><table class="blacktbl" width="450" cellspacing="0">
  <tr>
    <td class="EmphTd" width="30%">Class</td>
    <td class="EmphTd" width="70%">Examples</td>
  </tr>
  <tr>
    <td>Nitrates/Nitrites</td>
    <td>Nitroglycerin, nitroprusside, nitric oxide, nitrous oxide</td>
  </tr>
  <tr>
    <td>Local anesthetics</td>
    <td>Benzocaine, lidocaine, bupivacaine, mepivacaine, tetracaine, prilocaine, procaine, articaine</td>
  </tr>
  <tr>
    <td>Antineoplastic agents</td>
    <td>cyclophosphamide, flutamide, rasburicase, isofamide, hydroxyurea</td>
  </tr>
  <tr>
    <td>Antibiotics</td>
    <td>dapsone, sulfonamides, nitrofurantoin, paraaminosalicylic acid</td>
  </tr>
  <tr>
    <td>Antimalarials</td>
    <td>chloroquine, primaquine</td>
  </tr>
  <tr>
    <td>Anticonvulsants</td>
    <td>phenytoin, sodium valproate, phenobarbital</td>
  </tr>
  <tr>
    <td>Other drugs</td>
    <td>acetaminophen, metoclopramide, sulfa drugs (i.e., sulfasalazine), quinine</td>
  </tr>
</table>
</center></p>
            </div>
            <div id="667441035-5" class="medianet"><script type="text/javascript">try { window._mNHandle.queue.push(function () { window._mNDetails.loadTag("667441035-5", "510x175", "667441035"); }); } catch (error) { }</script></div>

        </div>
    </div>
</section>
<section class="pageSection">
    <div id="apPage" class="apPage">
        <div class="wrapper">
            <a class="bookmark" name="warnings"></a>
            <div class="pgContent">
                

                
<a name="W"></a><h2>Warnings for Rocephin</h2>
<h4>Hypersensitivity Reactions</h4>
<p>Before therapy with Rocephin is instituted, careful inquiry should be made to determine whether the patient has had previous hypersensitivity reactions to cephalosporins, penicillins and other beta-lactam agents or other drugs. This product should be given cautiously to <a href="https://www.rxlist.com/penicillin/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">penicillin</a> and other beta-lactam agent-sensitive patients. <a href="https://www.rxlist.com/antibacterial/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">Antibacterial</a> drugs should be administered with caution to any patient who has demonstrated some form of <a href="https://www.rxlist.com/allergy/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">allergy</a>, particularly to drugs. Serious acute hypersensitivity reactions may require the use of subcutaneous <a href="https://www.rxlist.com/epinephrine/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">epinephrine</a> and other emergency measures.</p>
<p>As with all beta-lactam antibacterial agents, serious and occasionally fatal hypersensitivity reactions (i.e., <a href="https://www.rxlist.com/anaphylaxis/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">anaphylaxis</a>) have been reported. In case of severe hypersensitivity reactions, treatment with ceftriaxone must be discontinued immediately and adequate emergency measures must be initiated.</p>
<h4>Methemoglobinemia</h4>
<p>Cases of <a href="https://www.rxlist.com/methemoglobinemia/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">methemoglobinemia</a> have been reported in association with local <a href="https://www.rxlist.com/anesthetic/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">anesthetic</a> use
(e.g. lidocaine). Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, <a href="https://www.rxlist.com/congenital/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">congenital</a> or <a href="https://www.rxlist.com/idiopathic/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">idiopathic</a> methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical manifestations of the condition. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended.</p>
<p>Signs and symptoms of methemoglobinemia may occur immediately or may be delayed some hours after exposure, and are characterized by a <a href="https://www.rxlist.com/cyanotic/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">cyanotic</a> skin discoloration and abnormal coloration of the blood. Methemoglobin levels may continue to rise; therefore, immediate treatment is required to avert more serious <a href="https://www.rxlist.com/central_nervous_system_cns/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">central nervous system</a> and <a href="https://www.rxlist.com/cardiovascular/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">cardiovascular</a> adverse effects, including seizures, coma, arrhythmias, and death. Discontinue Rocephin Kit and any other oxidizing agents. Depending on the severity of the symptoms, patients may respond to <a href="https://www.rxlist.com/supportive_care/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">supportive care</a>, i.e., oxygen therapy, hydration. More severe symptoms may require treatment with methylene blue, exchange <a href="https://www.rxlist.com/transfusion/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">transfusion</a>, or <a href="https://www.rxlist.com/hyperbaric/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">hyperbaric</a> oxygen.</p>
<h4>Interaction With Calcium-Containing Products</h4>
<p>Do not use diluents containing calcium, such as Ringer&rsquo;s solution or Hartmann&rsquo;s solution, to reconstitute Rocephin vials or to further dilute a reconstituted vial for IV administration because a precipitate can form. Precipitation of ceftriaxone-calcium can also occur when
Rocephin is mixed with calcium-containing solutions in the same IV administration line. Rocephin must not be administered simultaneously with calcium-containing IV solutions, including continuous calcium-containing infusions such as <a href="https://www.rxlist.com/parenteral_nutrition/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">parenteral nutrition</a> via a Y-site. However, in patients other than neonates, Rocephin and calcium-containing solutions may be administered sequentially of one another if the infusion lines are thoroughly flushed between infusions with a compatible fluid. <i>In vitro</i> studies using adult and <a href="https://www.rxlist.com/neonatal/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">neonatal</a> plasma from <a href="https://www.rxlist.com/umbilical_cord/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">umbilical cord</a> blood demonstrated that neonates have an increased risk of precipitation of ceftriaxone-calcium (see <a href="/rocephin-drug.htm#CP"><b>CLINICAL PHARMACOLOGY</b></a>, <a href="/rocephin-drug.htm#CI"><b>CONTRAINDICATIONS</b></a> and <a href="/rocephin-drug.htm#DAA"><b>DOSAGE AND ADMINISTRATION</b></a>).</p>
<h5>Clostridium Difficile</h5>
<p><i>Associated Diarrhea</i></p>
<p><i>Clostridium difficile</i> associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Rocephin, and may range in severity from mild diarrhea to fatal <a href="https://www.rxlist.com/colitis/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">colitis</a>. Treatment with antibacterial agents alters the normal <a href="https://www.rxlist.com/flora/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">flora</a> of the <a href="https://www.rxlist.com/colon/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">colon</a> leading to overgrowth of <i>C. difficile.</i></p>
<p><i>C. difficile</i> produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of <i>C. difficile</i> cause increased morbidity and mortality, as these infections can be <a href="https://www.rxlist.com/refractory/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">refractory</a> to antimicrobial therapy and may require <a href="https://www.rxlist.com/colectomy/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">colectomy</a>. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful <a href="https://www.rxlist.com/medical_history/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">medical history</a> is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</p>
<p>If CDAD is suspected or confirmed, ongoing antibiotic use not directed against <i>C. difficile</i> may need to be discontinued. Appropriate fluid and <a href="https://www.rxlist.com/electrolyte/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">electrolyte</a> management, protein supplementation, antibiotic treatment of <i>C. difficile,</i> and surgical evaluation should be instituted as clinically indicated.</p>
<h4>Hemolytic Anemia</h4>
<p>An immune mediated <a href="https://www.rxlist.com/hemolytic_anemia/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">hemolytic anemia</a> has been observed in patients receiving cephalosporin class antibacterials including Rocephin. Severe cases of <a href="https://www.rxlist.com/hemolytic/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">hemolytic</a> <a href="https://www.rxlist.com/anemia/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">anemia</a>, including fatalities, have been reported during treatment in both adults and children. If a patient develops anemia while on ceftriaxone, the diagnosis of a cephalosporin associated anemia should be considered and ceftriaxone stopped until the <a href="https://www.rxlist.com/etiology/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">etiology</a> is determined.</p>

            </div>
            
        </div>
    </div>
</section>
<section class="pageSection">
    <div id="apPage" class="apPage">
        <div class="wrapper">
            <a class="bookmark" name="precautions"></a>
            <div class="pgContent">
                

                <a name="P"></a><h2>Precautions for Rocephin</h2>
<h4>Development Of Drug-Resistant Bacteria</h4>
<p>Prescribing Rocephin in the absence of a proven or strongly suspected bacterial infection or a <a href="https://www.rxlist.com/prophylactic/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">prophylactic</a> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria. Prolonged use of Rocephin may result in overgrowth of nonsusceptible organisms. Careful observation of the patient is <a href="https://www.rxlist.com/essential/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">essential</a>. If superinfection occurs during therapy, appropriate measures should be taken.</p>
<h4>Patients With Renal Or Hepatic Impairment</h4>
<p>Ceftriaxone is excreted via both <a href="https://www.rxlist.com/biliary/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">biliary</a> and renal excretion (see <a href="/rocephin-drug.htm#CP"><b>CLINICAL PHARMACOLOGY</b></a>). Therefore, patients with renal failure normally require no adjustment in dosage when usual doses of Rocephin are administered.</p>
<p>Dosage adjustments should not be necessary in patients with hepatic dysfunction; however, in patients with both hepatic dysfunction and significant renal disease, caution should be exercised and the Rocephin dosage should not exceed 2 gm daily.</p>
<p>Ceftriaxone is not removed by <a href="https://www.rxlist.com/peritoneal/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">peritoneal</a>-or <a href="https://www.rxlist.com/hemodialysis/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">hemodialysis</a>. In patients undergoing <a href="https://www.rxlist.com/dialysis/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">dialysis</a> no additional supplementary dosing is required following the dialysis. In patients with both severe renal and hepatic dysfunction, close clinical monitoring for safety and efficacy is advised.</p>
<h4>Effect On Prothrombin Time</h4>
<p>Alterations in <a href="https://www.rxlist.com/prothrombin/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">prothrombin</a> times have occurred in patients treated with Rocephin. Monitor <a href="https://www.rxlist.com/prothrombin_time/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">prothrombin time</a> during Rocephin treatment in patients with impaired <a href="https://www.rxlist.com/vitamin_k/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">vitamin K</a> synthesis or low vitamin K stores (eg, chronic hepatic disease and <a href="https://www.rxlist.com/malnutrition/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">malnutrition</a>). Vitamin K administration (10 mg weekly) may be necessary if the prothrombin time is prolonged before or during therapy.</p>
<p>Concomitant use of ceftriaxone with Vitamin K antagonists may increase the risk of bleeding. <a href="https://www.rxlist.com/coagulation/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">Coagulation</a> parameters should be monitored frequently, and the dose of the <a href="https://www.rxlist.com/anticoagulant/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">anticoagulant</a> adjusted accordingly, both during and after treatment with ceftriaxone (see <a href="/rocephin-drug.htm#AR"><b>ADVERSE REACTIONS</b></a>).</p>
<h4>Gallbladder Pseudolithiasis</h4>
<p>Ceftriaxone-calcium precipitates in the <a href="https://www.rxlist.com/gallbladder/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">gallbladder</a> have been observed in patients receiving Rocephin. These precipitates appear on sonography as an echo without acoustical shadowing suggesting sludge or as an echo with acoustical shadowing which may be misinterpreted as <a href="https://www.rxlist.com/gallstones/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">gallstones</a>. The probability of such precipitates appears to be greatest in pediatric patients. Patients may be asymptomatic or may develop symptoms of gallbladder disease. The condition appears to be reversible upon discontinuation of ceftriaxone sodium and institution of conservative management. Discontinue ceftriaxone sodium in patients who develop signs and symptoms suggestive of gallbladder disease and/or the sonographic findings described above.</p>
<h4>Urolithiasis And Post-Renal Acute Renal Failure</h4>
<p>Ceftriaxone-calcium precipitates in the <a href="https://www.rxlist.com/urinary_tract/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">urinary tract</a> have been observed in patients receiving Rocephin and may be detected as sonographic abnormalities. The probability of such precipitates appears to be greatest in pediatric patients. Patients may be asymptomatic or may develop symptoms of <a href="https://www.rxlist.com/urolithiasis/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">urolithiasis</a>, and ureteral obstruction and post-renal <a href="https://www.rxlist.com/acute_renal_failure/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">acute renal failure</a>. The condition appears to be reversible upon discontinuation of ceftriaxone sodium and institution of appropriate management. Ensure adequate hydration in patients receiving Rocephin. Discontinue Rocephin in patients who develop signs and symptoms suggestive of urolithiasis, <a href="https://www.rxlist.com/oliguria/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">oliguria</a> or renal failure and/or the sonographic findings described above.</p>
<h4>Pancreatitis</h4>
<p>Cases of <a href="https://www.rxlist.com/pancreatitis/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">pancreatitis</a>, possibly secondary to biliary obstruction, have been reported in patients treated with Rocephin. Most patients presented with risk factors for biliary <a href="https://www.rxlist.com/stasis/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">stasis</a> and biliary sludge (preceding major therapy, severe illness, <a href="https://www.rxlist.com/total_parenteral_nutrition/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">total parenteral nutrition</a>). A cofactor role of Rocephin-related biliary precipitation cannot be ruled out.</p>
<h4>Carcinogenesis, Mutagenesis, Impairment Of Fertility</h4>
<h5>Carcinogenesis</h5>
<p>Considering the maximum duration of treatment and the class of the compound, carcinogenicity studies with ceftriaxone in animals have not been performed. The maximum duration of animal toxicity studies was 6 months.</p>
<h5>Mutagenesis</h5>
<p>Genetic toxicology tests included the Ames test, a micronucleus test and a test for chromosomal aberrations in human lymphocytes cultured <i>in vitro</i> with ceftriaxone. Ceftriaxone showed no potential for mutagenic activity in these studies.</p>
<h5>Impairment Of Fertility</h5>
<p>Ceftriaxone produced no impairment of fertility when given intravenously to rats at daily doses up to 586 mg/kg/day, approximately 20 times the recommended clinical dose of 2 gm/day.</p>
<h4>Pregnancy</h4>
<h5>Teratogenic Effects</h5>
<p><i>Pregnancy Category B.</i></p>
<p>Reproductive studies have been performed in mice and rats at doses up to 20 times the usual human dose and have no evidence of embryotoxicity, fetotoxicity or teratogenicity. In primates, no embryotoxicity or teratogenicity was demonstrated at a dose approximately 3 times the human dose.</p>
<p>There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproductive studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
<h5>Nonteratogenic Effects</h5>
<p>In rats, in the Segment I (fertility and general reproduction) and Segment III (<a href="https://www.rxlist.com/perinatal/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">perinatal</a> and postnatal) studies with intravenously administered ceftriaxone, no adverse effects were noted on various reproductive parameters during gestation and lactation, including postnatal growth, functional behavior and reproductive ability of the offspring, at doses of 586 mg/kg/day or less.</p>
<h4>Nursing Mothers</h4>
<p>Low concentrations of ceftriaxone are excreted in human milk. Caution should be exercised when Rocephin is administered to a nursing woman.</p>
<h4>Pediatric Use</h4>
<p>Safety and effectiveness of Rocephin in neonates, infants and pediatric patients have been established for the dosages described in the <a href="/rocephin-drug.htm#DAA"><b>DOSAGE AND ADMINISTRATION</b></a> section. <i>In vitro</i> studies have shown that ceftriaxone, like some other cephalosporins, can displace bilirubin from serum <a href="https://www.rxlist.com/albumin/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">albumin</a>. Rocephin should not be administered to hyperbilirubinemic neonates, especially prematures (see <a href="/rocephin-drug.htm#CI"><b>CONTRAINDICATIONS</b></a>).</p>
<h4>Geriatric Use</h4>
<p>Of the total number of subjects in clinical studies of Rocephin, 32% were 60 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</p>
<p>The pharmacokinetics of ceftriaxone were only minimally altered in geriatric patients compared to healthy adult subjects and dosage adjustments are not necessary for geriatric patients with ceftriaxone dosages up to 2 grams per day provided there is no severe renal and hepatic impairment. (see <a href="/rocephin-drug.htm#CP"><b>CLINICAL PHARMACOLOGY</b></a>).</p>
<h4>Influence On Diagnostic Tests</h4>
<p>In patients treated with Rocephin the Coombs&rsquo; test may become positive. Rocephin, like other antibacterial drugs, may result in positive test results for galactosemia.</p>
<p>Nonenzymatic methods for the glucose determination in urine may give false-positive results. For this reason, urine-glucose determination during therapy with Rocephin should be done enzymatically.</p>
<p>The presence of ceftriaxone may falsely lower estimated <a href="https://www.rxlist.com/blood_glucose/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">blood glucose</a> values obtained with some blood glucose monitoring systems. Please refer to instructions for use for each system. Alternative testing methods should be used if necessary.</p>
            </div>
            
        </div>
    </div>
</section>
<section class="pageSection">
    <div id="apPage" class="apPage">
        <div class="wrapper">
            <a class="bookmark" name="overdosage"></a>
            <div class="pgContent">
                

                
<a name="OD"></a><h2>Overdose Information for Rocephin</h2>
<p>In the case of overdosage, drug concentration would not be reduced by hemodialysis or <a href="https://www.rxlist.com/peritoneal_dialysis/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">peritoneal dialysis</a>. There is no specific <a href="https://www.rxlist.com/antidote/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">antidote</a>. Treatment of overdosage should be symptomatic.</p>
<a name="CI"></a><h2>Contraindications for Rocephin</h2>
<h4>Hypersensitivity</h4>
<p>Rocephin is contraindicated in patients with known hypersensitivity to ceftriaxone, any of its excipients or to any other cephalosporin. Patients with previous hypersensitivity reactions to penicillin and other beta lactam antibacterial agents may be at greater risk of hypersensitivity to ceftriaxone (see <a href="/rocephin-drug.htm#W"><b>WARNINGS</b></a> - <b>Hypersensitivity</b>).</p>
<h4>Neonates</h4>
<h5>Premature Neonates</h5>
<p>Rocephin is contraindicated in premature neonates up to a postmenstrual age of 41 weeks (gestational age + chronological age).</p>
<h5>Hyperbilirubinemic Neonates</h5>
<p>Hyperbilirubinemic neonates should not be treated with Rocephin. Ceftriaxone can displace bilirubin from its binding to serum albumin, leading to a risk of bilirubin encephalopathy in these patients.</p>
<h4>Neonates Requiring Calcium Containing IV Solutions</h4>
<p>Rocephin is contraindicated in neonates (&le; 28 days) if they require (or are expected to require) treatment with calcium-containing IV solutions, including continuous calcium-containing infusions such as <a href="https://www.rxlist.com/parenteral/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">parenteral</a> <a href="https://www.rxlist.com/nutrition/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">nutrition</a> because of the risk of precipitation of ceftriaxone-calcium (see <a href="/rocephin-drug.htm#CP"><b>CLINICAL PHARMACOLOGY</b></a>, <a href="/rocephin-drug.htm#W"><b>WARNINGS</b></a> and <a href="/rocephin-drug.htm#DAA"><b>DOSAGE AND ADMINISTRATION</b></a>).</p>
<p>Cases of fatal outcomes in which a crystalline material was observed in the <a href="https://www.rxlist.com/lungs/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">lungs</a> and kidneys at autopsy have been reported in neonates receiving Rocephin and calcium-containing fluids.</p>
<p>In some of these cases, the same intravenous infusion line was used for both Rocephin and calcium-containing fluids and in some a precipitate was observed in the intravenous infusion line. There have been no similar reports in patients other than neonates.</p>
<h4>Lidocaine</h4>
<p>Intravenous administration of ceftriaxone solutions containing lidocaine is contraindicated. When lidocaine solution is used as a solvent with ceftriaxone for intramuscular injection, exclude all contraindications to lidocaine. Refer to the prescribing information of lidocaine.</p>
            </div>
            
        </div>
    </div>
</section>
<section class="pageSection">
    <div id="apPage" class="apPage">
        <div class="wrapper">
            <a class="bookmark" name="clinpharm"></a>
            <div class="pgContent">
                <!--MOD_TOPOFPAGE_10-->
                
<a name="CP"></a><h2>Clinical Pharmacology for Rocephin</h2>
<p>Average plasma concentrations of ceftriaxone following a single 30-minute intravenous
(IV) infusion of a 0.5, 1 or 2 gm dose and intramuscular (IM) administration of a single 0.5 (250 mg/mL or 350 mg/mL concentrations) or 1 gm dose in healthy subjects are presented in Table 1.</p>
<p align="center"><b>Table 1 Ceftriaxone Plasma Concentrations After Single Dose Administration</b><br />
<center><table class="blacktbl" width="450" cellspacing="0">
  <tr>
    <td class="EmphTd" width="19%" rowspan="2">Dose/Route</td>
    <td class="EmphTd" colspan="9">Average Plasma Concentrations (&mu;g/mL)</td>
  </tr>
  <tr>
    <td class="EmphTd" width="9%">0.5 hr</td>
    <td class="EmphTd" width="9%">1 hr</td>
    <td class="EmphTd" width="9%">2 hr</td>
    <td class="EmphTd" width="9%">4 hr</td>
    <td class="EmphTd" width="9%">6 hr</td>
    <td class="EmphTd" width="9%">8 hr</td>
    <td class="EmphTd" width="9%">12 hr</td>
    <td class="EmphTd" width="9%">16 hr</td>
    <td class="EmphTd" width="9%">24 hr</td>
  </tr>
  <tr>
    <td>0.5 gm IV*</td>
    <td align="center">82</td>
    <td align="center">59</td>
    <td align="center">48</td>
    <td align="center">37</td>
    <td align="center">29</td>
    <td align="center">23</td>
    <td align="center">15</td>
    <td align="center">10</td>
    <td align="center">5</td>
  </tr>
  <tr>
    <td>0.5 gm IM<br /> &nbsp;&nbsp; 250 mg/mL</td>
    <td align="center">22</td>
    <td align="center">33</td>
    <td align="center">38</td>
    <td align="center">35</td>
    <td align="center">30</td>
    <td align="center">26</td>
    <td align="center">16</td>
    <td align="center">ND</td>
    <td align="center">5</td>
  </tr>
  <tr>
    <td>0.5 gm IM<br /> &nbsp;&nbsp;350 mg/mL</td>
    <td align="center">20</td>
    <td align="center">32</td>
    <td align="center">38</td>
    <td align="center">34</td>
    <td align="center">31</td>
    <td align="center">24</td>
    <td align="center">16</td>
    <td align="center">ND</td>
    <td align="center">5</td>
  </tr>
  <tr>
    <td>1 gm IV*</td>
    <td align="center">151</td>
    <td align="center">111</td>
    <td align="center">88</td>
    <td align="center">67</td>
    <td align="center">53</td>
    <td align="center">43</td>
    <td align="center">28</td>
    <td align="center">18</td>
    <td align="center">9</td>
  </tr>
  <tr>
    <td>1 gm IM</td>
    <td align="center">40</td>
    <td align="center">68</td>
    <td align="center">76</td>
    <td align="center">68</td>
    <td align="center">56</td>
    <td align="center">44</td>
    <td align="center">29</td>
    <td align="center">ND</td>
    <td align="center">ND</td>
  </tr>
  <tr>
    <td>2 gm IV*</td>
    <td align="center">257</td>
    <td align="center">192</td>
    <td align="center">154</td>
    <td align="center">117</td>
    <td align="center">89</td>
    <td align="center">74</td>
    <td align="center">46</td>
    <td align="center">31</td>
    <td align="center">15</td>
  </tr>
  <tr>
    <td class="credit" colspan="10">*IV doses were infused at a constant rate over 30 minutes.<br />
	 ND = Not determined.</td>
  </tr>
</table>
</center></p>
<p>Ceftriaxone was completely absorbed following IM administration with mean maximum plasma concentrations occurring between 2 and 3 hours post-dose. Multiple IV or IM doses ranging from 0.5 to 2 gm at 12-to 24-hour intervals resulted in 15% to 36% accumulation of ceftriaxone above single dose values.</p>
<p>Ceftriaxone concentrations in urine are shown in Table 2.</p>
<p align="center"><b>Table 2 Urinary Concentrations of Ceftriaxone After Single Dose Administration</b><br />
<center><table class="blacktbl" width="450" cellspacing="0">
  <tr>
    <td class="EmphTd" width="22%" rowspan="2">Dose/Route</td>
    <td class="EmphTd" colspan="6">Average Urinary Concentrations (&mu;g/mL)</td>
  </tr>
  <tr>
    <td class="EmphTd" width="13%">0-2 hr</td>
    <td class="EmphTd" width="13%">2-4 hr</td>
    <td class="EmphTd" width="13%">4-8 hr</td>
    <td class="EmphTd" width="13%">8-12 hr</td>
    <td class="EmphTd" width="13%">12-24 hr</td>
    <td class="EmphTd" width="13%">24-48 hr</td>
  </tr>
  <tr>
    <td>0.5 gm IV</td>
    <td align="center">526</td>
    <td align="center">366</td>
    <td align="center">142</td>
    <td align="center">87</td>
    <td align="center">70</td>
    <td align="center">15</td>
  </tr>
  <tr>
    <td>0.5 gm IM</td>
    <td align="center">115</td>
    <td align="center">425</td>
    <td align="center">308</td>
    <td align="center">127</td>
    <td align="center">96</td>
    <td align="center">28</td>
  </tr>
  <tr>
    <td>1 gm IV</td>
    <td align="center">995</td>
    <td align="center">855</td>
    <td align="center">293</td>
    <td align="center">147</td>
    <td align="center">132</td>
    <td align="center">32</td>
  </tr>
  <tr>
    <td>1 gm IM</td>
    <td align="center">504</td>
    <td align="center">628</td>
    <td align="center">418</td>
    <td align="center">237</td>
    <td align="center">ND</td>
    <td align="center">ND</td>
  </tr>
  <tr>
    <td>2 gm IV</td>
    <td align="center">2692</td>
    <td align="center">1976</td>
    <td align="center">757</td>
    <td align="center">274</td>
    <td align="center">198</td>
    <td align="center">40</td>
  </tr>
  <tr>
    <td class="credit" colspan="7">ND = Not determined.</td>
  </tr>
</table>
</center></p>
<p>Thirty-three percent to 67% of a ceftriaxone dose was excreted in the urine as unchanged drug and the remainder was secreted in the bile and ultimately found in the feces as microbiologically inactive compounds. After a 1 gm IV dose, average concentrations of ceftriaxone, determined from 1 to 3 hours after dosing, were 581 &mu;g/mL in the gallbladder bile, 788 &mu;g/mL in the common duct bile, 898 &mu;g/mL in the cystic duct bile, 78.2 &mu;g/gm in the gallbladder wall and 62.1 &mu;g/mL in the concurrent plasma.</p>
<p>Over a 0.15 to 3 gm dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour. Ceftriaxone is reversibly bound to human plasma proteins, and the binding decreased from a value of 95% bound at plasma concentrations of &lt;25 &mu;g/mL to a value of 85% bound at 300 &mu;g/mL. Ceftriaxone crosses the blood placenta barrier.</p>
<p>The average values of maximum plasma concentration, elimination half-life, plasma clearance and volume of distribution after a 50 mg/kg IV dose and after a 75 mg/kg IV dose in pediatric patients suffering from bacterial meningitis are shown in Table 3. Ceftriaxone penetrated the inflamed meninges of infants and pediatric patients; CSF concentrations after a 50 mg/kg IV dose and after a 75 mg/kg IV dose are also shown in Table 3.</p>
<p align="center"><b>Table 3 Average Pharmacokinetic Parameters of Ceftriaxone in Pediatric Patients With Meningitis</b><br />
<center><table class="blacktbl" width="450" cellspacing="0">
  <tr>
    <td width="60%" class="EmphTd">&nbsp;</td>
    <td class="EmphTd" width="20%">50 mg/kg IV</td>
    <td class="EmphTd" width="20%">75 mg/kg IV</td>
  </tr>
  <tr>
    <td>Maximum Plasma Concentrations (&mu;g/mL)</td>
    <td align="center">216<b> </b></td>
    <td align="center">275</td>
  </tr>
  <tr>
    <td>Elimination Half-life (hr)</td>
    <td align="center">4.6</td>
    <td align="center">4.3</td>
  </tr>
  <tr>
    <td>Plasma Clearance (mL/hr/kg)</td>
    <td align="center">49</td>
    <td align="center">60</td>
  </tr>
  <tr>
    <td>Volume of Distribution (mL/kg)</td>
    <td align="center">338</td>
    <td align="center">373</td>
  </tr>
  <tr>
    <td>CSF Concentration&mdash;inflamed meninges (&mu;g/mL)</td>
    <td align="center">5.6</td>
    <td align="center">6.4</td>
  </tr>
  <tr>
    <td>&nbsp;&nbsp;Range (&mu;g/mL)</td>
    <td align="center">1.3-18.5</td>
    <td align="center">1.3-44</td>
  </tr>
  <tr>
    <td>&nbsp;&nbsp;Time after dose (hr)</td>
    <td align="center">3.7 (&plusmn; 1.6)</td>
    <td align="center">3.3 (&plusmn; 1.4)</td>
  </tr>
</table>
</center></p>
<p>Compared to that in healthy adult subjects, the pharmacokinetics of ceftriaxone were only minimally altered in elderly subjects and in patients with renal impairment or hepatic dysfunction (Table 4); therefore, dosage adjustments are not necessary for these patients with ceftriaxone dosages up to 2 gm per day. Ceftriaxone was not removed to any significant extent from the plasma by hemodialysis; in six of 26 dialysis patients, the elimination rate of ceftriaxone was markedly reduced.</p>
<p align="center"><b>Table 4 Average Pharmacokinetic Parameters of Ceftriaxone in Humans</b><br />
<center><table class="blacktbl" width="450" cellspacing="0">
  <tr>
    <td class="EmphTd" width="40%">Subject Group</td>
    <td class="EmphTd" width="20%">Elimination Half-Life<br />(hr)</td>
    <td class="EmphTd" width="20%">Plasma Clearance<br /> (L/hr)</td>
    <td class="EmphTd" width="20%">Volume of Distribution<br />(L)</td>
  </tr>
  <tr>
    <td>Healthy Subjects</td>
    <td align="center">5.8-8.7</td>
    <td align="center">0.58-1.45</td>
    <td align="center">5.8-13.5</td>
  </tr>
  <tr>
    <td>Elderly Subjects (mean age, 70.5 yr)<br />
	 Patients With Renal Impairment</td>
    <td align="center">8.9</td>
    <td align="center">0.83</td>
    <td align="center">10.7</td>
  </tr>
  <tr>
    <td> &nbsp;&nbsp;Hemodialysis Patients (0-5 mL/min)*</td>
    <td align="center">14.7</td>
    <td align="center">0.65</td>
    <td align="center">13.7</td>
  </tr>
  <tr>
    <td>&nbsp;&nbsp;Severe (5-15 mL/min)</td>
    <td align="center">15.7</td>
    <td align="center">0.56</td>
    <td align="center">12.5</td>
  </tr>
  <tr>
    <td>&nbsp;&nbsp;Moderate (16-30 mL/min)</td>
    <td align="center">11.4</td>
    <td align="center">0.72</td>
    <td align="center">11.8</td>
  </tr>
  <tr>
    <td>&nbsp;&nbsp;Mild (31-60 mL/min)</td>
    <td align="center">12.4</td>
    <td align="center">0.70</td>
    <td align="center">13.3</td>
  </tr>
  <tr>
    <td>Patients With Liver Disease</td>
    <td align="center">8.8</td>
    <td align="center">1.1</td>
    <td align="center">13.6</td>
  </tr>
  <tr>
    <td class="credit" colspan="4">*Creatinine clearance.</td>
  </tr>
</table>
</center></p>
<p>The elimination of ceftriaxone is not altered when Rocephin is co-administered with probenecid.</p>
<h4>Pharmacokinetics In The Middle Ear Fluid</h4>
<p>In one study, total ceftriaxone concentrations (bound and unbound) were measured in middle ear fluid obtained during the insertion of tympanostomy <a href="https://www.rxlist.com/tubes/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">tubes</a> in 42 pediatric patients with <a href="https://www.rxlist.com/otitis_media/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">otitis media</a>. Sampling times were from 1 to 50 hours after a single intramuscular injection of 50 mg/kg of ceftriaxone. Mean (&plusmn;
SD) ceftriaxone levels in the middle ear reached a peak of 35 (&plusmn; 12) &mu;g/mL at 24 hours, and remained at 19 (&plusmn; 7) &mu;g/mL at 48 hours. Based on middle ear fluid ceftriaxone concentrations in the 23 to 25 hour and the 46 to 50 hour sampling time intervals, a half-life of 25 hours was calculated. Ceftriaxone is highly bound to plasma proteins. The extent of binding to proteins in the middle ear fluid is unknown.</p>
<h4>Interaction With Calcium</h4>
<p>Two <i>in vitro</i> studies, one using adult plasma and the other neonatal plasma from umbilical <a href="https://www.rxlist.com/cord/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">cord</a> blood have been carried out to assess interaction of ceftriaxone and calcium. Ceftriaxone concentrations up to 1 mM (in excess of concentrations achieved <i>in vivo</i> following administration of 2 grams ceftriaxone infused over 30 minutes) were used in combination with calcium concentrations up to 12 mM (48 mg/dL). Recovery of ceftriaxone from plasma was reduced with calcium concentrations of 6 mM (24 mg/dL) or higher in adult plasma or 4 mM (16 mg/dL) or higher in neonatal plasma. This may be reflective of ceftriaxone-calcium precipitation.</p>
<h4>Microbiology</h4>
<h5>Mechanism Of Action</h5>
<p>Ceftriaxone is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Ceftriaxone has activity in the presence of some beta-lactamases, both penicillinases and cephalosporinases, of <a href="https://www.rxlist.com/gram_measure/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">Gram</a>-negative and <a href="https://www.rxlist.com/gram-positive/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">Gram-positive</a> bacteria.</p>
<h5>Mechanism Of Resistance</h5>
<p>Resistance to ceftriaxone is primarily through hydrolysis by beta-lactamase, alteration of penicillin-binding proteins (PBPs), and decreased permeability.</p>
<p><i>Interaction with Other Antimicrobials</i></p>
<p>In an <i>in vitro</i> study antagonistic effects have been observed with the combination of chloramphenicol and ceftriaxone.</p>
<p>Ceftriaxone has been shown to be active against most isolates of the following bacteria, both <i>in vitro</i> and in clinical infections as described in the <a href="/rocephin-drug.htm#I"><b>INDICATIONS</b></a> section:</p>
<h5>Gram-negative Bacteria</h5>
<p class="EmphText"><i>Acinetobacter calcoaceticus</i>	<i><br />
  Enterobacter aerogenes</i>	<i><br />
  Enterobacter cloacae</i>	<i><br />
  Escherichia coli</i>	<i><br />
  Haemophilus influenzae</i>	<i><br />
  Haemophilus parainfluenzae</i>	<i><br />
  Klebsiella oxytoca</i>	<i><br />
  Klebsiella pneumoniae</i>	<i><br />
  Moraxella catarrhalis</i>	<i><br />
  Morganella morganii</i>	<i><br />
  Neisseria gonorrhoeae</i>	<i><br />
  Neisseria meningitidis</i>	<i><br />
  Proteus mirabilis</i>	<i><br />
  Proteus vulgaris</i>	<i><br />
  Pseudomonas aeruginosa</i>	<i><br />
  Serratia marcescens</i>
  
</p>
<h5>Gram-positive Bacteria</h5>
<p class="EmphText"><i>Staphylococcus aureus</i>  <i><br />
  Staphylococcus epidermidis</i>  <i><br />
  Streptococcus pneumoniae</i>  <i><br />
  Streptococcus pyogenes</i>  <i><br />
  Viridans group streptococci</i></p>
<h5>Anaerobic Bacteria</h5>
<p class="EmphText"><i>Bacteroides fragilis</i>  <i><br />
  Clostridium species</i>  <i><br />
  Peptostreptococcus species</i></p>
<p>The following <i>in vitro</i> data are available, but their clinical significance is unknown. At least 90 percent of the following microorganisms exhibit an <i>in vitro</i> minimum inhibitory concentration (MIC) less than or equal to the susceptible breakpoint for ceftriaxone. However, the efficacy of ceftriaxone in treating clinical infections due to these microorganisms has not been established in adequate and well-controlled clinical trials.</p>
<h5>Gram-negative Bacteria</h5>
<p class="EmphText"><i>Citrobacter diversus</i><i><br />
  Citrobacter freundii</i><i><br />
  Providencia</i> species (including <i>Providencia rettgeri</i>)<i><br />
  Salmonella</i><i> species</i> (including <i>Salmonella typhi</i>)<i><br />
  Shigella</i> species
</p>
<h5>Gram-positive Bacteria</h5>
<p class="EmphText"><i>Streptococcus agalactiae</i>
</p>
<h5>Anaerobic Bacteria</h5>
<p class="EmphText"><i>Porphyromonas (Bacteroides) melaninogenicus</i>  <i><br />
  Prevotella (Bacteroides) bivius</i></p>
<h4>Susceptibility Test Methods</h4>
<p>When available, the clinical microbiology laboratory should provide the results of <i>in vitro</i> susceptibility test results for antimicrobial drug products used in resident hospitals to the physician as periodic reports that describe the susceptibility profile of nosocomial and community-acquired pathogens. These reports should aid the physician in selecting an antibacterial drug product for treatment.</p>
<h5>Dilution Techniques</h5>
<p>Quantitative methods are used to determine antimicrobial minimal inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized test method <sup>1,3</sup>. The MIC values should be interpreted according to criteria provided in Table
5.</p>
<h5>Diffusion Techniques</h5>
<p>Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. The zone size provides an estimate of the susceptibility of bacteria to antimicrobial compounds. The zone size should be determined using a standardized test method.<sup>2,3</sup> This procedure uses paper disks impregnated with 30 mcg ceftriaxone to test the susceptibility of microorganisms to ceftriaxone. The disk diffusion interpretive criteria are provided in Table 5.</p>
<h5>Anaerobic Techniques</h5>
<p>For anaerobic bacteria, the susceptibility to ceftriaxone as MICs can be determined by a
standardized agar test method <sup>3,4</sup> . The MIC values obtained should be interpreted
according to the criteria provided in Table 5.</p>
<p align="center"><b>Table 5 Susceptibility Test Interpretive Criteria for Ceftriaxone</b><br />
<center><table class="blacktbl" width="650" cellspacing="0">
  <tr>
    <td class="EmphTd" width="28%" rowspan="2">Pathogen</td>
    <td class="EmphTd" colspan="3">Minimum Inhibitory Concentrations <br />(mcg/ml)</td>
    <td class="EmphTd" colspan="3">Disk Diffusion Zone Diameters <br />(mm)</td>
  </tr>
  <tr>
    <td class="EmphTd" width="12%" align="center">(S)<br /> 
      Susceptible</td>
    <td class="EmphTd" width="12%" align="center">(I)<br /> Intermediate</td>
    <td class="EmphTd" width="12%" align="center">(R)<br /> Resistant</td>
    <td class="EmphTd" width="12%" align="center">(S)<br /> Susceptible</td>
    <td class="EmphTd" width="12%" align="center">(I)<br /> Intermediate</td>
    <td class="EmphTd" width="12%" align="center">(R)<br /> Resistant</td>
  </tr>
  <tr>
    <td><i>Enterobacteriaceae<sup>a</sup></i></td>
    <td align="center">&le; 1</td>
    <td align="center">2</td>
    <td align="center">&ge;4</td>
    <td align="center">&ge; 23</td>
    <td align="center">20-22</td>
    <td align="center">&le;19</td>
  </tr>
  <tr>
    <td><i>Haemophilus influenzae<sup>b,c</sup></i></td>
    <td align="center">&le;2</td>
    <td align="center">-</td>
    <td align="center">-</td>
    <td align="center">&ge;26</td>
    <td align="center">-</td>
    <td align="center">-</td>
  </tr>
  <tr>
    <td><i>Neisseria gonorrhoeae<sup>a</sup></i></td>
    <td align="center">&le; 0.25</td>
    <td align="center">-</td>
    <td align="center">-</td>
    <td align="center">&ge; 35</td>
    <td align="center">-</td>
    <td align="center">-</td>
  </tr>
  <tr>
    <td><i>Neisseria meningitidis<sup>c</sup></i></td>
    <td align="center">&le; 0.12</td>
    <td align="center">-</td>
    <td align="center">-</td>
    <td align="center">&ge; 34</td>
    <td align="center">-</td>
    <td align="center">-</td>
  </tr>
  <tr>
    <td><i>Streptococcus<br />
	 &nbsp;&nbsp;pneumoniae <sup>d</sup></i> <br />&nbsp;&nbsp;meningitis isolates</td>
    <td align="center">&le; 0.5</td>
    <td align="center">1</td>
    <td align="center">&ge; 2</td>
    <td align="center">-</td>
    <td align="center">-</td>
    <td align="center">-</td>
  </tr>
  <tr>
    <td><i>Streptococcus<br />
	 &nbsp;&nbsp;pneumoniae
	    <sup>d</sup></i><br /> 
	     non-meningitis isolates</td>
    <td align="center">&le;1</td>
    <td align="center">2</td>
    <td align="center">&ge;4</td>
    <td align="center">-</td>
    <td align="center">-</td>
    <td align="center">-</td>
  </tr>
  <tr>
    <td><i>Streptococcus species</i><br />
	 &nbsp;&nbsp;beta-hemolytic group<sup>c</sup></td>
    <td align="center">&le;0.5</td>
    <td align="center">-</td>
    <td align="center">-</td>
    <td align="center">&ge; 24</td>
    <td align="center">-</td>
    <td align="center">-</td>
  </tr>
  <tr>
    <td>Viridans group 
	 streptococci</td>
    <td align="center">&le; 1</td>
    <td align="center">2</td>
    <td align="center">&ge; 4</td>
    <td align="center">&ge;27</td>
    <td align="center">25-26</td>
    <td align="center">&le;24</td>
  </tr>
  <tr>
    <td>Anaerobic bacteria<br />
	&nbsp;&nbsp;(agar method)</td>
    <td align="center">&le; 1</td>
    <td align="center">2</td>
    <td align="center">&ge; 4</td>
    <td align="center">-</td>
    <td align="center">-</td>
    <td align="center">-</td>
  </tr>
  <tr>
    <td class="credit" colspan="7"><sup>a</sup> Susceptibility interpretive criteria for Enterobacteriaceae are based on a dose of 1 gram IV q 24h. For isolates with intermediate susceptibility, use a dose of 2 grams IV q 24h in patients with normal renal function.<br />
      <sup>b</sup> For <i>Haemophilus influenzae</i>, susceptibility interpretive criteria are based on a dose of 2 grams IV every 24 hours in patients with normal renal function.<br />
      <sup>c</sup> The current absence of data on resistant isolates precludes defining any category other than &lsquo;Susceptible&rsquo;. If isolates yield MIC results other than susceptible, they should be submitted to a reference laboratory for additional testing.<br />
      <sup>d</sup> Disc diffusion interpretive criteria for ceftriaxone discs against <i>Streptococcus pneumoniae</i> are not available, however, isolates of pneumococci with oxacillin zone
      diameters of &gt;20 mm are susceptible (MIC &le; 0.06 mcg/mL) to penicillin and can be
      considered susceptible to ceftriaxone. <i>Streptococcus pneumoniae</i> isolates should not be reported as penicillin (ceftriaxone) resistant or intermediate based solely on an oxacillin
      zone diameter of &le; 19 mm. The ceftriaxone MIC should be determined for those isolateswith oxacillin zone diameters &le; 19 mm.</td>
  </tr>
</table>
</center></p>
<p>Susceptibility of staphylococci to ceftriaxone may be deduced from testing only penicillin
and either cefoxitin or oxacillin.</p>
<p>A report of <i>Susceptible</i> indicates that the antimicrobial drug is likely to inhibit growth of
the pathogen if the antimicrobial drug reaches the concentration at the site of infection. A
report of <i>Intermediate</i> indicates that the result should be considered equivocal, and if the
microorganism is not fully susceptible to alternative, clinically feasible drugs, the test
should be repeated. This category implies possible clinical applicability in body sites where
the drug is physiologically concentrated or in situations where a high dosage of drug can
be used. This category also provides a buffer zone that prevents small uncontrolled
technical factors from causing major discrepancies in interpretation. A report of <i>Resistant</i> indicates that the antimicrobial drug is not likely to inhibit growth of the pathogen if the
antimicrobial drug reaches the concentrations usually achievable at the infection site; other
therapy should be selected.</p>
<h5>Quality Control</h5>
<p>Standardized susceptibility test procedures require the use of laboratory controls to monitor
and ensure the accuracy and precision of supplies and reagents used in the assay, and the
techniques of the individual performing the test <sup>1,2,3,4</sup>.</p>
<p>Standard ceftriaxone powder should provide the following range of MIC values noted in Table 6. For the diffusion technique using the 30 mcg disk, the criteria in Table 6 should be achieved.</p>
<p align="center"><b>Table 6 Acceptable Quality Control Ranges for Ceftriaxone</b><br />
<center><table class="blacktbl" width="450" cellspacing="0">
  <tr>
    <td class="EmphTd" width="40%">QC Strain</td>
    <td class="EmphTd" width="30%">Minimum Inhibitory Concentrations (mcg/mL)</td>
    <td class="EmphTd" width="30%">Disk Diffusion Zone diameters (mm)</td>
  </tr>
  <tr>
    <td><i>Escherichia coli ATCC </i>25922</td>
    <td align="center">0.03 -0.12</td>
    <td align="center">29 -35</td>
  </tr>
  <tr>
    <td><i>Staphylococcus aureus ATCC </i>25923</td>
    <td align="center">-</td>
    <td align="center">22
      -28</td>
  </tr>
  <tr>
    <td><i>Staphylococcus aureus ATCC </i>29213</td>
    <td align="center">1 &ndash; 8</td>
    <td align="center">-</td>
  </tr>
  <tr>
    <td><i>Haemophilus influenzae ATCC </i>49247</td>
    <td align="center">0.06 -0.25</td>
    <td align="center">31 -39</td>
  </tr>
  <tr>
    <td><i>Neisseria gonorrhoeae ATCC </i>49226</td>
    <td align="center">0.004 -0.015</td>
    <td align="center">39 -51</td>
  </tr>
  <tr>
    <td><i>Pseudomonas aeruginosa ATCC</i> 27853</td>
    <td align="center">8-64</td>
    <td align="center">17-23</td>
  </tr>
  <tr>
    <td><i>Streptococcus pneumoniae ATCC </i>49619</td>
    <td align="center">0.03 -0.12</td>
    <td align="center">30 -35</td>
  </tr>
  <tr>
    <td><i>Bacteroides fragilis ATCC </i>25285 (agar method)</td>
    <td align="center">32 &ndash; 128</td>
    <td align="center">-</td>
  </tr>
  <tr>
    <td><i>Bacteroides thetaiotaomicron ATCC </i>29741 (agar method)</td>
    <td align="center">64 &ndash; 256</td>
    <td align="center">-</td>
  </tr>
</table>
</center></p>
<a name="CS"></a><h4>Clinical Studies</h4>
<h5>Clinical Trials In Pediatric Patients With Acute Bacterial Otitis Media</h5>
<p>In two adequate and well-controlled US clinical trials a single IM dose of ceftriaxone was compared with a 10 day course of oral antibiotic in pediatric patients between the ages of 3 months and 6 years. The clinical cure rates and statistical outcome appear in the table below:</p>
<p align="center"><b>Table 7 Clinical Efficacy in Pediatric Patients with Acute Bacterial Otitis Media</b><br />
<center><table class="blacktbl" width="450" cellspacing="0">
  <tr>
    <td class="EmphTd" colspan="5">Clinical Efficacy in Evaluable Population</td>
  </tr>
  <tr>
    <td width="20%" class="EmphTd">Study Day</td>
    <td width="20%" class="EmphTd">Ceftriaxone Single Dose</td>
    <td width="20%" class="EmphTd">Comparator &ndash; 10 Days of Oral Therapy</td>
    <td width="20%" class="EmphTd">95% Confidence Interval</td>
    <td width="20%" class="EmphTd">Statistical Outcome</td>
  </tr>
  <tr>
    <td><b>Study 1 &ndash; US</b></td>
    <td align="center" colspan="4"><b>amoxicillin/clavulanate</b></td>
  </tr>
  <tr>
    <td align="center">14</td>
    <td align="center">74% (220/296)</td>
    <td align="center">82% (247/302)</td>
    <td align="center">(-14.4%, -0.5%)</td>
    <td align="center" rowspan="2">Ceftriaxone is lower
      than control at study day 14 and
      28.</td>
  </tr>
  <tr>
    <td align="center">28</td>
    <td align="center">58% (167/288)</td>
    <td align="center">67% (200/297)</td>
    <td align="center">(-17.5%, -1.2%)</td>
  </tr>
  <tr>
    <td><b>Study 2 -US<sup>5</sup></b></td>
    <td align="center" colspan="4"><b>TMP-SMZ</b></td>
  </tr>
  <tr>
    <td align="center">14</td>
    <td align="center">54% (113/210)</td>
    <td align="center">60% (124/206)</td>
    <td align="center">(-16.4%, 3.6%)</td>
    <td align="center" rowspan="2">Ceftriaxone is
      equivalent to control at study day
      14 and 28.</td>
  </tr>
  <tr>
    <td align="center">28</td>
    <td align="center">35% (73/206)</td>
    <td align="center">45% (93/205)</td>
    <td align="center">(-19.9%, 0.0%)</td>
  </tr>
</table>
</center></p>
<p>An open-label bacteriologic study of ceftriaxone without a comparator enrolled 108 pediatric patients, 79 of whom had positive baseline cultures for one or more of the common pathogens. The results of this study are tabulated as follows:</p>
<p>Week 2 and 4 Bacteriologic Eradication Rates in the Per Protocol Analysis in the Roche Bacteriologic Study by pathogen:</p>
<p align="center"><b>Table 8 Bacteriologic Eradication Rates by Pathogen</b><br />
<center><table class="blacktbl" width="450" cellspacing="0">
  <tr>
    <td width="28%" class="EmphTd">&nbsp;</td>
    <td width="18%" class="EmphTd">Study Day <br />13-15</td>
    <td width="18%" class="EmphTd">&nbsp;</td>
    <td width="18%" class="EmphTd">Study Day <br />30+2</td>
    <td width="18%" class="EmphTd">&nbsp;</td>
  </tr>
  <tr>
    <td class="EmphTd">Organism</td>
    <td class="EmphTd">No. Analyzed</td>
    <td class="EmphTd">No. Erad. (%)</td>
    <td class="EmphTd">No. Analyzed</td>
    <td class="EmphTd">No. Erad. (%)</td>
  </tr>
  <tr>
    <td><i>Streptococcus pneumoniae</i></td>
    <td align="center">38</td>
    <td align="center">32 (84)</td>
    <td align="center">35</td>
    <td align="center">25 (71)</td>
  </tr>
  <tr>
    <td><i>Haemophilus influenzae</i></td>
    <td align="center">33</td>
    <td align="center">28 (85)</td>
    <td align="center">31</td>
    <td align="center">22 (71)</td>
  </tr>
  <tr>
    <td><i>Moraxella catarrhalis</i></td>
    <td align="center">15</td>
    <td align="center">12 (80)</td>
    <td align="center">15</td>
    <td align="center">9 (60)</td>
  </tr>
</table>
</center></p>
<a name="AP"></a><h4>Animal Pharmacology</h4>
<p>Concretions consisting of the precipitated calcium salt of ceftriaxone have been found in the gallbladder bile of dogs and baboons treated with ceftriaxone.</p>
<p>These appeared as a gritty sediment in dogs that received 100 mg/kg/day for 4 weeks. A similar phenomenon has been observed in baboons but only after a protracted dosing period (6 months) at higher dose levels (335 mg/kg/day or more). The likelihood of this occurrence in humans is considered to be low, since ceftriaxone has a greater plasma half-life in humans, the calcium salt of ceftriaxone is more soluble in human gallbladder bile and the calcium content of human gallbladder bile is relatively low.</p>
<p class="credit"><b>REFERENCES</b></p>
<p class="credit">1. Clinical and Laboratory Standards Institute (CLSI). <i>Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard -Tenth Edition.</i> CLSI document M07-A10, Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2015.</p>
<p class="credit">2. Clinical and Laboratory Standards Institute (CLSI). <i>Performance Standards for Antimicrobial Susceptibility Testing; Twenty-fifth Informational Supplement.</i> CLSI document M100-S25, Clinical and Laboratory Standards
	Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2015.</p>
<p class="credit">3. Clinical and Laboratory Standards Institute (CLSI). <i>Performance Standards for Antimicrobial Disk Diffusion Susceptibility Tests; Approved Standard &ndash; Twelfth Edition.</i> CLSI document M02-A12, Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2015.</p>
<p class="credit">4. Clinical and Laboratory Standards Institute (CLSI). <i>Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard -Eight Edition.</i> CLSI document M11-A8, Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, PA 19087 USA, 2012</p>
<p class="credit">Distributed by: <b>Genentech USA, Inc.</b> A Member of the Roche Group, 1 DNA Way, South San Francisco, CA 94080-4990. Revised: July 2018</p>
            </div>
            <!--MOD_BOTTOMOFPAGE_10-->
        </div>
    </div>
</section>
<section class="pageSection">
    <div id="apPage" class="apPage">
        <div class="wrapper">
            <a class="bookmark" name="medguide"></a>
            <div class="pgContent">
                <!--MOD_TOPOFPAGE_11-->
                
<a name="PI"></a><h2>Patient Information for Rocephin</h2>
<ul>
<li>Inform patients that use of local anesthetics may cause methemoglobinemia, a serious condition that must be treated promptly. Advise patients or caregivers to stop use and seek immediate medical attention if they or someone in their care experience the following signs or symptoms: pale, gray, or blue colored skin (<a href="https://www.rxlist.com/cyanosis/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">cyanosis</a>); headache; rapid heart rate; shortness of breath; <a href="https://www.rxlist.com/lightheadedness/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">lightheadedness</a>; or fatigue.</li>
<li>Patients should be counseled that antibacterial drugs including Rocephin should only be used to treat bacterial infections. They do not treat viral infections (eg, <a href="https://www.rxlist.com/common_cold/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">common cold</a>).</li>
<li>When Rocephin is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Rocephin or other antibacterial drugs in the future.</li>
<li>Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without <a href="https://www.rxlist.com/stomach_cramps/definition.htm" rel="dict" onclick="wmdTrack('embd-lnk');">stomach cramps</a> and fever) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs,  patients should contact their physician as soon as possible.</li>
</ul>

            </div>
            <!--MOD_BOTTOMOFPAGE_11-->
        </div>
    </div>
</section>
<!-- START US ONLY VISITOR RR2 --><div class="from_webmd">
    <h2>From <img class="logoTitle" src="https://images.medicinenet.com/images/promo/logo_webmd.gif" alt="WebMD Logo"></h2>
    <div class="content">
        <div class="wrapper">
    <h5>Infectious Disease Resources</h5>
    <ul>
        <li><a onclick="wmdPageLink('rs-4286-4286_1');" href="https://www.webmd.com/oral-health/guide/sore-throat-cold-strep-throat-tonsillitis" target="_blank" rel="nofollow">Is It a Cold, Strep, or Tonsillitis?</a></li>
    </ul>
</div>
        <div class="wrapper">
    <h5>Featured Centers</h5>
    <ul>
        <li><a onclick="wmdPageLink('fc-3785-1');" href="https://www.webmd.com/skin-problems-and-treatments/psoriasis/psa-22/psa-make-treatment-work
" target="_blank" rel="nofollow">What Are the Best PsA Treatments for You?</a></li><li><a onclick="wmdPageLink('fc-3709-2');" href="https://www.webmd.com/rheumatoid-arthritis/video/ra-biologic-drugs" target="_blank" rel="nofollow">Understanding Biologics
</a></li><li><a onclick="wmdPageLink('fc-5056-3');" href="https://blogs.webmd.com/depression/20220131/what-i-wish-people-knew-about-depression
" target="_blank" rel="nofollow">10 Things People With Depression Wish You Knew
</a></li>
    </ul>
</div>
    </div>
</div>
<!-- END US ONLY VISITOR RR2 -->
<div id="fdaWrapper">
	<img src="https://images.medicinenet.com/images/logo_fda.png" border="0" alt="FDA Logo"/>	
	<h2>Report Problems to the Food and Drug Administration</h2>
	<p>You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the <a href="https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program/reporting-serious-problems-fda" target="_blank" onclick="wmdPageLink('fda-prob');">FDA MedWatch</a> website or call 1-800-FDA-1088.</p>
</div>



                    </div>
                </article>
<scroll-page :max-pages="-1" next-page-uri="/rxl/api/art-rx-sli/97465?num=1" next-type="art-rx-sli" suffix=""></scroll-page>            </section>

                <aside class="stickyColRight">
                    <privacy-button></privacy-button>
                    <div class="sideBox promo">
                        <a onclick="wmdTrack('lr-pid');" href="https://www.rxlist.com/pill-identification-tool/article.htm">
                            <div class="rrpromo pid">
                                <span class="icon-arrow-right2"></span><span class="icon-pill-id"></span><p>Pill Identifier Tool <span>Quick, Easy, Pill Identification</span></p>
                            </div>
                        </a>
                        <a onclick="wmdTrack('lr-dic');" href="https://www.rxlist.com/drug-interaction-checker.htm">
                            <div class="rrpromo dic">
                                <span class="icon-arrow-right2"></span><span class="icon-drug-interaction "></span><p>Drug Interaction Tool <span>Check Potential Drug Interactions</span></p>
                            </div>
                        </a>
                        <a onclick="wmdTrack('lr-lrx');" href="https://www.rxlist.com/pharmacy/local_locations_pharmacies.htm">
                            <div class="rrpromo lrx">
                                <span class="icon-arrow-right2"></span><span class="icon-map"></span><p>Pharmacy Locator Tool <span>Including 24 Hour, Pharmacies</span></p>
                            </div>
                        </a>  
                    </div>
                    <sticky-polyfill top="120">
                        <!-- Start 300x250 Ad Tag -->
<div id="rightAd_rdr">
	<div class="rightAd_top_fmt"></div>
	<div id="rightAd_fmt" class="rightAd_BG_fmt">
        <div id="ads2-pos-121" class="ad_placeholder ad"
    data-is-mobile="false" 
    data-block-codes="_vac_t886_sex3_sex2_sex1_r529_r05_o92_o8_n97_n46_m32_k80_k7_k591_k51_j30_j10_i_h53_h52_h16_h10_gen2_gen1_g473_g00_food_fit_f65_f10_diet_cust9_cust4_bty21_age234_age123_age122_age121_age11_a55_a54_a49_a403_n952_cust017_cust022_a047_supplements_cust031_nn1_disx12_cust048_cust056_cust063_par_cust084_cust091_cust097_b962_n390_b972_cust126_n898_" 
    data-pos="121" 
    data-sizes="[[300,250],[300,600],[300,1050]]">
</div>

	</div>
	<div class="rightAd_bottom_fmt"></div>
</div>
<!-- End 300x250 Ad Tag -->

                        
                    </sticky-polyfill>

                </aside>	
        </main>
    
    <footer>
		<ul class="social-section">
        <li class="social fb">
            <offsite-button class="fb_share" theme="fb_share" url="https://www.facebook.com/rxlist" pagelink="soc-fb" icon="icon-facebook" title="Follow us on Facebook. Click Like, and we'll send authoritative health and medical information to your News Feed.">
            </offsite-button>
        </li>
        <li class="social tw">
            <offsite-button class="tw_share" theme="tw_share" url="https://www.twitter.com/rxlist" pagelink="soc-tw" icon="icon-twitter" title="Follow us on Twitter. Be the first to know the latest in health information.">
            </offsite-button>
        </li>
    </ul>
    <nav>
        <div class="col">
            <h4>Drug Categories</h4>
            <ul>
                <li><a href="/drugs/alpha_a.htm">Drugs &amp; Medications</a></li>
                <li><a href="/pill-identification-tool/article.htm">Pill Identification Tool</a></li>
                <li><a href="/supplements/article.htm">Vitamins, Herbs, &amp; Dietary Supplements</a></li>
                <li><a href="/drug-medical-dictionary/article.htm">Dictionary</a></li>
            </ul>
        </div>
        <div class="col">
            <h4>RxList</h4>
            <ul>
                <li><a href="/script/main/art.asp?articlekey=64467">About Us</a></li>
                <li><a href="javascript:void(0);" onclick="window.open('https://data.webmd.com/sdclive/SdcForm.aspx?FormId=rxlistContact','newWin','resizeable=yes,scrollbars=no,width=580,height=600');return false;">Consumer Contact RxList</a></li>
                <li><a href="/script/main/art.asp?articlekey=64473">Terms of Use</a></li>
                <li><a href="/script/main/art.asp?articlekey=64474">Privacy Policy</a></li>
                <li><a href="/script/main/art.asp?articlekey=77768">Sponsor Policy</a></li>                               
            </ul>
        </div>

    </nav>
    <div class="footerCopy">
        <div class="badge">
            <img class="rgb_tag" src="https://images.rxlist.com/images/footer/badges/rgb_tag_registered.png" width="60" height="60" />
            <a href="//privacy.truste.com/privacy-seal/validation?rid=07326333-3522-463d-81bf-f00fd7171fff" target="_blank"><img width="142" height="45" src="//privacy-policy.truste.com/privacy-seal/seal?rid=07326333-3522-463d-81bf-f00fd7171fff" alt="TRUSTe" /></a>
            <a onclick="TRUSTeWidget.Tab.link()"><img src="https://choices.truste.com/get?name=admarker2.png" width="77" height="16" border="0"></a>
        </div>            
        <div class="copyright">
            <a id="ot-sdk-btn1" class="ib-your-choices" onclick="OneTrust.ToggleInfoDisplay();" href="javascript:void(0);">Your Privacy Choices <img src="https://icons.internetbrands.com/ccpa/privacyoptions29x14.png"> </a>
            <p>Copyright &copy; 2024 by RxList Inc. An <a href="https://www.internetbrands.com" rel="nofollow">Internet Brands</a> company. RxList does not provide medical advice, diagnosis or treatment. <a href="https://www.rxlist.com/script/main/art.asp?articlekey=199773">See additional information</a>.</p>
        </div>
    </div>
		</footer>
	</div>
</div>
<!-- start ad 1x1 -->
<div id="ads2-pos-901" class="ad_placeholder ad"
    data-is-mobile="false" 
    data-block-codes="_vac_t886_sex3_sex2_sex1_r529_r05_o92_o8_n97_n46_m32_k80_k7_k591_k51_j30_j10_i_h53_h52_h16_h10_gen2_gen1_g473_g00_food_fit_f65_f10_diet_cust9_cust4_bty21_age234_age123_age122_age121_age11_a55_a54_a49_a403_n952_cust017_cust022_a047_supplements_cust031_nn1_disx12_cust048_cust056_cust063_par_cust084_cust091_cust097_b962_n390_b972_cust126_n898_" 
    data-pos="901" 
    data-sizes="[1,1]">
</div>
<script>
  (function(){      
    let adTags = document.querySelectorAll('.ad')
    if (window.ooAdTarget.targets) {
      let adTargets = JSON.stringify(window.ooAdTarget.targets).replaceAll(`"`,`'`)
      for (let adTag of adTags) {
        adTag.setAttribute('data-targets', adTargets)
      }
    }
  })()
</script>

<!-- end ad 1x1 -->


<script src="https://img.wbmdstatic.com/webmd_static_vue/webmd-share-static-files/webmd/PageBuilder_Assets/JS/api/oo_shim_body.min.js"></script>
    <script language="javascript1.2" type="text/javascript" src="https://img.webmd.com/bi_common/bi_oocommon.js"></script>
<script type="text/javascript">    webmd.ads2.adTarget = ['consumer', 'rxlist']; var bIsDFPAdTag = true;</script>
<script>
if(!window.asyncBeacon && typeof _satellite != "undefined"){_satellite.pageBottom();}
if (!window.gdprMatch)
{
try {
    var _comscore = _comscore || [];
    _comscore.push({ c1: "2", c2: "6035829" });
    (function () {
        var s = document.createElement("script"),
            el = document.getElementsByTagName("script")[0];
        s.async = true;
        s.src = "https://sb.scorecardresearch.com/cs/6035829/beacon.js";
        el.parentNode.insertBefore(s, el);
 
        // Dynamic Pageview Tracking
        window.document.addEventListener("onAdobeOmniBeforePv", function () {
            if (self.COMSCORE) {
                COMSCORE.beacon({ c1: "2", c2: "6035829" });
            }
        });
    })();
} catch (err) {}
}
if (window.videoembed) {
    if (globalAsyncAdsCode) {
        webmd.ads.cmd.push(function(){
            webmd.ads.disableInitialLoad();
            webmd.ads.disableAdsInit = true;   
        });
    } else {
        webmd.ads.disableInitialLoad();
        webmd.ads.disableAdsInit = true;   
    }
}
if (!globalAsyncAdsCode){webmd.ads2Consumer.display();}
$(function() {if (window.s_sponsor_program && window.s_sponsor_program!='') $('.medianet').hide();});
function insertWebMDVideo(html) {
return;
    console.info('insertWebMDVideo called');
    if (s_articletype.indexOf("-ap")>0) {
        $(".wrapper .subtitleAP:first").parent().after(html);
    } else {
       $('#artPromoCunk').after(html);
       $('.article-promo').after(html);
    }
}
</script>
<script>if (!window.gdprMatch)
{document.write('<img src="https://bi.medscape.com/pi/global/rxlist-1x1.gif?' + new Date().getTime() + '" alt="" height="1" width="1" border="0" />');
}
</script>
<script src="https://images.rxlist.com/oocommon/js/20190620/legacy-light.js"></script>

</body>
</html> contentType 9 text/html url 44 https://www.rxlist.com:443/rocephin-drug.htm responseCode 3 200 